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Pain is part of the somatosensory system, which informs individuals about 
objects in the external environment. Pain is also a nociceptive sensation, which 
implies that it is part of the body’s defense system, warning of potential threat or 
ongoing harm, such as harmful movements or skin burns. Nociceptive stimuli, 
in contrast to non-nociceptive stimuli, can be expected to induce a homeostatic 
response. When pain becomes chronic, pain processing becomes altered. Chron-
ic, or persistent, pain, is, according to the standard definition of the International 
Association for the Study of Pain, defined by pain that persists past the healing 
phase following an injury [1]. Chronic pain likely reflects, due to long-term nocicep-
tive input, a state of pathological neuroplasticity that results in increased excitabil-
ity of central nociceptive circuits such that normally innocuous inputs can activate 
the pain system and the perceptual responses to noxious inputs are exaggerated, 
prolonged and spread widely [1,37,78]. Chronic pain is a symptom of numerous 
conditions, for example, back pain, migraine, rheumatoid arthritis, fibromyalgia, or 
inflammatory diseases. In Europe, about 1 in 5 adults suffer from pain on a chronic 
basis and impaired daily functioning - also as a result of symptoms frequently as-
sociated with chronic pain, such as fatigue or psychological distress [10,78]. 
Like pain, itch, or pruritus, is a somatosensory experience that can also be 
considered as nociceptive, because it also serves as a defense mechanism against 
threat, for example, by warning the individual to remove offending debris or para-
sites from the skin [82]. Itch is a common sensation and is reported by more than 
50% of patients visiting a general practitioner for chronic skin conditions, such 
as atopic dermatitis, contact dermatitis, melanoma, or psoriasis, which together 
account for a substantial proportion of all diseases seen by general practitioners 
[70]. A relatively large proportion of people also suffer from itch on a chronic basis. 
About 17% of the people reported chronic itch within the past 12 months in a ran-
domly selected sample [42]. In patients with chronic itch, itch processing may also 
become altered, thus a reorganization of central processing similar to chronic pain 
may also underlie chronic itch. Chronic itch has also serious consequences for the 
patient’s well-being and functioning in daily life, for example, as a result of fatigue 
or symptoms of psychological distress, such as depressive and anxiety symptoms 
[56,83]. Despite the high prevalence and impact of both itch and pain on patients 
and society, much less research has been conducted on itch than on pain.
Similarities and differences between itch and pain
Beside the common burden of itch and pain, there are many similarities 
in the physiological mechanisms of acute itch and pain. Moreover, comparable 
processes of peripheral and central sensitization are thought to have a major role 
in the aggravation of symptoms of both chronic itch and pain. 
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In both localized pruritic and painful lesions, levels of nerve growth factor 
are increased, and inflammatory mediators, such as bradykinin, histamine, and 
prostaglandins, have an acute sensitizing effect on peripheral nociceptors and 
provoke both itch and pain [32,55]. Chronic pain is characterized by altered pro-
cessing of nociceptive signals, such that nociceptive stimuli can be perceived with 
increased pain (i.e. hyperalgesia) and non-nociceptive stimuli can be perceived as 
painful (i.e. allodynia) as a result of central sensitization and associated functional 
and anatomical neuroplasticity [1,2,53,78]. Similar phenomena have been demon-
strated in itch: alloknesis, by which touch evokes pruritus around an itching site, 
and hyperknesis, by which pricking evokes itch [32,55]. The cortical representation 
of brain areas activated by both sensations also shows a broad overlap, with the 
primary and secondary somatosensory cortex (S1 and S2), anterior cingulate cor-
tex (ACC), prefrontal cortex (PFC), premotor cortex, and cerebellum being involved 
in both acute itch and pain [32]. The differences between itch and pain processing 
are thought to be based more on differences in patterns of activation of basically 
identical brain centers than on activation of different brain areas; however, the 
processing of itch and pain occurs via distinct sets of neurons [17,32,55,59]. For 
example, itch is thought to be processed by both an itch-specific neuronal path-
way and an unspecific pathway induced by activated nociceptors with a selective 
projection to supraspinal neurons. In addition, both itch and pain can be consi-
dered as nociceptive stimuli, because both sensations are part of the body’s de-
fense system. Nociceptive signals can result in a homeostatic response, due to the 
potential threat of these signals [15,25]. Acute nociceptive input is considered to 
be a short-term stressor, which can lead to hypothalamic activation. This, in turn, 
activates the autonomic nervous system (ANS) and the hypothalamic pituitary ad-
renal (HPA) axis, prompting the release of hormones, such as cortisol, into the 
circulation, and affecting the heart rate, perspiration, and respiration [15,18,25,43]. 
Thus both itch and pain can be accompanied by neuroendocrine and autonomous 
responses [43,58,65]. Finally, in line with chronic pain, chronic itch may also in-
duce a reorganization of the patterns of peripheral and central processing as a 
result of long-term input from itch signals. More insight into possible similarities 
and differences in factors involved might be beneficial to the management of dif-
ferent symptoms such as itch and pain. In this thesis, various psychophysiological 
factors expected to be of influence on the sensitivity to both itch and pain were 
investigated at a sensory, cognitive, and affective level.
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Psychophysiological model of itch and pain
Itch and pain are complex sensations encompassing sensory-discrim-
inative, affective-motivational, cognitive-evaluative, and behavioral domains 
[11,33,81]. A model of psychophysiological factors that affect the perception of 
itch and pain has been proposed (see Figure 1), based on different models of 
the role of psychophysiological factors in somatosensory sensations, such as 
itch and pain, which take both automatic and strategic processes into account 
[25,36,43,60]. 
Figure 1 Proposed model of psychophysiological factors influencing sensations 
of itch and pain. 
Sensory factors
Sensory factors, such as altered sensitivity and sensitization processes, 
have been extensively studied in pain. Studies have shown that patients with 
chronic pain of different causes (e.g., osteoarthritis, fibromyalgia) seem to be more 
sensitive to pain in general, and that central, and peripheral, sensitization pro-
cesses are thought to play a key role in this increased sensitivity [14,37,77]. This 
enhanced sensitivity is reflected by a decreased pain threshold, exaggerated re-
sponse to noxious stimuli, and increased pain after the end of a stimulus. This 
enhanced sensitivity is frequently not limited to the affected body areas, and is 
assumed to be due to central amplification of pain signals as a result of increased 
excitation or reduced inhibition of neural pathways, due to long-term nociceptive 
input [1,37]. While the relevance of central sensitization processes in chronic pain 
is generally recognized, less is known about the role of sensitization processes 
in itch. There is some evidence that patients with chronic itch or pain perceive 
somatosensory stimuli in the context of their main symptom. For example, these 
patients may not only be more sensitive in comparison to subjects without chronic 
symptoms [31,77], but they may also show an increased sensitivity in relation to 
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their main symptom, such that itch stimuli can be perceived as painful by patients 
with different chronic pain disorders [5,8], and pain stimuli can be perceived as 
itchy by patients with chronic itch [29,31]. However, studies have not systemati-
cally investigated whether the sensitization patterns of generalized sensitivity and 
sensitivity in the context of the main symptom are similar in chronic itch.
On a neurophysiological level, different pathways for the control of pain 
have been described [11,28]. One concerns the peripheral, spinal segmental in-
fluences, which has been described in the gate control model with inhibitory and 
activating influences from peripheral segmental neurons (non-nociceptive Aα and 
Aβ fibers) [44]. Next, phasic pain inhibition is activated by descending noxious 
inhibitory controls (DNIC) from the caudal medulla in the brain stem. DNIC can 
be triggered by heterotopic nociceptive stimuli, i.e., at any body site outside the 
receptive field of the inhibited neuron. It is thought that DNIC mainly serves as a fil-
ter extracting nociceptive signals from the background of non-nociceptive signals 
[11,28,38]. Furthermore, a main tonic descending pain control pathway arises from 
the periaqueductal gray - rostral ventromedial medulla (PAG-RVM) system, which 
exerts bidirectional control through ON- and OFF-cells, resulting in a net facili-
tatory or inhibitory effect on nociceptive signals [28]. This system can be controlled 
top-down, by receiving afferent input from higher centers, such as the hypothala-
mus, amygdala, and prefrontal cortex, providing a neural substrate for the influ-
ence of cognitive and affective factors on pain [28]. Current research is particularly 
focused on DNIC. In human studies DNIC is investigated using a conditioned pain 
modulation (CPM) paradigm. DNIC is intact when a painful conditioning stimulus 
inhibits pain in a remote area [48,80]. However, DNIC functioning is impaired in 
groups of patients with chronic pain of different causes, such as idiopathic pain 
syndromes, and worse DNIC functioning can be predictive for postoperative pain 
[66,79]. Deficient DNIC has also been related to central sensitization [28]. More-
over, it has been shown that DNIC functioning can be restored after effective treat-
ment of pain in patients with chronic pain [35].
Although less is known about the role of sensory factors in itch, there is 
some evidence that central and peripheral sensitization mechanisms also play a 
role in the increased sensitivity to itch of patients with chronic itch [27,30-32]. 
Earlier studies investigating the modulation of itch mainly focused on the inhibi-
tion of itch by painful stimuli, with distally applied noxious counter-stimuli (e.g., 
scratching, electrical stimulation, heat, and cold) causing activation of mechani-
cally sensitive polymodal C- and Aδ-fibers [17]. The mechanism underlying the 
descending inhibition of itch by painful stimulation is thought to be comparable 
to the descending inhibition of pain at the level of the spinal cord [17]. However, 
endogenous modulation of itch by itch stimuli has not yet been investigated.
General IntroductIon 
15
1
Taken together, in line with the proposed psychophysiological model of 
itch and pain, sensory factors, such as altered sensitivity and sensitization pro-
cesses, are thought to play a key role in the maintenance and aggravation of itch 
and interact with cognitive-evaluative, affective-motivational, and behavioral fac-
tors in modulating itch and pain. However, the role of sensory factors, such as 
altered sensitivity and endogenous modulation, in itch has not yet been systemati-
cally investigated, and in particular not in comparison to their role in pain.
Cognitive-evaluative factors
Cognitive factors, such as attention, expectations, and appraisal, partly 
determine the meaning an individual ascribes to physical sensations and how he 
or she experiences these sensations. Several models have been developed to ex-
plain the perception of symptoms in terms of cognitive factors [25,36,40,43,60,73]. 
In these models a key component of the amplification of physical sensations, such 
as pain, is hypervigilance, or heightened attention for bodily sensations. Both spe-
cific hypervigilance for threat-related (pain-specific) stimuli and general hypervigi-
lance may increase the sensitivity to pain, with individuals tending to focus on 
a variety of (previously irrelevant) stimuli associated with pain [73]. In addition, 
there is a large amount of evidence that a person’s expectations about physical 
sensations, for example, catastrophizing thoughts or expectations of an increase 
or decrease in symptoms, play an important role in the perception of many symp-
toms, including pain [33,46,62]. The role of expectations in sensation perception is 
also evident from the placebo effect, which can, based on an expected decrease 
in symptoms, be effective in reducing a wide variety of symptoms [6], while the 
nocebo effect, which is based on an expected worsening of symptoms can result 
in an increase in symptoms [7]. 
The role of cognitive factors in the sensitivity to itch has not yet been 
extensively investigated. Verhoeven and colleagues reviewed the possible influ-
ence of cognitive evaluation on itch and found that more perceived helplessness 
and worrying were associated with higher levels of itch, similar to what is known 
from chronic pain [67]. Furthermore, parallel to the selective cognitive processing 
of pain signals seen in patients with chronic pain [52], there is some evidence for 
the role of attentional factors in itch [67]. For example, patients with psoriasis are 
more focused on stimuli associated with itch, e.g., itch and disease-related words, 
than are healthy subjects [23]. There is also some evidence that negative expecta-
tions and catastrophizing influence itch [57,67,72]. Indirect evidence, for example, 
comes from a study showing that the frequency of scratching of an uninformed 
audience was higher when listening to a lecture about itch than when listening to 
a neutral lecture [45]. In addition, expectations of worsening of skin reactions and 
itch were associated with an increased sensitivity to itch in patients with atopic 
dermatitis or psoriasis [57,72]. In addition, worrying has been shown to contribute 
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to changes in itch and disease severity over time in patients with psoriasis [71] and 
to predict the outcome of UVB therapy [24].
The above-mentioned studies support the notion that cognitive factors, 
particularly focusing attention on bodily sensations or negative expectations re-
garding somatosensory sensations, may be involved in the sensitivity to itch in a 
similar way as in the sensitivity to pain. In line with the proposed psychophysiolo-
gical model of itch and pain, these cognitive factors are also thought to interact 
with sensory, affective-motivational, and behavioral factors to influence itch and 
pain. However, the role of these cognitive factors in itch has not yet been system-
atically investigated, and in particular not in comparison to their role in pain. 
Affective-motivational factors
The pain sensation itself is considered to be a sensory as well as an emo-
tional experience and, consequently, affective-motivational factors interact with 
pain [11]. Different models of the development and maintenance of chronic pain 
emphasize the affective domain of pain, which mainly incorporates negative emo-
tions as a consequence of the burden of pain [25,43]. It is further assumed that 
there is a reciprocal relationship between pain and negative emotions. Symptoms 
of psychological distress, such as anxiety and depressive symptoms, are associ-
ated with an increased sensitivity to acute and chronic pain [12,16,41,73]. Similar 
patterns have been described to be involved in dermatological problems, and as-
sociated symptoms of itch [60]. For example, in the diathesis-stress model, psy-
chological distress influences the onset and exacerbation of dermatological con-
ditions [60]. 
When experimentally studying the influence of emotions on somatosen-
sory sensations, such as pain, negative emotions seem to be associated with 
increased sensitivity to pain, whereas positive emotions are associated with re-
duced pain perception, both in patients with chronic pain and in healthy sub-
jects [49-51,63,75,76]. Such a relationship has not yet been demonstrated for itch, 
although experimental and prospective studies have shown that psychological 
distress can have an itch-enhancing effect in both healthy subjects and patients 
with chronic skin disease [3,13,22,60,68]. 
Comparable to the role of affective factors in pain sensitivity, negative and 
positive emotions could also influence the sensitivity to itch. In line with the proposed 
psychophysiological model of itch and pain, affective factors are further thought to 
interact with sensory, cognitive-evaluative, and behavioral factors to modulate itch 
and pain. However, the role of affective factors in itch has not yet been investigated 
systematically, and in particular not in comparison to their role in pain.
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Behavioral responses to itch and pain
The behavioral response to acute pain primarily consists of retreat from 
the causative agent. Psychological factors, such as attention to pain and fear of 
pain, can exacerbate this retreat response and promote inactivity and avoidance 
behavior [73]. Patterns of avoidance behavior play a prominent role in chronic pain 
as these may lead to increased pain over time [9,25,73]. That there is a behavioral 
component to itch is implied by its definition: itch is defined as an unpleasant 
sensation of the skin leading to the desire to scratch [54]. The behavioral response 
to acute itch (see also figure 1) is to remove or avoid itch-inducing stimuli, for ex-
ample, by scratching. Although rubbing or scratching can reduce itch, by remov-
ing the causative agent, patients with chronic itch due to skin disease can persist 
in their scratching behavior [59,60,67]. As scratching may damage the skin, and 
healing of skin causes itch, uncontrollable scratching may result in a vicious itch-
scratch cycle. This itch-scratch cycle may also be amplified by psychological, 
cognitive, and affective factors, such as negative mood and worrying. Persistent 
itch may, similarly to pain, lead to avoidance behavior, such as resting and retreat-
ing from environmental stimuli or activities that may induce itch, which can ulti-
mately lead to impaired functioning [59,60,67,72]. 
Thus, although the goal of both acute itch and pain is similarly aimed at 
avoiding or escaping from these sensations, the response patterns to acute itch 
and pain diverge, as indicated by scratching responses to acute itch versus with-
drawal responses to acute pain [72]. The physiological correlates of behavioral 
responses to acute itch and pain may also be different. For example, brain imag-
ing studies have shown that, in contrast to pain, itch is specifically associated with 
predominant activation of ipsilateral motor areas and brain areas involved in moti-
vational processes (e.g., orbitofrontal regions) that have been linked to the desire 
and planning to scratch [32,39]. In the long term, common behavioral responses 
might play a role for chronic itch and pain, in that persistent avoidance behavior 
might lead to avoidance of daily activities and inactivity, which might result in a 
reduced quality of life and increased levels of itch or pain [25,67,72,73].
Although several studies have focused on the behavioral responses to itch 
and pain as target for treatment [19,20,32,47,74], the mechanisms by which these 
behavioral responses are influenced, for example, by different sensory, cognitive, 
and affective factors, should be further elucidated. 
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Personality and disease characteristics 
Sensory, cognitive, affective, and behavioral factors are also influenced 
by individual factors that modulate itch and pain. Thus, in patients with chronic 
itch and pain, condition-specific factors, such as disease duration, disease se-
verity, and current levels of itch and pain, might influence how itch and pain are 
perceived [e.g., 1,69]. Personality characteristics, such as neuroticism and anxiety 
sensitivity, can also influence both the perception of itch and pain, and the related 
sensory, cognitive, affective, and behavioral factors [4,34,61,67,84]. For example, 
neuroticism has been associated with the burden of pain in patients with chronic 
pain [e.g., 21,26] and with increased itch perception in patients with chronic itch 
[67]. Moreover, anxiety sensitivity has been associated with increased attentional 
focusing, which may lead to enhanced pain perception [34,64]. However, the role 
of these factors has not yet systematically been investigated in itch. As sensitivity 
to itch and pain might also vary as a function of demographic variables, such as 
age, gender, educational level, body mass index, and menopausal status, it is also 
important to take these factors into consideration. The role of sensory, cognitive, 
and affective factors in the perception of itch and pain cannot be investigated 
without taking individual factors, such as personality and disease characteristics, 
into account. 
Focus and outline of the thesis
The reviewed literature suggests that different psychophysiological fac-
tors associated with the etiology, maintenance, and aggravation of pain may also 
be relevant to itch. Comparison of itch with pain might provide new insights into 
specific and generic mechanisms underlying these symptoms and the increased 
sensitivity to different somatosensory sensations. Moreover, the fact that both 
acute itch and pain are nociceptive signals that protect the individual from poten-
tial harm via autonomic and homeostatic reactions further supports the similarity 
of these sensations [15,43]. From the pain literature, it is known that sensory fac-
tors (such as sensitization and pain modulation), cognitive factors (such as atten-
tional focus and negative expectations), affective factors (such as negative and 
positive emotions), and behavioral factors can influence the perception of pain. As 
mentioned above, itch and pain are likely to have corresponding sensory, cogni-
tive, and affective factors, whereas the associated acute behavioral responses are 
more divergent. For this reason, the studies of this thesis focused on the role of 
sensory, cognitive, and affective factors in the perception of itch and pain. To this 
end, quantitative sensory testing was used to induce both itch and pain within one 
design. We hypothesized that different sensory, cognitive, and affective factors, 
which have been described to play a role in altering the perception of pain, may 
similarly affect the perception of itch. Comparison of the mechanisms underlying 
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different somatosensory sensations might reveal specific and generic factors that 
play a role in the altered sensitivity to different somatosensory sensations. 
The studies reported in this thesis were designed to investigate the ba-
sic psychophysiological mechanisms by studying different sensory, cognitive, 
and affective factors influencing the sensitivity to itch, in comparison to pain. The 
studies take into account the influence of various individual personality, condition-
specific, and demographic characteristics in patients with chronic itch or pain, 
and/or healthy subjects. Part I of this thesis investigated sensory factors. To this 
end, studies assessed both generalized and symptom-specific sensitivity to so-
matosensory stimuli that evoke itch and pain in patients with chronic itch or pain 
(Chapters 2 and 4), and investigated central modulation processes of itch and pain 
in healthy subjects and patients with chronic itch or pain (Chapters 3 and 4). Part 
II focused on cognitive factors. The study described in Chapter 5 investigated the 
effect of positive and negative expectations, i.e., placebo and nocebo effects, on 
the perception of itch and pain in healthy subjects, and the study described in 
Chapter 6 investigated whether attentional focusing affects the sensitivity to itch 
and pain in healthy subjects. Part III focused on affective factors, particularly the 
role of inducing negative or positive emotions on the perception of itch and pain 
by healthy subjects (Chapter 7). Chapter 8 and Chapter 9 provide a summary and 
an integrative discussion of the results described in the different studies in this 
thesis, including some limitations of the studies and directions for future research 
and clinical practice. 
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Abstract
Physicians are frequently confronted with patients reporting severe itch 
and pain. Particularly in patients suffering from persistent itch and pain, central 
and peripheral sensitization processes are assumed to be involved in the long-
term maintenance and aggravation of the symptoms. The present study explores 
generalized and symptom-specific sensitization processes in patients suffer-
ing from persistent itch and pain. Specifically, it examines whether patients with 
chronic itch and pain are more sensitive to somatosensory stimuli (generalized 
sensitization) and simultaneously perceive somatosensory stimuli as a symptom 
of their main physical complaint, e.g., pain in chronic pain patients (symptom-
specific sensitization). Thresholds for different mechanical and electrical sensory 
stimuli of Quantitative Sensory Testing were determined in 15 female patients suf-
fering from chronic itch associated with atopic dermatitis, 15 female chronic pain 
patients diagnosed with fibromyalgia, and 19 female healthy controls. Intensities 
of itch and pain sensations were rated on a visual analogue scale. As expected, 
the patient groups had significantly lower tolerance thresholds for the somatosen-
sory stimuli applied than the healthy controls, supporting generalized sensitiza-
tion. Moreover, patients with chronic itch consistently reported more itch, while 
patients with chronic pain partly reported more pain in response to analogous 
somatosensory stimuli than the healthy controls and the other patient group, in-
dicating symptom-specific sensitization. The present study provides preliminary 
support that both generalized and symptom-specific sensitization processes play 
a role in the regulation and processing of somatosensory stimulation of patients 
with chronic itch and pain.
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Introduction 
Physicians are frequently confronted with patients with high symptom re-
ports that lack a clear pathophysiological etiology, driving up healthcare costs due 
to lengthy diagnostic procedures and ineffective treatment. Central and peripheral 
sensitization (i.e., enhanced sensory sensitivity) has been proposed as one of the 
mechanisms responsible for these high symptom reports. Particularly in patients 
suffering from chronic physical symptoms such as persistent itch and pain, sensi-
tization processes are assumed to be involved in the long-term maintenance and 
aggravation of the symptoms. 
Consistent with basic psychophysiological theories on the regulation and 
processing of somatosensory and affective stimuli, two processes are distin-
guished with respect to physical sensations: the tendency of an individual to react 
with various degrees of intensity and the tendency to ascribe a specific quality to 
the sensation [10,25,28]. The first tendency concerns the quantification of sensa-
tions and solely regards intensity independently of the type of sensation. The sec-
ond is a qualitative interpretation that labels the sensations primarily based on their 
incorporation into contextual information. Sensations are perceived in a specific 
sensory modality, a classification parameter according to which the brain habitu-
ally organizes information. New input of sensory information matching the modal-
ity has a higher probability of being processed than information from a mismatch-
ing modality. Consequently, both processes might be involved in sensitization and 
altered in patients with chronic physical complaints, resulting in generalized sen-
sitization - a tendency to experience an overall lowered threshold to somatosen-
sory stimuli; and symptom-specific sensitization - a tendency to perceive sensory 
stimuli in correspondence with the main physical symptom. Patients with chronic 
itch or pain may hence be more sensitive to all kinds of somatosensory stimuli 
than healthy individuals and may tend to perceive sensory stimuli in terms of their 
primary symptom, e.g., pain in chronic pain (CP) patients [7,10,20,25,28,29,34].
There is a longstanding history of research into sensitization processes in 
CP patients, mainly focused on either generalized or symptom-specific sensitiza-
tion processes. Quantitative sensory testing (QST) is a validated and frequently 
applied assessment method for sensitization with various sensory stimulus moda-
lities [6,19,31,35,36]. Numerous QST studies have shown that patients with chro-
nic pain, including patients with fibromyalgia or rheumatoid arthritis, have lowered 
tolerance thresholds and an altered sensation perception in comparison to healthy 
controls, suggesting generalized sensitization [1,16-18,21,23,32]. There is also 
some preliminary support for symptom-specific sensitization in CP: when asked 
to describe the quality of a mechanical stimulus, patients with fibromyalgia used 
more pain-related descriptors for the stimulus than healthy controls [4]. In addi-
tion, histamine iontophoresis resulted in burning pain instead of itch in patients 
with neuropathic pain [2,5].
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Less attention has been directed to sensitization processes in chronic itch 
(CI) sufferers, although itch and pain bear many similarities [33]. Despite specific 
neurophysiological differences, both use the lateral spinothalamic tract, in two sep-
arate, centrally located systems, and the pattern of brain activation shows a broad 
overlap [13,38]. Furthermore, both concern adverse body conditions that generate 
reflexive autonomic and motor responses under central control [9,33]. Ikoma and 
colleagues have recently delivered evidence for symptom-specific sensitization in 
CI patients [21,22]. They showed that by varying the electrical stimulus intensity, 
QST could induce both pain and itch and that CI patients experienced itch to a 
stimulus healthy subjects experienced as pain. Consequently, the QST paradigm 
seems to allow the investigation of both generalized and symptom-specific sensi-
tization processes in both populations of chronic itch and pain. However, to date, 
comparative research examining the two sensitization processes in patient groups 
with different physical symptoms is lacking. 
With the present study, both sensitization processes were explored in pa-
tients suffering from chronic pain and itch. We hypothesized that in reaction to a 
somatosensory stimulus, the patients with CP and CI would show an overall lower 
tolerance threshold than the controls consistent with the hypothesis of general-
ized sensitization. Following the symptom-specific sensitization hypothesis, we 
expected the CP patients to report more pain and the CI patients more itch in 
response to the same stimuli relative to the other patient group and the controls. 
Methods
Participants
Fifteen female CP patients (mean age = 44.5, SD = 7.9) diagnosed with fi-
bromyalgia by a rheumatologist (American College of Rheumatology criteria, Wolfe 
et al. [37]) and 15 female CI patients (mean age = 33.2, SD = 12.5) diagnosed with 
atopic dermatitis by a dermatologist were recruited from two hospitals in the Neth-
erlands. Mean symptom duration for the CP and CI patients was 13.7 years (SD = 
9.0) and 23.0 years (SD = 13.2), respectively. Inclusion criteria were a minimum age 
of 18 years and a diagnosis of either fibromyalgia or atopic dermatitis. Exclusion 
criteria were comorbid conditions (e.g., multiple sclerosis, diabetes mellitus and 
arthritis psoriatica), double diagnoses with regard to the conditions investigated, 
severe psychiatric disorders and pacemaker use. In addition, 19 healthy female 
controls (mean age = 43.3, SD = 12.1) were recruited via advertisements.
The protocol was approved by the regional medical ethics committee and 
all participants gave their informed consent prior to the investigation. Upon ar-
rival to the test facility, participants were informed about the procedure and asked 
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about their menstruation cycle, cigarette smoking and intake of medication, caf-
feine and alcohol over the previous 24 h. Participants had earlier been asked not 
to alter their regular medication usage on the day of testing. Five CP patients and 
eight CI patients had not taken any medication at the time of testing. Two CP 
patients and two CI patients took selective serotonin reuptake inhibitor/serotonin-
norepinephrine reuptake inhibitor antidepressants, one CP patient took cortico-
steroids, seven CP patients and one CI patient took (combinations of) non-steroi-
dal anti-inflammatory drugs (NSAID). Five of the CI patients took antihistaminics 
(of whom one patient took a combination with antidepressants) and one healthy 
control took beta blockers as treatment for high blood pressure. In the CI patients, 
the severity and extent of the skin disease was measured using a validated skin 
severity scale [14], showing that all patients had at least one body area affected 
by the skin disease and that 73% of the patients had at least one body area that 
was severely affected. In addition, the baseline degree of itch and pain of all par-
ticipants was determined before the start of the experiment by having the patients 
indicate the current level of itch and pain on a visual analog scale (VAS) ranging 
from 0 to 10. As expected, the CI patients reported a significantly higher baseline 
level of itch (M = 3.0, SD = 1.9) than the controls (M = 0.7, SD = 1.1) (t = 4.27, P < 
0.001) and the CP patients (M = 0.6, SD = 0.8) (t = -4.56, P < 0.001), while patients 
with CP reported significantly more pain (M = 5.4, SD = 2.0) than the patients with 
CI (M = 0.8, SD = 0.9) (t = 8.13, P < 0.001) and the controls (M = 1.0, SD = 1.5) (t 
= 7.48, P < 0.001). No significant differences were found for the itch level between 
the CP patients and the controls (t = -0.19, P = 0.85) nor for the baseline pain level 
between the CI patients and the controls (t = -0.45, P = 0.66). 
General procedure
The QST was performed using von Frey filaments for mechanical stimu-
lation as well as electrical stimulation [1,8,16,21,32]. All tests were administered 
by the same investigator in the same order. On the test day the subjects were 
informed about the tests and familiarized with the procedure in a pretest trial. 
They were told that the stimuli could provoke different sensations, for example, 
itch and pain. After each stimulus, they were asked to rate down their sensa-
tion using a 10-point VAS for both itch and pain ranging from no itch/pain to the 
worst itch/pain imaginable. Measurements were made at two sites: 2 cm distal 
to the epicondyle of the humerus on the non-dominant forearm (corresponding 
to dermatome C5) and at the midpoint of upper trapezius on the dominant side 
(corresponding to dermatome C4). The first area is a tender point in fibromyalgia 
and a frequently affected site in patients with atopic dermatitis, while the latter is 
not a tender point and only infrequently affected in patients with atopic dermatitis 
[26,37]. In the present study, 12 of the CI patients had lesions on the target site at 
the forearm and three at the trapezius.
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Mechanical stimulation
At both sites mechanical stimuli were delivered using 20 Semmes-Wein-
stein von Frey calibrated filaments in the range in the range of 0.0045 to 447.0 g 
[3]. The filaments were applied vertically once, with increasing force and avoiding 
contact with body hair. Subjects were asked to report the Aδ-fiber threshold, de-
fined as “the moment that the stimulus perception changed into an unpleasant, 
stinging sensation” (specified by the hair number out of a total of 20 hairs).
Electrical stimulation
Cutaneous electrodes (4 x 3.5 cm, 3M Red Dot) were applied at both body 
sites. The electrical stimuli consisted of 0.3-ms pulses with a 100-Hz frequency 
with a continuous increasing intensity of 0.2 mA/s, delivered by a nerve stimula-
tor (Pajunk, Germany). Stimulus intensity was increased at a rate with a maximum 
of 25 mA [30]. After a pretest trial at the trapezius, tolerance measurements were 
started at the forearm. The electrical tolerance threshold was defined as “the mo-
ment that the subject did not wish to experience a higher intensity and wanted to 
stop”. The means of two repeated thresholds (three in those cases where both 
values differed more than 0.5 mA) were defined. Interstimulus time was set at at 
least 30 s [22]. 
Statistical analysis
The reported threshold intensities and VAS ratings for itch and pain were 
analyzed with one-tailed analyses of variance (ANOVA) using SPSS 13.0 for Win-
dows. Between-group differences were taken as the independent variable. To test 
the hypothesis of generalized sensitization, the healthy controls were compared to 
the merged CP/CI patients group. To evaluate symptom-specific sensitization, the 
patient group matching the modality of the stimulus under investigation (e.g., pain 
in CP) was compared to the merged group of the controls and the other patient 
group that thus mismatched the modality of the stimulus tested (e.g., pain in CI). 
The dependent variables were the threshold values for generalized sensitization 
and the patients’ itch and pain VAS ratings for symptom-specific sensitization. 
Post-hoc testing included a pairwise multiple comparison test of the least signifi-
cant difference (LSD) with statistical significance set at P < 0.05. 
The same procedure was applied with the repeated measures analyses 
of covariance (ANCOVA) with the control variables age, educational level, meno-
pausal status, disease duration, smoking and current medication intake for pa-
tients with CP and CI as well as VAS pain and itch at the day of testing. Meno-
pausal status was found to be a significant covariate in three, disease duration in 
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one and medication use in two of the 12 ANCOVAS. However, when the results 
were corrected for these variables by ANCOVA, no significant differences emerged 
with regard to the main effects. Consequently, the results reported are based on 
the ANOVAS only.
Results
 Mechanical stimulation
Table 1 summarizes the means and standard deviations and ANOVA re-
sults for the QST thresholds and the pain and itch ratings. As to generalized sen-
sitization, the patients reported lowered thresholds for mechanical stimulation at 
both the forearm and the trapezius [F(1,48) = 6.75, P < 0.05; F(1,48) = 30.92, P < 
0.001, respectively] relative to controls. Regarding symptom-specific sensitization, 
the CI patients reported more itch than the other two groups at both sites [forearm: 
F(1,48) = 10.62 P < 0.05; trapezius: F(1,48) = 23.90, P < 0.001]. In contrast, the 
CP patients reported more pain at the trapezius than the other groups [F(1,48) = 
9.26, P < 0.05]. Only at the forearm this result was not significant for pain [F(1,48) 
= 0.95, P = 0.25].
Electrical stimulation
With regard to generalized sensitization, the CI and CP patients reported 
lower electrical tolerance thresholds than the controls both at the forearm [F(1,48) 
= 11.79 P < 0.01] and at the trapezius [F(1,48) = 6.21, P < 0.05]. With respect to 
symptom-specific sensitization, the patients with CI reported significantly more in-
tense itching sensations at both sites than the other two groups [forearm: F(1,48) = 
8.76 P < 0.05; trapezius: F(1,48) = 17.64 P < 0.001], while the patients with CP re-
ported significantly more pain in the forearm in comparison with the other groups 
[F(1,48) = 10.58, P < 0.05]. Only at the trapezius was this result not significant for 
pain [F(1,48) = 0.03, P = 0.45] (see Table 1). 
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Table 1
Analysis of variance results of quantitative sensory testing at the forearm and the 
upper trapezius of patients with chronic itch (CI), chronic pain (CP) and healthy 
controls (HC). 
CP (n = 15) CI (n = 15) HC (n = 19) F Post hoc
Tactile stimulation M (SD) M (SD) M (SD)
Forearm Threshold 13.13 (5.76) 13.20 (5.36) 16.00 (4.91)   6.75* HC>CI,CP
 VAS itching   1.31 (1.69)   2.21 (2.10)   0.85 (1.07) 10.62* CI>HC,CP
 VAS pain   1.23 (1.44)   1.08 (2.11)   0.87 (0.94)   0.95  
Trapezius Threshold 11.27 (5.81) 11.87 (3.44) 16.79 (4.24) 30.92*** HC>CI,CP
 VAS itching   1.63 (1.51)   2.91 (2.85)   0.32 (0.61) 23.90*** CI>HC,CP
 VAS pain   2.00 (2.48)   1.40 (1.35)   0.68 (0.93)   9.26* CP>HC,CI
Electrical stimulation
Forearm Threshold 4.07 (2.51) 3.72 (1.59) 7.34 (7.36) 11.79** HC>CI,CP
VAS itching 0.89 (1.09) 2.48 (2.56) 1.60 (1.61)   8.76* CI>HC,CP 
  VAS pain 2.30 (1.09) 1.56 (1.20) 1.40 (1.52) 10.58* CP>HC,CI
Trapezius Threshold 6.74 (6.64) 5.25 (2.48) 8.08 (4.51)   6.21* HC>CI,CP
 VAS itching 0.95 (1.27) 3.31 (3.30) 1.59 (1.59) 17.64*** CI>HC,CP
 VAS pain 3.21 (2.30) 3.21 (2.74) 3.04 (1.86)   0.03  
* P = 0.05; ** P = 0.01; *** P = 0.001; one-tailed; bold values indicate significant differences between 
groups for thresholds (HC vs. CP and CI), VAS itch (CI vs. CP and HC) and VAS pain (CP vs. CI and 
HC).
Discussion
The results of the current study suggest that both generalized and symp-
tom-specific sensitization processes are implicated in the symptom regulation of 
the two patient samples suffering from chronic physical complaints. In line with our 
expectations regarding generalized sensitization, patients with chronic pain (CP) 
and itch (CI) have lower thresholds for the applied somatosensory stimuli than the 
healthy controls. At the same time, we found indications for symptom-specific sen-
sitization as the CI patients report more intense itching and the CP patients partly 
more intense pain sensations in response to similar stimuli than the other patient 
group and the healthy controls.
With regard to generalized sensitization, our findings underpin earlier stud-
ies that showed patients with CP and CI to have lower electrical tolerance thresholds 
than healthy controls [1,27]. With our paradigm we also demonstrate correspond-
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ing effects in response to mechanical stimulation. More importantly, as both our 
patient groups proved to have lowered tolerance thresholds for electrical as well as 
mechanical stimulation relative to the healthy controls, it is likely that corresponding 
generalized sensitization mechanisms play a role in the regulation and processing 
of somatosensory stimulation of patients with different chronic physical symptoms. 
Our results thus seem to support the assumption of a common sensitization process 
in a wide range of chronic complaints, including sensitization processes of adverse 
bodily conditions that are under central and peripheral control [9,15,33,34].
The current study has also provided preliminary support for symptom-spe-
cific sensitization in the two patient populations investigated: the CI patients re-
ported higher levels of itching following all four somatosensory stimuli and the CP 
sample reported more intense pain for two of the four stimuli. These findings are 
relatively consistent with earlier studies, e.g., Berglund and her colleagues found 
that mechanical stimulation was perceived with more pain-related descriptors in 
fibromyalgia patients than in healthy controls [4]. Ikoma and colleagues [21] demon-
strated that in CI patients with atopic dermatitis mechanical and electrical stimula-
tion evoked itchy sensations, in contrast to the painful sensations reported by the 
healthy subjects. By comparing patients with two different chronic symptoms with 
the same paradigm, preliminary support for the symptom-specific sensitization was 
for the first time found in patients with different physical symptoms; demonstrating 
that a patient’s sensation report to somatosensory stimuli tend to be in accordance 
with his or her main physical complaint. 
Taken together, the study results deliver preliminary support for altered sen-
sitization processes in patients with chronic pain and itch, suggesting that these 
patients are more sensitive to somatosensory stimuli in terms of a lowered sensory 
tolerance threshold, i.e., generalized sensitization, and largely tend to perceive the 
same somatosensory stimulus as a symptom of their main physical complaint, i.e., 
symptom-specific sensitization. 
Several limitations need to be taken into account. First, although the stim-
uli in our study were mostly experienced according to the patient’s main physical 
symptom within its matching sensory modality, suggesting that the applied stimuli 
were ambiguous and interpretable in different ways, the symptom-specific pain ra-
tings in the CP patients were not as clear as the itch reports in the CI patients. In 
future research, it might be important to vary the stimulus intensity, duration and 
sensory modality as well as to study the responses to other stimuli (e.g., cold, warm, 
acoustic) [22]. Second, alternative explanations for the symptom-specific sensitiza-
tion processes have to be taken into account. For example, it has been suggested 
that central sensitization of itch pathways might upset the regular mechanism that 
pain inhibits itch in CI patients [33]. Third, although we observed corresponding 
effects for both the lesioned (forearm) and non-lesioned (trapezius) sites in most 
patients and the level of baseline daily itch and pain proved not to have affected 
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our results, a generally non-affected body site is to be preferred [21]. Additional 
measurements of erythema and flare reactions should also be carried out to obtain 
more insight into the basis of central and peripheral (e.g., nerve growth factor, C-
fiber damage and sensitization of neuroreceptors) sensitization processes [21,22]. 
Fourth, there is some evidence that sensitization processes appear to differ de-
pending on the pathophysiological etiology for the patients’ symptoms [27], which 
makes it worthwhile to compare groups with different pathophysiological origins of 
their symptoms (e.g., fibromyalgia and rheumatoid arthritis). Fifth, although the use 
of pain- or itch-relieving medication generally did not affect the main results, future 
studies should address the issue of possible (side) effects of specific medication 
(e.g., corticosteroids, selective serotonin reuptake inhibitors) on psychophysiologi-
cal responses. The same was the case for our analyses of menopausal status, and 
possible influences of this and other hormonal factors (e.g., phase of the menstrual 
cycle) as well as gender differences should be taken into account in future studies 
[24]. Finally, specific affective, cognitive and central processes, such as negative af-
fectivity, cognitive expectations and central processing of sensory information, have 
been put forward as factors affecting both sensitization phenomena [7,11,12,29]. 
For example, negative affectivity have been shown to impinge on the conditioning 
processes of symptoms in patients with chronic physical complaints, possibly due 
to their attentional bias toward internal sensations, catastrophizing expectations 
towards aversive stimuli or interpretation bias to attribute ambiguous symptoms 
to their main symptom [34]. Further scrutiny of these mechanisms might provide 
deeper insights into the generalized and symptom-specific sensitization processes 
in patients suffering from chronic physical symptoms of pain and itch. On the long-
term, insight into these sensitization processes might contribute to improvements in 
diagnostics, such as the clinical use of QST to screen for patients at risk as early as 
possible, and the development of new desensitization treatments for patients with 
chronic pain and itch.
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Abstract
Pain can be endogenously modulated by heterotopic noxious conditioning 
stimulation (HNCS) through a mechanism which is known as diffuse noxious inhib-
itory control (DNIC). Since DNIC can be impaired in patients suffering from chronic 
pain, a comparable impaired itch inhibition may exist in patients suffering from 
chronic itch. The aim of the present study was to investigate whether heterotopic 
pruritic conditioning stimulation (HPCS) would display an impaired modulation of 
itch in patients suffering from chronic itch compared with healthy subjects. To this 
end, electrical stimuli were applied before and after histamine application (HPCS) 
to female patients with psoriasis and healthy female control subjects. Subjects 
reported the intensity of electrically evoked itch before and after HPCS. In order 
to replicate earlier findings for DNIC, electrically evoked pain was additionally in-
vestigated before and after cold stimulation (HNCS). As expected, the intensity 
of itch evoked by the electrical stimulus was significantly less after than before 
HPCS in healthy subjects, and the same was found for the intensity of electrically 
evoked pain after compared to before HNCS. Contrarily, in the patients levels of 
electrically evoked itch were significantly higher after than before HPCS, and no 
significant difference in pain intensity before and after HNCS was observed. In line 
with pain modulation, results suggest that there is a DNIC analogous mechanism 
for itch, i.e., diffuse pruritic inhibitory control (DPIC), which is impaired in patients 
with chronic itch, possibly due to a dysregulation of descending itch modulatory 
systems. 
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Introduction
Diffuse Noxious Inhibitory Controls (DNIC) have been proposed to play a 
major role in the modulation of pain, by which painful conditioning stimulation of 
one part of the body inhibits pain in a remote area [8,36,39]. When a spinal wide-
dynamic range neuron receives conditioning afferent nociceptive input from within 
its receptive field, DNIC strongly inhibits convergent spinal afferent nociceptive 
input outside the neuron’s receptive field via descending bulbo-spinal pathways. 
DNIC will thus reduce pain originating from any area outside the receptive field be-
ing stimulated by the conditioning stimulus [35,51,52]. However in patients suffer-
ing from chronic pain, dysregulation of the balance between descending inhibitory 
and facilitating pathways is supposed to play a main role in central sensitization 
processes. In particular, the descending control by DNIC mechanisms seems to 
be inefficient in these patients, as shown by the finding that heterotopic noxious 
conditioning stimulation (HNCS) in different patient groups suffering from chronic 
pain does not result in the modulation of experimentally induced pain [2,28-30,33]. 
For central sensitization processes in patients suffering from chronic itch, a similar 
dysfunction of inhibitory control mechanisms, i.e., Diffuse Pruritic Inhibitory Con-
trols (DPICs), may play a role in the maintenance and increase of chronic itch 
symptoms [19,21,22,47]. However, to our knowledge, inhibitory control mecha-
nisms for itch have not been investigated yet. In addition, cognitive-affective fac-
tors, such as attentional focus on bodily sensations or negative outcome expec-
tancies, measured by concepts such as negative affectivity, anxiety, worrying and 
catastrophizing, are known to play an important role in pain processing and may 
influence DNIC-like mechanisms [14-16,18,26,27,48]. 
The aim of the present study was to investigate whether itch can be cen-
trally modulated by the application of a pruritic stimulus to another location, i.e., 
by heterotopic pruritic conditioning stimulation (HPCS) in both healthy subjects 
and patients suffering from chronic itch. We also attempted to replicate earlier 
findings on pain modulation by DNIC in healthy subjects and investigated pain 
modulation in patients with chronic itch. A secondary goal was to explore the role 
of cognitive-affective factors, specifically attention to bodily sensations, anxiety 
sensitivity, worrying and neuroticism in the modulation of itch and pain by DNIC-
like mechanisms. 
Methods
Participants
Twenty-five female outpatients (mean age 47 years, range 20 – 75 years) 
of the Department of Dermatology of the Radboud University Nijmegen Medical 
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Centre diagnosed with psoriasis by a dermatologist and suffering from chronic 
itch due to psoriasis as well as thirty-one healthy female controls (mean age of 
52 years, range 19 – 71 years), recruited via advertisements, were included in this 
study. Exclusion criteria for both groups were comorbid conditions (e.g., multiple 
sclerosis, diabetes mellitus, rheumatoid arthritis, and fibromyalgia), severe psy-
chiatric disorders and pacemaker use. In addition, patients were excluded when 
their current levels of acute itch or pain at the start of the experiment were 1.0 or 
higher on a visual analogue scale (VAS) which ranged from 0 to 10 for reasons 
other than their skin disease. In this study, one patient was excluded because of 
pain due to headache on the day of testing (VAS pain 4.0). Healthy subjects were 
not included in the study if they suffered from chronic itch or pain complaints either 
currently or in the past. Healthy subjects were also excluded if they had acute itch 
or pain le-vels of 1.0 or higher (on a VAS ranging from 0 to 10) at the start of the 
experiment. In this study we excluded one healthy subject because of baseline 
pain levels of 5.0 on the day of testing. Mean disease duration of the patients was 
23 years (range 2 – 57 years). Seventy-six percent of the patients and 65% of the 
healthy controls had completed secondary education, and 24% of the patients 
and 35% of the controls had completed tertiary education. Seventy-two percent of 
the patients and 48% of the healthy controls were married or lived with a partner, 
and 20% of the patients and 35% of the controls used oral contraceptives. There 
were no significant differences between patients and healthy controls in age, edu-
cation level or proportion of subjects living with a partner. All participants were of 
Caucasian ethnicity.
The protocol was approved by the regional medical ethics committee and 
all participants gave their informed consent prior to investigation. Patients were 
asked not to alter their use of medication on the test day. On arrival at the test 
facility, participants were informed about the procedure and asked about their 
menstrual cycle, cigarette smoking, and intake of caffeine and alcohol over the 
previous 24 h. Participants had earlier been asked not to drink black tea or coffee 
1 h before testing. Subjects were asked about their use of (topical) medication 
over the previous 24 h. Ninety-two percent of the patients used topical creams or 
ointments, 79% of whom used corticosteroid creams. Ten patients had taken sys-
temic medication: 4 patients had taken medication for the treatment of psoriasis 
[methotrexate (n = 3) and ciclosporin (n = 1)] and 5 patients used other medication 
[antihypertensives (n = 3), benzodiazepines (n = 1), thyroid hormones (n = 1), plate-
let aggregation inhibitors (n = 1), or selective serotonin reuptake inhibitors (SSRIs) 
(n = 1), alone or a combination of medication]. Of the healthy controls, 2 HC had 
taken systemic medication [antihypertensives (n = 2), or statins (n = 1)]. The sever-
ity and extent of the skin disease of the patients measured with the validated skin 
status scale of the impact of chronic skin disease on daily life (ISDL) showed that 
the severity of skin disease in our sample (M = 15.8, SD = 3.4) was representative 
of that of norm groups of psoriasis outpatients (M = 16.9, SD = 3.7) [11]. Patients 
also reported significantly higher levels of current baseline itch (M = 2.7, SD = 2.3) 
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and current baseline pain (M = 1.4, SD = 2.6) than the healthy controls (M = 0.2, 
SD = 0.4 and M = 0.2, SD = 0.4, respectively) at the start of the experiment, as 
assessed with a VAS ranging from 0 to 10 (t = 5.5, P < 0.001 for itch and t = 2.2, 
P < 0.05 for pain). Of the patients with psoriasis, 76% and 24% suffered from itch 
(ranging from 1 to 8) and pain (ranging from 3 to 8), respectively, on the day of 
testing due to their skin disease, which is comparable to norm groups of psoriasis 
outpatients [44,49].
General procedure
Self-report questionnaires were sent to the participants 1 week before 
the experiment. On the test day, the subjects were told about the procedure and 
familiarized with the stimuli in a pretest trial with the electrical thresholds. Sub-
jects were told that the stimuli could provoke any type of sensation, for example 
itch and pain. For each stimulus, participants were asked to rate their perceived 
sensation using a 10-point-VAS for both itch and pain ranging from no itch/pain 
(0) to the worst itch/pain imaginable (10). Sensitivity to itch and pain was mea-
sured by applying the same two single electrical test stimuli before and after both 
the pruritic and noxious conditioning stimuli which were applied contralaterally 
to the test stimuli. Stimuli were applied to unaffected body areas of the patients 
with psoriasis. We used iontophoretically applied histamine as pruritic condition-
ing stimulus and a cold pressor test as noxious conditioning stimulus. The same 
experimenter administered all stimuli. First, electrical thresholds were determined, 
and test stimulus intensities were calculated (see section Somatosensory stimuli 
– Electrical stimulation), and the first electrical test stimulus was applied 5 min-
utes later. After a 4-minute interval, histamine (HPCS) was applied, followed by a 
4-minute interval after which the second electrical test stimulus was applied. After 
a 20-minute break, the participants received again the first electrical test stimulus 
and 4 minutes later the cold pressor test was applied. After an interval of 4 min, 
the second electrical test stimulus was applied. 
Somatosensory stimuli
Electrical stimulation
Self-adhesive skin electrodes (3M Red Dot Monitoring Electrode 2560; 
surface 40 x 35 mm) were applied to the non-dominant forearm (2 cm distal to 
the lateral epicondyle of the humerus, C5 dermatome). A constant current nerve 
stimulator (MultiStim Vario, Pajunk, Geisingen, Germany) was used to deliver elec-
trical stimuli. These stimuli were applied as 0.3-ms pulses at a frequency of 100 
Hz to evoke itch [23]. First, electrical thresholds for perception, unpleasantness 
and tolerance were determined in a ramping paradigm by continuously increasing 
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the intensity by about 0.2 mA/s until the participant said the respective threshold 
had been reached (with an upper limit of 15 mA). The perception threshold was 
defined as “the moment that you experience a sensation for the first time”, the un-
pleasantness threshold was defined as “the moment that the sensation becomes 
unpleasant for the first time” and the tolerance threshold was defined as “the mo-
ment that the sensation becomes unbearable and you want to stop immediately”. 
The definitions of these thresholds were based on the definitions of the thresholds 
in pain literature [1,7], however without defining the nature of the sensation, i.e., 
by replacing painful by unpleasant or unbearable. The thresholds were determined 
twice using a ramping paradigm. Subsequently the mean current intensities of 
these thresholds were calculated which served as an indicator for the intensity 
of the short-lasting test stimuli. Definition of acceptable intensities for the test 
stimuli was based on two considerations. Firstly, previous studies [47,48] show-
ing that the levels of itch and pain evoked by ramping tolerance stimulation are 
low to moderate. Secondly, the fact that at identical current intensities, electrical 
test stimuli of short duration are generally perceived as less itching/painful than 
stimulation by ramping up to tolerance, probably because energy transmission 
of short-lasting stimuli is less than that of longer-lasting tolerance stimulation by 
ramping [25,42]. Taking these considerations into account, electrical test stimuli of 
3-s duration were applied, at 100-Hz frequency with 0.3-ms pulse length, at 300% 
of the intensity of the (ramping) unpleasantness threshold, with a maximum of 
150% of the (ramping) tolerance threshold and an upper cut-off limit of 15 mA for 
safety reasons. Our preparatory pilot study confirmed that electrical test stimuli at 
the chosen intensity were, firstly, adequate to induce itch and pain, but, secondly, 
that they were experienced as not inducing more than low to moderate mean itch 
and pain levels. 
Conditioning stimulation
Heterotopic pruritic conditioning stimulation (HPCS) by histamine ionto-
phoresis
Histamine was applied by iontophoresis (Chattanooga Group, Hixson, 
USA). Histamine dihydrochloride (0.5%) was dissolved in a gel of 2% methylcel-
lulose in distilled water and 2.5 ml was placed in an electrode (Chattanooga Ionto 
Ultra Electrode medium, Hixson, USA) applied to the dominant forearm, 2 cm dis-
tal to the lateral epicondyle of the humerus (C5 dermatome). The reference elec-
trode was applied to the skin of the lateral side of the triceps brachial muscle. The 
current was set at 0.4 mA and histamine was delivered for 2.5 minutes. Subjects 
were asked to rate itch levels every 30 s during application and 3 minutes after 
histamine application. 
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Heterotopic noxious conditioning stimulation (HNCS) by cold pressor 
Subjects were instructed to place their dominant hand in a tank of cold 
water at about 4°C (mean temperature 4.1°C, SD = 0.6) “for as long as possible, 
until the moment that the sensation becomes unbearable and you want to stop 
directly”. The participants were not aware of the maximum time limit of 3 minutes 
[6]. The immersion time was recorded and the level of pain during the test was 
asked at the moment the subjects withdrew their hands. In addition, levels of pain 
were assessed 3 minutes after immersion. 
Self-report questionnaires
All self-report questionnaires used in the present study have previously 
been shown to have satisfactory reliability and validity.
The Anxiety Sensitivity Index (ASI) was used to measure the subjects’ fear 
of bodily sensations that are interpreted as having potentially harmful, physical 
or psychological consequences. The ASI consists of 16 items, rated on a 5-point 
Likert scale (1 = very little, 2 = little, 3 = some, 4 = much, 5 = very much). The total 
score was obtained by summing the scores for the 16 items (range 0 – 64) [43]. 
Cronbach alpha for the ASI in the present study was 0.90 in healthy controls and 
0.89 in patients with psoriasis. 
Negative affectivity was measured with the neuroticism subscale of the Ey-
senck Personality Questionnaire (EPQ) [12]. Cronbach alpha in the present study 
was 0.89 in healthy controls and 0.85 in patients with psoriasis. 
Worrying was measured with the Penn State Worrying Questionnaire 
(PSWQ) [38]. The PSWQ is a 16-item self-report questionnaire that measures con-
cerns about worries, the extent to which one is bothered by worries, and the ex-
tent to which one is engaged in worries. Each item is rated on a 5-point scale (1 = 
not at all typical to 5 = very typical), and a total score was obtained by summing 
the items. Cronbach alpha for the PSWQ in the present study was 0.84 in healthy 
controls and 0.91 in patients with psoriasis. 
Attentional focus (i.e. the tendency to attend to internal bodily sensations) 
was measured with the Body Vigilance Scale (BVS) [45], which consists of four 
items, three of which assess the degree of attentional focus, perceived sensitivity 
to changes in bodily sensations, and the average amount of time spent attend-
ing to sensations. The fourth item contains 13 items concerning anxiety-related 
bodily sensations (heart palpitations, chest pain, numbness, tingling, shortness of 
breath, faintness, vision changes, dizziness, hot flash, sweating/clammy hands, 
upset stomach, nausea, choking/throat closing). Items were rated on a 10-point 
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VAS. The ratings for the bodily sensations of item 4 were averaged to obtain an 
overall score for item 4. The total score of the BVS is the sum of items 1 – 4. Cron-
bach alpha for the BVS in the present study was 0.85 in healthy subjects and 0.84 
in patients with psoriasis.
The severity of skin disease was measured with the skin status scale of 
the ISDL, which has previously been validated in patients with psoriasis [11]. Items 
were rated for different body parts (face, hairy scalp, neck, hands, arms, torso, 
legs, feet and genitals/anus) on a 4-point Likert scale (1 = not at all, 2 = to some 
extent, 3 = to a great extent, 4 = totally). The sum score reflects the overall severity 
of the skin condition [11]. At the day of testing, all participants were also asked to 
indicate the current levels of itch and pain at the start of the experiment as well 
as the itch and pain levels during the past two weeks on a VAS ranging from 0 (no 
itch/pain) to 10 (worst itch/pain imaginable).
Statistical analysis
All analyses were performed with SPSS 16.0 for Windows. Variables were 
checked for normal distribution. Slightly skewed distributions were only found for 
electrically evoked itch before and after HPCS. For these variables, square root 
transformation was performed that resulted in a normal distribution. As measures 
of DNIC and DPIC, change scores were calculated by subtracting the scores for 
electrically evoked itch and pain after HPCS and HNCS, respectively, from the 
scores obtained before HPCS and HNCS. Changes in itch and pain scores before 
and after applying the conditioning stimuli were analyzed in patients and healthy 
controls separately, using GLM repeated measures ANOVA. The within-subjects 
factors were electrically evoked itch/pain scores before and after itch/pain condi-
tioning stimulation. 
Pearson correlation coefficients were calculated between change scores 
for electrically evoked itch and pain, and the following variables: age, body mass 
index, educational level, menopausal status, itch and pain scores evoked by the 
conditioning stimuli (histamine and cold pressor, respectively), the cold pressor 
immersion time and individual characteristics (neuroticism, anxiety sensitivity, 
worrying and attentional focus on bodily sensations) for both patients and healthy 
controls, and the current skin disease severity and VAS itch and pain on the day 
of testing for the patients.
3
heterotopIc prurItIc condItIonInG and Itch - analoGous to dnIc In paIn?
50
Results
Conditioning stimuli and electrical test stimuli
Histamine evoked itch in 81% of the healthy controls and 88% of the 
patients, with mean itch scores of 2.5 (SD = 2.0) for healthy controls and 2.9 (SD 
= 2.5) for patients. The cold pressor test caused pain in 87% of the healthy con-
trols and 88% of the patients, with mean pain scores of 4.1 (SD = 2.9) for healthy 
controls and 4.1 (SD = 2.9) for patients. The mean cold pressor immersion time 
was 51.6 s (SD = 51.6) for healthy controls and was 51.4 s (SD = 60.8) for the 
patients. There were no significant between-group differences in intensity of itch 
and pain evoked by the conditioning stimuli or in the duration of cold pressor im-
mersion time for the patients or healthy controls except for a significant correla-
tion between a longer cold pressor immersion time and higher pain levels evoked 
by cold pressor immersion in the patients (r = 0.44, P < 0.05), but not in healthy 
controls. There were finally no significant correlations between the change scores 
for electrically evoked itch and pain and the cold pressor immersion time or the in-
tensity of itch and pain evoked by histamine and cold pressor conditioning stimuli, 
respectively (data not shown). 
HPCS and electrically evoked itch
In healthy controls, the repeated measures ANOVA results for analyzing 
the effectivity of itch modulation showed that the intensity of electrically evoked 
itch was significantly lower after than before histamine application (HPCS) [F(1,30) 
= 10.96, P = 0.002] (Figure 1). In contrast, the patients with psoriasis had signifi-
cantly higher levels of electrically evoked itch after than before histamine applica-
tion [F(1,24) = 5.28, P = 0.03]. Similar results were obtained when the data were 
analyzed only for those participants who reported itch elicited by histamine [F(1,24) 
= 7.72, P = 0.01 for healthy controls; F(1,21) = 4.61, P = 0.04 for patients].
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Figure 1 Electrically evoked itch before and after histamine application. Mean 
levels of itch evoked by electrical stimulation before and after application of HPCS 
(heterotopic pruritic conditioning stimulation) by means of a histamine application 
in both healthy controls (HC, n = 31) and patients with psoriasis (PSO, n = 25). 
* P < 0.05; ** P < 0.01; data are means ± S.E.M.
HNCS and electrically evoked pain
In healthy subjects, the repeated measures ANOVA results for analyzing 
the effectivity of pain modulation showed that the intensity of pain evoked by 
electrical stimulation was significantly lower after the cold pressor test (HNCS) 
than before [F(1,30) = 5.84, P = 0.02] (Figure 2). However, no such significant dif-
ference was found in the patients with psoriasis, [F(1,24) = 0.05, P = 0.83]. Similar 
results were obtained when the analysis was restricted to only those subjects who 
reported pain evoked by the cold pressor test [F(1,26) = 4.62, P = 0.04 for healthy 
subjects; F(1,21) = 0.05, P = 0.83 for patients]. 
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Figure 2 Electrically evoked pain before and after cold pressor application. Mean 
levels of pain evoked by electrical stimulation before and after application of HNCS 
(heterotopic noxious conditioning stimulation) by means of the cold pressor test in 
both healthy controls (HC, n = 31) and patients with psoriasis (PSO, n = 25). 
* P < 0.05; ** P < 0.01; data are means ± S.E.M.
Role of individual characteristics
The self-report measures of worrying, anxiety sensitivity, neuroticism, and 
degree of attentional focus on bodily sensations were not significantly correlated 
with change scores of electrically evoked itch and pain before and after HPCS and 
HNCS (data not shown). In addition, these change scores were not significantly 
associated with age, body mass index, educational level and menopausal status 
in patients and healthy controls, or the current intensity of itch or pain and disease 
severity of the patients with psoriasis.
Discussion
The present study adds to our knowledge of pain and itch inhibitory pro-
cesses in healthy subjects and patients with chronic itch. We investigated whether 
the application of heterotopic pruritic conditioning stimulation would alter levels of 
induced itch by central mechanisms, analogous to the modulation of pain by het-
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erotopic noxious conditioning stimulation via DNIC. DNIC is a descending endog-
enous pain-modulatory system activated by excitatory afferent signals from Aδ- or 
C-fibers, acting on all levels of the spinal cord via processes originating and con-
trolled supraspinally [35,39]. Itch modulation may be based on similar mechanisms 
involving multireceptive neurons with a “whole-body-receptive-field” [35,37]. Our 
findings show that in healthy subjects experimentally induced itch can be modu-
lated by a pruritic stimulus such as histamine by a mechanism analogous to DNIC, 
suggesting DPIC. As expected, HPCS did not result in decreased itch induced after 
conditioning in patients with psoriasis suffering from chronic itch. This is in line with 
earlier findings in chronic pain, showing that descending pain control mechanisms 
are dysregulated in these patients [2,29,30,33]. 
The conditioning stimuli applied in this study were appropriate pruritic and 
noxious conditioning stimuli since more than 80% of the subjects experienced itch 
with histamine application and pain with the cold pressor test. Studies have shown 
that the effectiveness of endogenous analgesia mediated by DNIC is independent 
of the conditioning stimulus location or modality, e.g., mechanical, electrical or 
chemical, as long as the conditioning stimulus is perceived as painful [18,40,41]. 
We found that both the pruritic and noxious stimuli were able to modulate experi-
mentally evoked itch and pain, respectively, in healthy controls, which shows that 
the conditioning stimuli were of sufficient intensity and duration [41]. Even healthy 
individuals who did not report itch (19%) or pain (13%) for the conditioning stimuli 
showed on average modulation responses (mean decrease 0.9 [SD = 1.3] for itch; 
0.8 [SD = 1.5] for pain), suggesting that itch and pain may be modulated even 
when the conditioning stimulation is not perceived as itching of painful. This is 
congruent with reports showing DNIC-like responses to conditioning stimulation 
not overtly experienced as painful [34,39]. Nevertheless, descriptive comparison 
suggested that the modulation responses were less when subjects did not experi-
ence the conditioning stimuli in the expected way. Future research should eluci-
date whether modulation is more effective when conditioning is overtly perceived 
as itch or pain. 
The lack of the itch and pain modulation in the patients with chronic itch 
suggests a role of central modulation of itch and pain in chronic physical symp-
toms. This is supported by earlier studies which showed that less efficacious DNIC 
was associated with chronic pain [10,39,53], while after surgical relief of pain DNIC 
responses returned to normal in patients with osteoarthritis [30]. Our results, and 
specifically the significant increase in itch in the patients with psoriasis after itch 
conditioning, might be indicative of symptom-specific sensitization and a dys-
regulated itch and pain modulation in patients with chronic itch. Future research is 
needed to gain more insight into the underlying mechanisms of sensitization and 
central modulation, for example, whether the ongoing chronic complaints induce 
dysregulation of DPIC and DNIC, or whether patients are more predisposed to less 
efficient DPIC and DNIC modulation mechanisms. 
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Regarding the quality of sensation perception, patients with chronic pain 
can perceive itch stimuli as painful [5] and patients with chronic itch can perceive 
pain stimuli as itchy [22], which are both in contrast to what is observed in healthy 
subjects. This difference in sensation perception may be related to a dysregulated 
itch and pain modulation in patients, possibly due to the long-term time course 
and widespread localization of symptoms. However, in the present study, mean 
levels of electrically evoked itch and pain did not significantly differ between these 
groups. Furthermore, as we did not compare patients suffering from chronic itch 
with patients suffering from chronic pain in the present study, we cannot conclude 
whether itch and pain modulation are sensation-specific or generic processes. 
With regard to the specific itch-pain interactions, it is well known that pain can 
inhibit itch [54], for example by scratching. One could thus expect that pain con-
ditioning (e.g., cold stimulation) might also have a central modulating effect on 
itch - in addition to its central pain modulating effects. Conversely, we would not 
expect itch conditioning to affect pain heterotopically, since pain has not been 
described to be inhibited by itch to date. Future research should elucidate whether 
DNIC and DPIC are separate processes or (partly) based on the same mechanisms 
and structures. 
The individual characteristics of negative affectivity, anxiety sensitivity, 
worrying and attentional focus on bodily sensations were not associated with itch 
and pain modulation. Previous studies also showed negative affectivity and state 
and trait anxiety not to be associated with the magnitude of DNIC [10,17,18]. In 
addition, while attentional focus might influence the experience of itch and pain 
[26,27,48], we found no correlation with the modulation responses. This finding 
is consistent with earlier findings showing that DNIC-like effects are not depen-
dent on attentional distraction [32]. However, as catastrophizing has recently been 
found to be associated with less effective DNIC [15,18], we expected worrying 
may also be related to DNIC or DPIC, since this cognitive strategy has been shown 
to play a prominent role in itch and pain [9,50]. Future research should further 
clarify the role of worrying and catastrophizing in itch and pain modulation in ex-
perimental and field settings. 
While our findings suggest that central inhibitory control mechanisms have 
a role in modulating itch by heterotopic pruritic stimulation, it is important to take 
some limitations and directions for future research into consideration. First, test 
stimuli were applied only once after conditioning stimulation, which meant that 
we could not study the temporal effects of itch and pain modulation. Second, 
although results of the HNCS in healthy subjects and patients with chronic itch 
were completely in line with the previous findings on DNIC in healthy subjects 
and patients with chronic pain, we cannot exclude that results with regard to the 
subsequent application of HNCS might be affected by the HPCS applied previ-
ously. Third, although we tailored the intensity of the electrical test stimuli based 
on the individual unpleasantness and tolerance thresholds in a ramping paradigm, 
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the absolute levels of itch and pain evoked by the short electrical test stimuli were 
still relatively low. Data from earlier studies [47,48] and our preparatory pilot study 
indicated that the electrical test stimuli applied are perceived as less itching/pain-
ful than ramping tolerance stimuli for identical current intensities. This is prob-
ably because energy transmission of short-lasting test stimuli is less than that of 
longer-lasting tolerance stimulation by ramping [25,42]. In future research, it might 
be preferable to apply test stimuli tailored to subjects’ subjective ratings for itch 
or pain, e.g., determined by a score of 6 of 10 for itch or pain [3,18]. Fourth, the 
patients’ levels of itch (and pain) on the day of testing as well as during the past 
two weeks were not related to the modulation responses, as might have been ex-
pected since worse DNIC responses have been related to more clinical pain [10]. 
However, itch levels on the day of testing or during the last two weeks may not 
be representative for disease related itch levels in general. Future research should 
determine clinical itch and pain over a longer period. Fifth, we studied women only, 
and so we cannot comment on the inhibitory control mechanisms of itch in men. 
Besides gender differences in sensitivity to clinical and experimental pain [13], 
there is inconsistent evidence about the role of gender in pain modulation, while 
some studies did not find any gender effect [4,31,40], others indicated that DNIC 
might be less effective in females [18,46]. Future research should investigate the 
role of gender differences in central itch modulation. Sixth, since itch perception 
can differ according to type of disease or evoking somatosensory stimuli, e.g., 
patients with atopic dermatitis have been shown to be generally less sensitive 
to histamine-induced itch [20,24], investigation of patient groups suffering from 
chronic itch other than psoriasis, would also provide further insight into itch modu-
lation mechanisms.
To conclude, we showed for the first time that, analogous to DNIC in pain, 
DPIC mechanisms modulate itch. The combination of histamine as heterotopic 
pruritic stimulation with electrical test stimuli would appear to be a valid model 
to investigate the central modulation of itch. In contrast to healthy subjects, itch 
and pain modulation seemed to be dysregulated in patients with psoriasis suffe-
ring from chronic itch. The ability to modulate pain in a pain-free state has been 
found to be a predictor of postoperative pain [10,53], which suggests that a per-
son’s susceptibility to pain disorders might depend on the effectiveness of pain 
modulation. Our results suggest that similar mechanisms might play a role in itch 
modulation. In line with a study of patients with osteoarthritis showing that the 
DNIC response can be normalized by relieving pain [30], future studies can offer a 
greater insight into whether it is possible to restore dysregulated DPIC and DNIC 
mechanisms by therapies aimed at rebalancing descending inhibition and facilita-
tion mechanisms of itch and pain.
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Abstract
Patients with chronic itch may process somatosensory stimuli differently. 
Continuing on our previous study showing that endogenous modulation of itch 
and pain were disturbed in patients with chronic itch, the present study inves-
tigates whether patients’ sensitivity and modulation are altered in line with their 
main symptom of itch or pain in patients with chronic itch or pain, respectively. Fe-
male patients with chronic itch due to psoriasis were compared with patients with 
chronic pain due to rheumatoid arthritis regarding sensitivity to and modulation of 
itch and pain. In psoriasis, induced itch in response to the stimuli was higher, while 
in rheumatoid arthritis tolerance to the stimuli was lower compared with the other 
patient group. Itch and pain modulation were impaired in both patient groups. 
Results suggest that somatosensory stimuli are processed in line with patients’ 
main symptom, while endogenous modulation of itch and pain may generally be 
disturbed across different symptoms.
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Introduction
Itch is a frequently reported symptom of patients with skin disease, with 
a prevalence of about 50% of these patients reporting itch [47,53]. Alike chronic 
pain, also in chronic itch central and peripheral sensitization is suggested to play 
a role in the heightened symptom reporting which does not completely corre-
spond to pathophysiological findings [6,23,28,38]. Both patients with chronic itch 
and pain have been shown to be frequently more sensitive to experimentally ap-
plied somatosensory stimuli than healthy controls and experience different types 
of stimuli in line with their main symptom, i.e., as itching in patients with chronic 
itch [19-21,43]. The tendency for patients with chronic pain to react to stimuli with 
higher levels of pain than healthy controls, and perceive itch stimuli as painful 
rather than itchy may be indicative of sensitization in the context of the patient’s 
main symptom, i.e., pain [4,43]. Heightened sensitivity to itch and pain could be 
attributed to impaired endogenous modulation processes of itch and pain. It has 
repeatedly been shown that patients with chronic pain have deficient endogenous 
pain modulation compared with healthy subjects [25,50]. Pain modulation can be 
tested using a conditioned pain modulation (CPM) paradigm [51], where diffuse 
noxious inhibitory controls (DNIC) are elicited via application of test stimuli at one 
part of the body and noxious conditioning stimulation, e.g., tonic painful stimula-
tion, at another part [33]. In line with these findings for chronic pain, we found 
preliminary evidence for deficient conditioned itch modulation (CIM) in patients 
with psoriasis suffering from chronic itch [45]. Continuing on these data, it remains 
unknown whether CIM and CPM are impaired generally or specifically in line with 
the patient’s main symptom. Investigation of these concepts of sensitivity and 
endogenous modulation in patients with different complaints, such as itch and 
pain, adds to our knowledge of specific and generic mechanisms contributing to 
various sensations. 
The aim of the present study was to investigate whether patients with 
chronic itch specifically have heightened sensitivity to itch and disturbed modula-
tion of itch, in comparison to patients with chronic pain. Therefore, the measures 
of itch and pain modulation in patients with chronic itch due to psoriasis [45] were 
extended with data on the modulation of itch and pain in patients with chronic pain 
due to rheumatoid arthritis, as well as with different measures of sensitivity to itch 
and pain in both patient groups. We hypothesized that heightened sensitivity to 
somatosensory stimuli and impairment of endogenous modulation of itch and pain 
are both dependent on the patient’s main complaints, i.e., patients with chronic 
itch and pain would show a higher sensitivity to itch and pain respectively, and 
more impaired endogenous modulation of itch and pain respectively. 
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Methods
Patients
Patients were recruited from the outpatient clinics of the Departments of 
Dermatology and Rheumatology, Radboud University Nijmegen Medical Centre. 
Twenty-five females diagnosed with psoriasis and suffering from chronic itch (PS; 
mean age 47 years, range 20 – 75 years) and 25 females diagnosed with rheuma-
toid arthritis and suffering from chronic pain (RA; mean age 61 years, range 27 – 75 
years) participated. Exclusion criteria for both groups were comorbid physical or 
psychiatric conditions (e.g., multiple sclerosis, diabetes mellitus, psychosis), pace-
maker use, and double diagnoses with regard to the conditions investigated. 
Mean disease duration was 23 years (range 2 – 57 years) for patients with 
PS and 16 years (range 3 – 37 years) for patients with RA. The severity and extent 
of the skin disease measured with the validated skin status scale of the impact 
of chronic skin disease on daily life (ISDL) (see section Questionnaires) showed 
that the severity of skin disease in our patients with PS (M = 15.8, SD = 3.4) was 
comparable to that of norm groups of PS outpatients (M = 16.9, SD = 3.7) [12]. The 
severity of RA assessed with the self-administered, validated rheumatoid arthritis 
disease activity index (RADAI) (see section Questionnaires) showed that our pa-
tients with RA (median = 1.5; range 0.3 – 5.0) were relatively mildly affected when 
compared to norm groups of patients with RA (median = 2.8; range 0.0 – 10.0) 
[14,35,36]. All patients with PS were affected at different body parts. On the day of 
testing, all participants were asked to indicate the current levels of itch and pain at 
the start of the experiment on a VAS ranging from 0 (no pain/itch) to 10 (worst pain/
itch imaginable). Patients with PS reported significantly higher levels of baseline 
itch (M = 2.7, SD = 2.3) than the patients with RA (M = 0.6, SD = 1.2), and the pa-
tients with RA reported higher, but not significantly different, levels of baseline pain 
(M = 2.4, SD = 2.2) than the patients with PS (M = 1.4, SD = 2.6) [F(1,48) = 17.1, 
P < 0.001 for itch, and F(1,48) = 2.4, P = 0.13 for pain]. Of the patients with PS, 
36% had taken systemic medication: 16% had taken medication for the treatment 
of psoriasis (methotrexate (n = 3) and cyclosporine (n = 1)) and 20% had taken 
(a combination of) other medication (antihypertensive (n = 3), benzodiazepines (n 
= 1), thyroid hormones (n = 1), platelet aggregation inhibitors (n = 1) or selective 
serotonin reuptake inhibitors (SSRIs) (n = 1)). All patients with RA had taken (a 
combination of) medication for the treatment of rheumatoid arthritis (non-steroidal 
anti-inflammatory drugs (NSAID; n = 18), disease-modifying antirheumatic drugs 
(DMARD; n = 19), biologic agents (n = 15), glucocorticoids (n = 6) or non-opioids 
(n = 6), and 64% had taken (a combination of) other medication (antihypertensives 
(n = 5), benzodiazepines (n =1), statins (n = 2), diuretics (n = 1), biophosphonates 
(n = 2) or gastric acid inhibitors (n = 13). 
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Seventy-six percent of the patients with PS and 60% of the patients with 
RA had completed secondary education, and 24% of the patients with PS and 
36% of the patients with RA had completed tertiary education. Seventy-two per-
cent of the patients with PS and 80% of the patients with PS were married or 
lived with a partner, and 20% of the patients with PS and 8% of the patients with 
RA used oral contraceptives. Body mass index and educational level did not sig-
nificantly differ between the two groups, but patients with PS were significantly 
younger than the patients with RA [F(1,48) = 14.9, P < 0.001], and the proportion 
of patients in the postmenopausal phase was smaller for PS than for RA (52% and 
92% respectively; P < 0.01). 
General procedure
The protocol was approved by the regional Medical Ethics Committee and 
all participants gave their informed consent prior to investigation. Patients were 
asked not to alter their regular medication on the test day. On the test day, the 
patients were told about the experiment and filled out a questionnaire about their 
disease severity (see section Questionnaires). The patients were instructed about 
and familiarized with the stimuli in a pretest trial. All patients with PS and RA re-
ceived the same stimuli that were applied at the shoulder and arms of the patients 
(unaffected skin of patients with PS). Patients were told that the sensory stimuli 
could provoke any type of sensation, for example itch and pain. For each stimu-
lus, patients were asked to rate their perceived sensation using a 10-point VAS for 
both itch and pain ranging from no itch/pain (0) to the worst itch/pain imaginable 
(10). 
Measuring sensitivity to itch and pain
Sensitivity to itch and pain was measured by applying first mechanical and 
electrical stimuli, and then applying the CIM and CPM procedures (including hista-
mine and the cold pressor test) [44,45]; see Table 1 and Figure 1). The order of the 
stimuli was chosen in such a way that the stimuli with the lowest mean intensity 
of itch and pain were applied at first. Thresholds were determined for mechanical 
(Aδ-fiber threshold), electrical and cold stimuli. Histamine was applied for a pre-
determined time period. At the tolerance thresholds of the mechanical, electrical 
and cold stimuli as well as during histamine iontophoresis, subjects were asked 
to indicate on a 10-point VAS both the levels of itch and pain they experienced, 
except for histamine for which only the levels of itch, and the cold pressor test, for 
which only the levels of pain were assessed.
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Table 1
Overview of the somatosensory stimuli applied (mechanical stimulation, electrical 
stimulation, histamine iontophoresis and the cold pressor test) and outcome mea-
sures to test sensitivity to and conditioned modulation of itch and pain. 
Somatosensory stimuli Outcome measures
Sensitivity to itch and pain
    Mechanical stimulation Tolerance threshold (Aδ-fiber threshold), 
VAS itch, VAS pain
    Electrical stimulation Tolerance threshold, VAS itch, VAS pain
    Histamine iontophoresis VAS itch
    Cold pressor test Tolerance threshold, VAS pain
Conditioned modulation of itch and pain
     Histamine iontophoresis + electrical test 
stimuli (itch)
VAS itch for electrical test stimuli before 
and after itch conditioning stimulation
     Cold pressor test + electrical test  
stimuli (pain)
VAS pain for electrical test stimuli before 
and after pain conditioning stimulation
Figure 1 Schematic overview of the order of the somatosensory stimuli applied to 
investigate sensitivity to itch and pain and conditioned modulation of itch and pain 
(CIM and CPM). 
Measuring endogenous modulation
Endogenous modulation of pain can be tested using a conditioned pain 
modulation (CPM) paradigm involving a painful stimulus (conditioning pain stimu-
lus) preceded and followed by painful stimuli upon which the conditioning effect 
is tested (test stimuli) [33]. The intensity of both test stimuli can be predetermined, 
and the difference in pain evoked by the second minus the first stimulus is a mea-
sure of the effectiveness of endogenous pain modulation. Endogenous modulation 
of itch can be similarly tested using a pruritic stimulus (conditioning itch stimulus) 
and pruritic test stimuli [45]. In the present study, histamine iontophoresis and 
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the cold pressor test were used as itch and pain conditioning stimuli respectively. 
Test stimuli for both itch and pain modulation were applied by means of electrical 
stimulation. The electrical test stimuli applied for testing both CIM and CPM were 
identical and individually tailored on basis of the unpleasantness and tolerance 
thresholds (see section Somatosensory stimuli - Electrical stimulation). Electrical 
test stimuli of identical intensity were then administered 4 minutes before and 4 
minutes after the contralaterally applied conditioning stimuli for itch (histamine ap-
plication) or pain (cold stimulation). The difference in itch before and after the itch-
conditioning stimulus (histamine) is a measure of endogenous itch modulation, 
while the difference in pain evoked by the test stimuli before and after the pain-
conditioning stimulus (cold pressor) is a measure of endogenous pain modulation 
(see also Table 1 and Figure 1). 
Somatosensory stimuli
Mechanical stimulation
 Twenty Semmes-Weinstein von Frey calibrated monofilaments were used 
in a range of 0.00045 to 447.0 grams. Filaments were applied once to the non-
dominant forearm (2 cm distal to the lateral epicondyle of the humerus, C5 der-
matome) vertically and with increasing force, while avoiding contact with body 
hair. Subjects were asked to report the Aδ-fiber threshold, which was specified 
by the von Frey hair number [43], and the itch and pain ratings for that threshold. 
Levels of itch and pain were assessed as measures of itch and pain sensitivity.
Electrical stimulation
Self-adhesive skin electrodes (3M Red Dot Monitoring Electrodes 2560, 
surface 40x35 mm, diameter stimulation area ca. 20 mm) were applied to the 
non-dominant forearm (2 cm distal to the lateral epicondyle of the humerus, C5 
dermatome) and the trapezius on the dominant side (at the midpoint of upper 
trapezius, C4 dermatome). A constant current nerve stimulator (MuliStim Vario, 
Pajunk, Geisingen, Germany) was used to deliver electrical stimuli, consisting of 
0.3-ms pulses at 100-Hz frequency to evoke itch [22], with a continuously increas-
ing intensity of about 0.2 mA/s, applied until the subject reported the respective 
threshold (with an upper limit of 15 mA). After a pretest trial with the trapezius, the 
unpleasantness and tolerance thresholds were determined twice on the forearm 
with an interval of 30 seconds in-between [44,45]. Subjects were asked to rate 
the itch and pain intensities at the tolerance threshold as a measure of sensitivity 
to itch and pain. For endogenous modulation of itch and pain, the mean current 
intensities of the unpleasantness and tolerance thresholds were calculated. Elec-
trical test stimuli (100-Hz frequency and 0.3-ms pulse-length) for testing both itch 
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and pain modulation were applied to the non-dominant forearm (2 cm distal to the 
lateral epicondyle of the humerus, C5 dermatome) before and after both itch (his-
tamine) and pain (cold pressor test) conditioning stimuli using the same procedure 
as described in our previous study on itch and pain modulation [45]. 
Histamine iontophoresis
Histamine was applied by iontophoresis (Chattanooga Group, Hixson, 
USA). Histamine dihydrochloride (0.5%) was dissolved in a gel of 2% methylcel-
lulose in distilled water and 2.5 ml was placed in an electrode (Chattanooga Ionto 
Ultra Electrode medium, Hixson, USA). This electrode was applied to the dominant 
forearm, 2 cm distal to the lateral epicondyle of the humerus (C5/T1 dermatome). 
The reference electrode was applied to the skin of the lateral side of the triceps 
brachial muscle. Current level was set at 0.4 mA and histamine was delivered for 
2.5 minutes [45]. Subjects were asked to rate itch levels during histamine applica-
tion every 30 s. Mean scores for itch during histamine application were calculated 
and served as measure for itch sensitivity. Histamine also served as an itch-condi-
tioning stimulus to investigate endogenous modulation of itch. 
Cold pressor test
Subjects were instructed to place their dominant hand in a tank of cold 
water at about 4°C (mean temperature 3.9°C, SD = 0.9) “for as long as possible, 
until the moment that the sensation becomes unbearable and you want to stop 
directly”. The participants were not aware of the maximum time limit of 3 minutes. 
The immersion time was recorded (tolerance threshold) and subjects were asked 
about the level of pain during the test at the moment they withdrew their hand. 
Pain evoked by the cold pressor test was a measure of sensitivity to pain. The cold 
pressor test also served as pain-conditioning stimulus to investigate the endo-
genous modulation of pain. 
Questionnaires
The severity and extent of the skin disease of patients with PS was mea-
sured with the validated skin status scale of the ISDL, which has previously been 
validated in patients with PS [12]. Items were rated for different body parts (face, 
hairy scalp, neck, hands, arms, torso, legs, feet and genitals/anus) on a 4-point 
Likert scale (1 = not at all, 2 = to some extent, 3 = to a great extent, 4 = totally). The 
sum score reflects the overall severity of the skin condition.
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The severity of the rheumatic disease activity of the patients with RA was 
assessed with the validated self-administered rheumatoid arthritis disease activity 
index (RADAI) calculated by the sum score of 5 items. Item 1 of the RADAI is about 
global disease activity in the last 6 months, but was adjusted to global disease 
activity on the day of the experiment. The other four items asked about disease 
activity in terms of current swollen and tender joints, arthritis pain, the duration of 
morning stiffness and tender joints rated in a joint list [14].
Statistical analysis
All analyses were performed with SPSS 16.0 for Windows. Variables were 
checked for normal distribution. Slightly skewed distributions were only found for 
itch and pain evoked by mechanical stimulation and itch evoked at the electrical 
tolerance threshold. Square root transformation was performed for these variables 
which resulted in a normal distribution. 
To test the hypothesis regarding tolerance thresholds and sensitivity to itch 
and pain between patients with PS and RA, GLM multivariate analyses of vari-
ance (MANOVA) were performed with the patient groups as between-subjects fac-
tor and thresholds of the somatosensory stimuli and VAS itch and pain scores as 
dependent variables in separate analyses. To test the hypothesis regarding itch and 
pain modulation, GLM repeated measures ANOVA was performed for both patient 
groups separately with as within-subjects variables the electrically evoked itch and 
pain scores before and after conditioning stimulation by histamine iontophoresis 
and the cold pressor test, respectively. The same analyses were conducted to test 
the influence of the use (yes/no) of analgesics (NSAID or non-opioids). To explore 
the relationship between endogenous itch and pain modulation and sensitivity to 
itch and pain, Pearson correlation coefficients were calculated between the change 
scores in itch and pain after conditioning modulation (i.e. the difference in itch and 
pain scores evoked by electrical test stimuli before and after conditioning stimula-
tion) and the measures of sensitivity to itch and pain evoked by the different soma-
tosensory stimuli. Finally, for both patient groups separately, Pearson correlation 
coefficients were calculated between the tolerance thresholds, levels of itch and 
pain evoked by the different somatosensory stimuli, the change scores in electrical-
ly evoked itch and pain and the following control variables: age, educational level, 
menopausal status, baseline levels of itch and pain on the day of testing, disease 
duration, and current skin disease and rheumatic disease severity. 
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Results
Sensitivity: tolerance thresholds
Sensitivity to different somatosensory stimuli that could evoke itch or pain 
(mechanical, electrical, histamine and cold stimuli) was measured by determining 
the tolerance thresholds and itch and pain evoked by these stimuli (see Table 1). 
The overall test (MANOVA) of the tolerance thresholds for the different 
somatosensory stimuli showed that tolerance thresholds were significantly lower 
in the patients with RA than in the patients with PS [Wilks Lambda (Λ) = 0.72, 
F(3,46) = 5.84, P < 0.01]. For each stimulus, the mean Aδ-fiber threshold intensity 
for mechanical stimulation was significantly lower [F(1,48) = 8.14, P < 0.01] in the 
patients with RA (M = 11.3, SD = 3.5) than in the patients with PS (M = 14.7, SD 
= 4.8). The mean cold pressor immersion time was also significantly shorter in the 
patients with RA (M = 25.8 s, SD = 10.8) than in the patients with PS (M = 51.4 s, 
SD = 60.8) [F(1,48) = 4.29, P < 0.05]. The electrical tolerance threshold (M = 9.0 
mA, SD = 4.4 for RA, and M = 8.0 mA, SD = 4.2 for PS) was not significantly differ-
ent between the two patient groups [F(1,48) = 0.64, P = 0.43]. After controlling for 
the use of analgesics, the MANCOVA test for the tolerance thresholds still showed 
a borderline significant difference (P = 0.05). 
Sensitivity: itch and pain scores
Means and SD of itch and pain evoked by the different somatosensory 
stimuli (mechanical, electrical, histamine and cold stimuli) are given in Table 2. 
Scores for stimuli-evoked itch (mechanical, electrical and histamine together) were 
higher in the patients with PS than in the patients with RA [MANOVA Λ = 0.85, 
F(3,46) = 2.80, P = 0.05]. For each stimulus separately, univariate analyses showed 
that levels of itch evoked by histamine were significantly higher in the patients 
with PS than in the patients with RA [F(1,48) = 7.80, P < 0.01]. No significant dif-
ferences were found between the patient groups in itch evoked by mechanical 
or electrical stimulation [F(1,48) = 0.40, P = 0.53 and F(1,48) = 0.77, P = 0.39, 
respectively]. There were no between-group differences in pain levels evoked by 
the mechanical, electrical and cold stimuli together [MANOVA Λ = 0.94, F(3,46) = 
0.93, P = 0.43]. The levels of significance for the MANOVA tests of VAS itch and 
pain remained the same after controlling for the use of analgesics.
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Table 2
Means, standard deviations (SD) and range of visual analogue scale (VAS) scores 
for itch and pain evoked by the different somatosensory stimuli of quantitative 
sensory testing (QST) in patients with psoriasis (n = 25) and patients with rheuma-
toid arthritis (n = 25).
Psoriasis Rheumatoid Arthritis
Somatosensory stimuli Mean (SD) Range Mean (SD) Range
    Mechanical stimulation
VAS itch 0.7 (1.3) 0.0 – 4.0 0.4 (0.7) 0.0 – 3.0
VAS pain 0.7 (1.3) 0.0 – 4.0 0.5 (0.8) 0.0 – 3.0
    Electrical stimulation
VAS itch 1.1 (1.8) 0.0 – 6.0 0.7 (1.5) 0.0 – 6.0
VAS pain 2.9 (2.9) 0.0 – 9.0 3.4 (2.8) 0.0 – 8.0
     Histamine iontopho-
resis
VAS itch 2.9 (2.5) 0.0 – 8.7 1.4 (1.3) 0.0 – 4.4
    Cold stimulation VAS pain 4.1 (2.9) 0.0 – 9.0 3.6 (2.8) 0.0 – 8.0
Endogenous modulation
Endogenous modulation of itch and pain was tested by the repeated ap-
plication of electrical test stimuli applied before and after conditioning stimulation 
with histamine (conditioned itch modulation, CIM) or the cold pressor test (condi-
tioned pain modulation, CPM). Table 3 displays the levels of itch and pain evoked 
by the electrical test stimuli applied before and after conditioning stimulation (with 
histamine and the cold pressor test respectively) for both patient groups. The pa-
tients with RA showed no significant change in itch or pain after itch [F(1,24) = 
0.03, P = 0.86] and pain [F(1,24) = 1.07, P = 0.31] conditioning, respectively. As 
previously reported, in the patients with PS electrically evoked itch worsened sig-
nificantly after itch-conditioning stimulation [F(1,24) = 5.28, P < 0.05] and there was 
no significant change in electrically evoked pain after pain-conditioning [F(1,24) = 
0.05, P = 0.83] [45]. After controlling for the use of analgesics, levels of significance 
in the repeated measures ANOVAs remained the same. 
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Table 3
Means and standard deviations (SD) of electrically evoked itch before and after 
itch conditioning stimulation using histamine, and of electrically evoked pain be-
fore and after pain conditioning stimulation using the cold pressor test in patients 
with psoriasis (n = 25) and patients with rheumatoid arthritis (n = 25).
Psoriasis Rheumatoid Arthritis
Somatosensory stimuli Mean (SD) Mean (SD)
    VAS itch before conditioning stimulation 0.55 (1.29) 0.75 (1.66)
    VAS itch after conditioning stimulation 0.87 (1.60) 0.59 (1.18)
    VAS pain before conditioning stimulation 2.68 (2.64) 2.92 (2.41)
    VAS pain after conditioning stimulation 2.72 (2.38) 2.49 (2.42)
Relationship between endogenous modulation and sensitivity
The relationship between sensitivity to itch and pain and the effective-
ness of itch and pain modulation was explored. Pearson correlation coefficients 
between the change scores in electrically evoked itch (itch modulation) and pain 
(pain modulation) and the measures of itch and pain sensitivity (mechanical, elec-
trical, histamine and cold stimuli) were all not significant, except for a significant 
correlation between more effective itch modulation and lower itch evoked by elec-
trical stimulation at tolerance threshold in the patients with PS (r = -0.47, P < 0.05), 
indicating that these patients are less sensitive to electrically evoked itch when 
they have a better endogenous itch modulation. 
Individual characteristics
In the two groups, itch and pain evoked by the somatosensory stimuli 
and the change scores for the modulation of itch and pain were overall not sig-
nificantly correlated with the control variables age, BMI, educational level, meno-
pausal status, baseline clinical levels of itch and pain, disease duration, current 
skin or rheumatic disease severity, and (change scores for itch and pain with) itch 
and pain evoked by the conditioning stimulation. However, in the patients with PS 
significant correlations were found between: lower electrical tolerance thresholds 
and higher levels of clinical itch (r = -0.49, P < 0.05), higher mechanically induced 
pain and higher BMI (r = 0.46, P < 0.05), higher levels of histamine-induced itch 
and a shorter disease duration (r = -0.41, P < 0.05), and higher mechanically and 
histamine induced levels of itch and younger age (r = -0.40, P < 0.05 and r = -0.41, 
P < 0.05, respectively). Premenopausal patients with PS also had higher mechan-
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ical Aδ-fiber thresholds and reported higher levels of itch elicited by mechani-
cal stimulation and histamine than did postmenopausal patients [F(1,23) = 5.37, 
P < 0.05, F(1,23) = 5.25, P < 0.05 and F(1,23) = 8.42, P < 0.01, respectively]. Sig-
nificant correlations were found in the patients with RA between: higher levels of 
electrically evoked itch and higher BMI (r = 0.47, P < 0.05), and higher levels of 
histamine-induced itch and younger age (r = -0.60, P < 0.01). 
The results of the MANCOVA for the tolerance thresholds and itch and 
pain evoked by the stimuli overall remained the same after controlling for these 
variables, with the exception that differences in itch sensitivity between the 
patients with PS and RA diminished after controlling for BMI [F(3,44) = 2.56, 
P < 0.10], menopause [F(3,45) = 0.68, P = 0.57] and age [F(3,45) = 0.73, P = 
0.54]. 
Discussion
In the present study we investigated whether patients with chronic itch 
display heightened sensitivity specific to itch and have an impaired modulation of 
itch specifically, when comparing with sensitivity to pain and modulation of pain in 
patients with chronic pain. We expected that patients with chronic itch would be 
more sensitive to itch and would have an impaired modulation specifically of itch, 
while patients with chronic pain would display heightened pain sensitivity and a 
specific disturbance of pain modulation. In line with our hypothesis results indicat-
ed that patients may indeed be more sensitive to sensations in line with their main 
symptom, e.g., to itch in patients with chronic itch. However, endogenous modula-
tion of itch and pain showed to be disturbed across symptoms, e.g., both itch and 
pain modulation were impaired in patients with chronic itch or pain. More specifi-
cally, results indicated that, in comparison with the patients with chronic pain, the 
patients with chronic itch were more sensitive to itch regarding stimulation with 
histamine. Patients with chronic pain did not report higher levels of pain than the 
patients with chronic itch, but displayed lower tolerance thresholds for mechanical 
(Aδ-fiber threshold) and cold stimulation. In both groups of patients, the modula-
tion of itch and pain (i.e. CIM/DPIC or CPM/DNIC) seemed to be impaired, since 
itch and pain levels were not reduced after conditioning stimulation in both patient 
groups, in contrast to what we found previously in healthy subjects [45], and might 
consequently be indicative of loss of inhibitory modulation of itch and pain. 
In the present study the pain scores at the tolerance thresholds did not sig-
nificantly differ between the two patient groups, but the intensity of the tolerance 
thresholds for mechanical stimulation (Aδ-fiber threshold) and the cold pressor 
test (immersion time) were significantly lower in the patients with RA compared to 
the patients with PS. It has repeatedly been shown that patients with chronic pain 
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display heightened levels of pain and/or lowered tolerance thresholds for experi-
mental mechanical, electrical or thermal stimuli [8,11,17,24,39,43]. This phenom-
enon of heightened sensitivity is supported by earlier studies in diverse patients 
with chronic pain, e.g., in fibromyalgia, osteoarthritis, whiplash pain, and muscu-
loskeletal pain [3,5,30,40]. Our results extend these findings, by showing that PS 
patients with chronic itch seemed to be more sensitive to itch than were patients 
with RA, especially for an itch-specific stimulus such as histamine. This is in line 
with our previous results showing that patients with AD react with heightened lev-
els of itch to experimental stimuli [43]. Studies showing that patients with chronic 
pain can perceive itch stimuli as painful [4], and painful stimuli can be perceived 
as itching in patients with chronic itch [20,21], further support the assumption of 
an enhanced sensitivity to stimuli in line with the patient’s main symptom, e.g., as 
itching in patients with chronic itch. 
In addition to some symptom-specific sensitivity effects, our results also 
support generalized sensitivity processes with regard to deficient modulation of itch 
and pain in these patient groups, in contrast to the intact modulation responses for 
itch and pain we demonstrated earlier for healthy subjects [45]. This is in line with 
earlier studies reporting deficient CPM in patients with various diseases suffering 
from chronic pain, such as fibromyalgia, osteoarthritis, and irritable bowel syn-
drome [46]. Moreover, our findings indicate that pain modulation seems not only to 
be impaired in patients with chronic pain, but also in patients with chronic itch, and 
that itch modulation also seems to be impaired in patients with chronic pain. Since 
the literature is not completely consistent on whether CPM is impaired in patients 
with chronic pain, for example, an earlier study showed that patients with RA had 
a CPM-response similar to healthy subjects [29,46], our findings should be repli-
cated, also in other patient groups. For example, variation in CPM between pain 
conditions may be related to the intensity or type of chronic pain e.g., intermittent 
versus long-term, or widespread versus localized pain. Another explanation for the 
impaired CIM and CPM in these patients is that some patients with PS also report 
pain associated with their disease [37,47], and some medications used by patients 
with RA may give rise to itch [34]. However, explorative post-hoc analyses in pa-
tients with PS with clinical levels of pain below 2.0 and in patients with RA with 
clinical levels of itch below 2.0 during the past two weeks also showed that CIM 
and CPM were also deficient (data not shown). Together, these results support the 
idea that endogenous modulation of itch and pain involves generic sensitivity pro-
cesses, independent of the main symptom associated with the disease, e.g., itch 
in patients with skin disease. Additionally, the sensitivity to itch and pain elicited by 
the specific somatosensory stimuli was not correlated with the extent to which the 
endogenous modulation was impaired, such as has been found in earlier studies in 
pain [10], suggesting that the itch and pain sensitivity of these patients cannot be 
explained by the effectiveness of endogenous modulation. This might indicate that 
sensitivity to itch and pain stimuli and endogenous modulation are to some degree 
independent processes, and, consequently, it seems to be important to take both 
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processes into consideration in future research. 
The study had some limitations. First, the two patient groups were not 
completely comparable regarding age, menopausal status, clinical levels of itch 
and pain, disease severity and duration, and the use of medication. Younger age, 
a shorter disease duration and premenopausal status also seemed to affect his-
tamine-related itch sensitivity, possibly contributing to the difference in itch sen-
sitivity between patients with PS and RA. Little is known about the role of these 
different individual characteristics in sensitivity to itch and pain. However, pain 
sensitivity varies for different groups of subjects and stimuli [16], and age and 
menopause might be related to the variance in itch and pain sensitivity and modu-
lation [31], for example, the extent of pain inhibition decreases across the adult 
lifespan [27], which could be related to hormonal influences [9,42]. Future research 
should focus on these characteristics to unravel psychophysiological mechanisms 
in itch and pain sensitivity. Second, validated questionnaires were used to mea-
sure the patients’ disease activity. Future research should include not only self-
report, but also clinical measures of disease activity such as the psoriasis activity 
severity index (PASI) for PS [15], or the disease activity score (DAS) for RA [32]. 
Third, levels of itch and pain evoked by the stimuli are generally mild (e.g., for me-
chanical stimulation and the electrical test stimuli), even when patients were asked 
to report the tolerance (or Aδ-fiber) threshold. This may be related to the relatively 
mild disease activity and medication use of the patients in the present study. In 
future studies results might be replicated with (test) stimuli inducing higher levels 
of itch and pain, for example by using stimuli of different modality or intensity 
[41]. Fourth, tolerance thresholds for the different mechanical, electrical and cold 
stimuli cannot be compared, since, in general, various stimuli and intensities, e.g., 
phasic versus tonic and sub-versus suprathreshold stimulation, may, for example, 
be associated with different nervous processing and brain activation [2,7]. Further-
more, the conditioning stimuli, i.e., cold pressor test and histamine iontophoresis, 
may not be completely comparable, since histamine can also provoke low levels 
of pain and has pro-inflammatory, vasodilatatory effects, while the cold pressor 
test has vasoconstrictive properties. Fifth, future research should also include ex-
perimental control conditions in which electrical test stimuli are applied without 
conditioning stimulation and stimuli applied in a counterbalanced order. Sixth, in 
view of the possible sex differences in sensitivity to somatosensory stimuli and 
endogenous pain modulation [13,31], comparison of the present data with male 
patients is desirable. 
To conclude, the results of this study indicate that the sensitivity to itch and 
pain measured with different somatosensory stimuli might be indicative of sensiti-
zation processes in line with the patients’ main symptom, e.g., specific heightened 
itch sensitivity in patients with chronic itch, and specific heightened pain sensiti-
vity in patients with chronic pain. In contrast, modulation of itch and pain, by DPIC 
and DNIC, may both be impaired in patients with chronic itch or pain, suggesting a 
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generic process of disturbed endogenous modulation of itch and pain in patients 
with chronic itch or pain as described for, for example, the concept of central 
sensitivity syndromes [54]. Earlier studies indicate that both heightened sensitivity 
to pain and less effective modulation of pain in a pain-free state might be risk fac-
tors for chronic pain after surgery [18,48,49,52]. Both indicators of sensitivity and 
endogenous modulation may consequently be used as tools to identify patients 
at risk and as a target for treatment in clinical practice in patients with chronic itch 
and pain, e.g., for surgical or cognitive-behavioral interventions [1,26].
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Abstract
Patients frequently report high levels of physical symptoms, such as itch 
and pain, which do not completely correspond to pathophysiological findings, 
possibly indicating heightened sensitivity to physical symptoms. Sensitivity to itch 
and pain is thought to be affected by processes such as attentional focus on 
bodily sensations. We investigated the role of attentional focus in sensitivity to 
various somatosensory stimuli evoking both itch and pain sensations in healthy 
female subjects. Different mechanical, chemical and electrical stimuli of quanti-
tative sensory testing were applied. Attentional focus on bodily sensations was 
measured using validated questionnaires. The results indicated that focusing on 
bodily sensations is associated with higher levels of experienced itch and pain 
but not with tolerance to stimuli. This suggests that attentional focusing on bodily 
sensations is a mechanism responsible for sensitivity to different physical sensa-
tions, such as itch and pain. 
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Introduction
Patients often report levels of itch and pain that are not correlated with 
other signs of disease, with the severity of the disease or with the intensity of itch 
and pain expected according to pathophysiology. There is increasing evidence 
that heightened sensitivity to physical sensations plays a role in the maintenance 
and aggravation of complaints such as itch and pain. For example, patients with 
chronic itch or pain have been shown to be generally more sensitive to itch and 
pain, respectively, than healthy controls [8,15,17,35]. Information processes, such 
as attentional focus towards sensations, are thought to play a main role in sen-
sitivity to different complaints, such as pain [5,6,22,29,38]. The extent to which 
individuals focus on bodily sensations is also of importance in conditions as-
sociated with chronic pain. For example, there are indications that patients with 
chronic pain have heightened attention towards pain-related information [9,26,27]. 
Attention also plays a role in the response to experimentally applied pain stimuli 
[20,21,25]. Given that there is an overlap in psychophysiological mechanisms of 
itch and pain [30,37,40], attentional focus could also play a role in sensitivity to 
itch. There is preliminary evidence that patients with psoriasis display heightened 
attentional focus on disease-specific words (including itch words) compared with 
healthy subjects [12]. However, the role of attentional focus on bodily sensations 
in itch has not been investigated systematically. In addition, individual differences 
in personality are thought to be partly responsible for a heightened perception of 
sensations or hypervigilance to symptoms. For example, subjects relatively high 
in physical anxiety sensitivity or in neuroticism pay more attention to physically 
threatening stimuli and are more hypervigilant to physical symptoms [18,19,42]. 
Consequently, personality characteristics of anxiety sensitivity and neuroticism 
may affect the relationship between attentional processes and sensitivity to soma-
tosensory stimuli [2,20,22,31,33,36]. 
Taking all these factors into account, it is likely that focusing attention on 
bodily sensations plays a role in the experience of sensations of both pain and 
itch. Since there is some evidence that both itch and pain are affected by similar 
mechanisms of sensitization [30,35,40], with both patients with chronic itch and 
pain being relatively more sensitive to somatosensory stimuli than healthy controls, 
comparison of itch and pain may clarify the differences in peoples’ sensitivity to 
different bodily sensations such as itch and pain. However, no studies have inves-
tigated the role of attentional focus on bodily sensations in sensitivity to itch and 
pain. The aim of this study was to investigate the role of attentional focus on bodily 
sensations in the sensitivity to various somatosensory stimuli, including mechani-
cal, electrical and chemical stimuli, eliciting sensations of itch and pain, controlling 
for the role of the personality characteristics anxiety sensitivity and neuroticism. 
We hypothesized that individuals with a greater attentional focus on bodily sensa-
tions would be more sensitive to the test stimuli; in particular, that attentional focus 
would be related to the higher reports of itch and pain. In addition, it is suggested 
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that attentional focus might be affected by anxiety-based personality character-
istics (e.g., neuroticism and anxiety sensitivity) and that it would mediate the rela-
tionship between personality characteristics and sensitivity to itch and pain.
Methods
Participants
Thirty-two women (mean age = 38 years, SD = 18) without acute or chron-
ic itch or pain complaints were recruited via advertisements. Subjects with a mini-
mum age of 18 years were included. Exclusion criteria were: severe morbidity 
(e.g., multiple sclerosis, diabetes mellitus); severe psychiatric disorders; pacema-
ker use; and levels of current itch and pain above 1.0 on a scale from 0 to 10. Of 
the subjects 59% had completed secondary education and 41% had completed 
tertiary education. Forty-four percent of the subjects were married or lived with a 
partner. The protocol was approved by the regional medical ethics committee and 
all participants gave their informed consent prior to the investigation. On arrival at 
the test facility, participants were informed about the procedure and asked about 
their menstrual cycle, smoking, and use of medication, and intake of caffeine, and 
alcohol over the previous 24 h. Participants had earlier been asked not to drink 
black tea or coffee 1 h before testing. Three subjects had taken medication for high 
blood pressure, of which one had taken a selective serotonin reuptake inhibitor an-
tidepressant and one had taken an antihistamine within 24 h prior to testing. 
General procedure
Self-report questionnaires were sent to the participants one week before 
testing. On the day of testing, the participants were asked to indicate the current 
level of itch and pain at the start of the test on a visual analogue scale (VAS) rang-
ing from 0 to 10. Mean levels of current itch and current pain were 0.1 (SD = 0.3) 
and 0.2 (SD = 0.4), respectively. Subsequently, quantitative sensory testing (QST) 
was performed using mechanical, electrical, chemical and thermal stimuli, in the 
following order: tactile stimulation, electrical stimulation, histamine iontophoresis, 
cold stimulation and capsaicin application. The same investigator administered all 
stimuli. The inter-stimulus interval was at least 10 min, with a 15-minute interval 
after the histamine and cold pressor stimuli. On the day of testing, subjects were 
informed about the procedure and familiarized with the stimuli in a pretest trial. 
Subjects were told that stimuli could provoke any type of sensation, for example 
itch and pain. After each stimulus, subjects were asked to rate their perceived 
sensation using a 10-point VAS for both itch and pain ranging, from no itch/pain 
(0) to the worst itch/pain imaginable (10). 
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Self-report questionnaires
Attentional focus on the occurrence of bodily sensations 
The Body Sensations Questionnaire (BSQ) [7] was used as a measure of 
attentional focus on the occurrence of bodily sensations. This questionnaire con-
taining 15 items concerning bodily sensations was used by asking subjects to rate 
the frequency of bodily sensations (e.g., heart palpitations, dizziness or sweating) 
occurring when in a nervous or feared situation. Each item was rated on a 5-point 
Likert scale, ranging from “the sensation never occurs” to “the sensation occurs 
almost always or always”. The total score was obtained by calculating the mean 
score of the items. Cronbach alpha for the BSQ in the present study was 0.66. 
Attentional focus on bodily sensations 
The tendency to attend to internal bodily sensations was measured with 
the Body Vigilance Scale (BVS) [28], consisting of four items, three of which as-
sess the degree of attentional focus, perceived sensitivity to changes in bodily 
sensations, and the average amount of time spent attending to sensations. The 
fourth item contains 13 items concerning anxiety-related bodily sensations (heart 
palpitations, chest pain, numbness, tingling, shortness of breath, faintness, vision 
changes, dizziness, hot flash, sweating/clammy hands, upset stomach, nausea, 
choking/throat closing). Items were rated on a 10-point VAS. The ratings for the 
bodily sensations of item 4 were averaged to obtain an overall score for item 4. 
The total score of BVS is the sum of items 1 to 4. Cronbach alpha for the BVS in 
the present study was 0.82
Personality characteristics
The Anxiety Sensitivity Index (ASI) [24] measured the subjects’ fear of 
bodily sensations that are interpreted as having potentially harmful, physical or 
psychological, consequences. The ASI consists of 16 items, rated on a 5-point 
Likert scale (1 = very little, 2 = little, 3 = some, 4 = much, 5 = very much). The total 
score was obtained by summing the scores for the 16 items (range 0 – 64). The 
Cronbach alpha for the ASI in the present study was 0.91. In order to measure 
neuroticism, the neuroticism subscale (22 items) of the Eysenck Personality Ques-
tionnaire (EPQ) was used [11]. In the present study the Cronbach alpha was 0.88.
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Somatosensory stimuli
Mechanical stimulation
Twenty Semmes-Weinstein von Frey calibrated monofilaments were used 
in a range of 0.00045 to 447.0 grams. Filaments were applied to the non-dominant 
forearm (2 cm distal to the lateral epicondyle of the humerus, C5 dermatome) once 
vertically and with increasing force while avoiding contact with body hair. Subjects 
were asked to report the Aδ-fiber threshold as well as the itch and pain ratings for 
that threshold [35]. 
Electrical stimulation
Cutaneous electrodes were applied to the non-dominant forearm (2 cm 
distal to the lateral epicondyle of the humerus, C5 dermatome) and the trapezius 
on the dominant side. The electrical tolerance thresholds were measured using a 
constant current nerve stimulator (MultiStim Vario, Pajunk, Geisingen, Germany). 
Electrical stimuli consisted of 0.3-ms pulses at 100-Hz frequency with a continu-
ous increasing intensity of about 0.2 mA/s applied until the subject reported the 
tolerance threshold which was defined by “the moment that the sensation be-
comes unbearable and you want to stop immediately”. After a pretest trial with 
the trapezius, the tolerance threshold was determined on the forearm and then 
subjects were asked to rate itch and pain intensity at the tolerance threshold. The 
mean of two repeated threshold measurements was calculated [35].
Histamine iontophoresis
Histamine [16,41] was applied by means of an iontophoresis system (Chat-
tanooga Group, Hixson, USA). Histamine dihydrochloride (0.5%) was dissolved in 
a gel of 2% methylcellulose in distilled water and 2.5 ml was placed in an electrode 
(Chattanooga Ionto Ultra Electrode medium, Hixson, USA). This electrode was ap-
plied to the dominant forearm, 2 cm distal to the lateral epicondyle of the humerus 
(C5 dermatome). The reference electrode was applied to the skin of the lateral 
side of the triceps brachial muscle. Current level was set at 0.4 mA and histamine 
was delivered for 2.5 minutes. Subjects were asked to rate itch and pain during 
histamine application every 30 s. Mean scores for itch and pain during histamine 
application were calculated.
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Capsaicin application 
Capsaicin (Bufa Spruyt-Hillen, Utrecht, the Netherlands) was applied topi-
cally, according to the guidelines of Green [13], in a non-evaporative vehicle (Lan-
ette I cream). Capsaicin cream in a concentration of 1% was applied to the volar 
aspect of the dominant forearm laterally (2 cm proximal of the distal wrist crease, 
dermatome C5) over an area of 10 cm2 for 7 minutes. Levels of itch and pain were 
scored every minute during application and the mean scores for itch and pain were 
calculated. 
Cold pressor test
Subjects were instructed to place their dominant hands in a tank of ice wa-
ter at about 4°C (mean temperature 4.3°C, SD = 0.6) as long as possible, until they 
could no longer tolerate it. The participants were not aware of the upper time limit of 
3 minutes [4]. The immersion time was recorded and the level of itch and pain during 
the test was assessed immediately after the subjects had withdrawn their hands. 
Statistical analysis
All analyses were performed using SPSS 16.0 for Windows. All stimuli 
evoked both itch and pain, except the cold pressor test, for which only 2 subjects 
had itch scores above 1.0 (M = 0.1, SD = 0.5) and the capsaicin application, for 
which only 3 subjects had pain scores above 1.0 (M = 0.3, SD = 0.5). Consequent-
ly, these variables (itch scores for the cold pressor test and pain scores for capsai-
cin) were not included in analyses. Variables were checked for normal distribution. 
Square root transformation was performed to obtain a normal distribution for one 
stimulus: VAS pain elicited by tactile stimulation. Pearson correlation coefficients 
were calculated to determine the intercorrelations between the itch and pain re-
ported for each stimulus and between the thresholds and itch and pain reported at 
the thresholds. In order to test the hypotheses, composite endpoints were made 
for both the tolerance thresholds and itch and pain scores separately by calculat-
ing the means of the standardized thresholds and means of the standardized itch 
and pain scores for the different stimuli [34]. Pearson correlation coefficients were 
then calculated between attentional focus and these composite scores for the 
thresholds and itch and pain scores (one-tailed). Additional explorative analyses 
were further conducted by calculating the single correlations between sensory 
thresholds and the VAS ratings for itch and for pain for each stimulus separately 
(one-tailed). In addition, we studied the role of attentional focus as a mediator 
between personality and itch and pain sensitivity according to the procedure de-
scribed by Baron & Kenny [3]. A necessary condition for mediation is that a sig-
nificant linear relation exists between the independent variable and mediator, in-
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dependent variable and outcome, and mediator and outcome variable. Therefore 
these correlations were calculated with, as independent variables, neuroticism 
and anxiety sensitivity, as possible mediator attentional focus, and as outcome 
variables the measures of itch and pain sensitivity. Mediation is then specified by a 
decrease in the significant relationship between the independent variable and the 
outcome variable, when controlling for the mediator. 
Furthermore, all analyses were controlled by conducting partial correlation 
analyses for the following possible confounders: age, body mass index, educa-
tional level, menopausal status, medication intake and VAS itch and pain at the 
day of testing. Since these control variables did not significantly correlate with 
any of the measures for attentional focus and the same levels of significance were 
found when controlling for these variables by use of partial correlation analyses, 
the uncorrected data are presented.
Results
Quantitative sensory testing outcome measures and outcome measures for 
attention
The means, SD and range of the thresholds and VAS scores for itch and 
pain elicited by the stimuli are presented in Table 1. Means, SD and range of both 
measures of attentional focus are displayed in Table 2. The itch and pain scores for 
the same QST stimulus were not significantly correlated for all applied stimuli (data 
not shown). There were also no significant correlations between the thresholds 
and itch or pain scores for the same stimulus for all applied stimuli, except for a 
significant correlation between the tolerance threshold of electrical stimulation and 
the pain score at this threshold (r = 0.37, P < 0.05). 
Association between attentional focus and tolerance thresholds
There were no significant associations between the measures of atten-
tional focus and the composite scores for the tolerance thresholds for the applied 
somatosensory stimuli (Table 3). There were also no significant correlations when 
exploratively testing the single correlations between attentional focus and the dif-
ferent measures of the tolerance thresholds for the tactile, electrical or cold pres-
sor stimuli (Table 3). 
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Association between attentional focus and itch and pain elicited by the stimuli
The composite scores for itch and pain both were significantly correlated 
with the BVS, indicating that a greater attentional focus on bodily sensations was 
significantly associated with higher levels of itch and pain evoked by the soma-
tosensory stimuli applied. In addition, the composite score for itch, but not the 
composite score for pain, was significantly correlated with the BSQ, indicating 
that a greater attention to the occurrence of sensations was significantly associ-
ated with higher levels of itch evoked by the somatosensory stimuli (Table 3). The 
explorative correlations for each of the stimuli separately further showed that a 
greater attention to the occurrence of sensations (BSQ) was significantly asso-
ciated with a higher itch score during tactile, electrical, histamine, and capsai-
cin stimuli and to a higher pain score during the cold pressor test. In addition, a 
greater attentional focus on bodily sensations (BVS) was significantly correlated 
with a higher itch score for capsaicin application and a higher pain score for both 
histamine iontophoresis and the cold pressor test (see Table 3). 
Role of personality characteristics
Means, SD and range of the questionnaires measuring neuroticism and 
anxiety sensitivity are displayed in Table 2. Personality characteristics were not 
significantly associated with the measures of attentional focus or the thresholds or 
itch and pain scores at these thresholds. Consequently the personality character-
istics did not play a role in the relationship between attentional focus and itch and 
pain sensitivity to the somatosensory stimuli. 
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Table 1
Means, standard deviations (SD) and range of tolerance thresholds and visual 
analogue scale (VAS) scores for itch and pain elicited by different somatosensory 
stimuli.
Mean (SD) Range
Thresholds
    Tactilea  13.0 (4.6) 6 – 20
    Electricalb    7.2 (4.0) 1.5 – 15.0
    Cold pressorc 55.6 (50.7) 4 – 180
Itch and pain ratings - VASd
    Tactile
    VAS itch 0.9 (1.3) 0.0 – 4.0
    VAS pain 0.8 (1.1) 0.0 – 5.0
    Electrical stimulation
    VAS itch 1.6 (2.2) 0.0 – 7.0
    VAS pain 2.9 (2.5) 0.0 – 8.5
    Cold pressor
    VAS pain 4.5 (2.8) 0.0 – 8.5
    Histamine
    VAS itch 2.9 (2.1) 0.0 – 7.0
    VAS pain 1.8 (2.1) 0.0 – 6.7
    Capsaicin
    VAS itch 1.1 (1.4) 0.0 – 5.4
aTactile threshold: hair number out of a total of 20 von Frey monofilaments; bElectrical tolerance thres-
hold: electrical current in mA; cCold pressor immersion time in seconds. dVAS itch/pain: score of itch/
pain evoked by the stimuli on a visual analogue scale ranging from 0 to 10. 
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Table 2 
Means, standard deviations (SD) and range of both measures of attentional focus 
(BSQ and BVS) and the measures of the personality characteristics neuroticism 
and anxiety sensitivity (EPQ and ASI).
Mean (SD) Rangea
Attention to occurrence of sensations (BSQ) 1.86 (0.36) 1.13 – 2.87
Attentional focus (BVS) 3.42 (1.55) 1.32 – 6.81 
Neuroticism (EPQ) 6.13 (4.85) 0 – 22
Anxiety Sensitivity (ASI) 1.35 (0.66) 0.27 – 2.87
aTheoretical scale ranges of questionnaires: BSQ: 1 – 4; BVS: 0 – 10; EPQ: 0 – 22; ASI: 0 – 4. 
BSQ: Body Sensations Questionnaire; BVS: Body Vigilance Scale; EPQ: Eysenck Personality Question-
naire; ASI: Anxiety Sensitivity Index.
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Table 3
Pearson correlations between attentional focus on bodily sensations and the com-
posite and single scores for the tolerance thresholds and visual analogue scale 
(VAS) scores for itch and pain elicited by different somatosensory stimuli.
Attention to occurrence 
of sensations (BSQ)
Attentional focus 
(BVS)
Thresholds
    Composite score for thresholdsa -0.22 -0.01
        Tactileb -0.05   0.01
        Electricalc -0.15   0.12
        Cold pressord -0.21 -0.14
Itch and pain scores - VASe 
    Composite score for itcha   0.55***   0.30*
    Composite score for paina   0.05   0.50**
    Tactile
    VAS itch   0.34*   0.13
    VAS pain -0.23   0.25
    Electrical stimulation
    VAS itch   0.49**   0.24
    VAS pain -0.15   0.27
    Cold pressor
    VAS pain   0.40*   0.52***
    Histamine
    VAS itch   0.34*   0.13
    VAS pain   0.10   0.39*
    Capsaicin
    VAS itch   0.43**   0.36*
*: P < 0.05; **: P < 0.01; *** P < 0.001 (one-tailed).
aComposite score for tolerance thresholds: means of the standardized scores for the tolerance thresholds 
for tactile, electrical and cold pressor stimuli. Composite score for VAS scores: means of the standardized 
scores for itch and pain evoked by the tactile, electrical, cold pressor, histamine, and capsaicin stimuli.
bTactile threshold: hair number out of a total of 20 von Frey monofilaments; cElectrical threshold: electrical 
current in mA; dCold pressor immersion time in seconds. 
eVAS itch/pain: score of itch/pain evoked by the stimuli on a visual analogue scale ranging from 0 to 10. 
Corresponding levels of significance were found after controlling for the variables age, body mass index, 
educational level, menopausal status, medication intake, and current itch and pain at the day of testing.
BSQ: Body Sensations Questionnaire; BVS: Body Vigilance Scale.
5
role of attentIonal focus on bodIly sensatIons In sensItIvIty to Itch and paIn
96
Discussion
Focusing attention on bodily sensations might play a role in heightened 
sensitivity or hypervigilance of patients with symptoms of itch or pain [6,22,29]. In 
the present study, we therefore examined the role of attentional focus on bodily 
sensations on the experience of both itch and pain. A relatively high attentional fo-
cus on bodily sensations was associated with higher scores for itch and pain elic-
ited by different somatosensory stimuli. Our results are consistent with previous 
studies in pain [5,25] and preliminary results for itch [12], indicating that attentional 
focus, next to pain, also plays a role in the sensitivity to itch. This suggests that 
attentional focusing is a generic mechanism which plays a role in the sensitivity to 
different somatosensory stimuli.
The association between heightened attentional focus on bodily sensa-
tions and increased sensitivity to itch and pain sensations could be analogous 
to anxiety related symptoms [32]. Generally speaking, aggravation of common 
sensations could increase awareness of these sensations, which may in turn ag-
gravate the occurrence or intensity of the sensations. This increased awareness 
of the occurrence of sensations could influence the interpretation and expectancy 
of consequences, which may lead to negative misinterpretations of normal physi-
ological sensations [10,32]. The combination of an increased awareness of bodily 
sensations and a negative interpretation of these sensations may, in turn, lead to 
a higher reporting of the frequency and/or intensity of a given sensation. These 
information processing mechanisms are thought to play a role in the experience of 
pain [21,22,29] and similar mechanisms may also play a role in the experience of 
itch. Especially in patients with chronic itch and pain, attentional focus thus might 
be relevant in the high symptom reporting and, in turn, might also be involved in 
processes of both peripheral and central sensitization. Future research might elu-
cidate the role of attentional focus in central sensitization processes of itch and 
pain, for example by assessing temporal summation, hyperalgesia, or hyperknesis 
as measures for central sensitization of pain and itch. 
While the degree of attention paid to bodily sensations seemed to be re-
lated to reported levels of itch and pain, attentional focus was not associated with 
the tolerance thresholds. This is in line with the previous findings for the tolerance 
threshold for the cold pressor test [38] and suggests that attentional mechanisms 
particularly play a role in the subjective experience of sensations, probably reflect-
ing the more cognitive-affective sensitivity, while the tolerance to stimuli, reflecting 
the more sensory-discriminative part of sensitivity, may be more dependent on, for 
example, genetic factors [4,23]. 
With regard to the influence of personality on sensitivity to itch and pain, 
we expected that attentional focus might be affected by anxiety-based personal-
ity characteristics, thus that attentional focus might mediate the relationship be-
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tween, for example, anxiety sensitivity and itch and pain reporting. However, our 
results showed no association between personality and attentional focus or sensi-
tivity to itch and pain. Our results, that anxiety sensitivity and neuroticism were not 
associated with the measures of attentional focus, are in line with earlier findings 
in healthy individuals [1,25]. However, mean scores of anxiety sensitivity and neu-
roticism were relatively low in this sample of healthy subjects, which may explain 
the low correlation with the level of itch and pain sensations experienced [18,42]. 
In future research it may be important to also include subjects with high levels of 
anxiety (e.g., generalized anxiety disorder) to investigate whether anxiety based 
mechanisms of attentional focus in relation to itch and pain sensitivity might be 
particularly relevant to subjects scoring high on anxiety measures [18]. In addition, 
as it has been shown that not only anxiety processes, but also other emotional 
states such as depression play an important role in the perception of itch [14], fu-
ture research should also focus on the role of emotional states such as depression 
in relation to attentional focus and the sensitivity to itch or pain. Also, the role of 
a threatening character of stimuli may be further explored, for example by giving 
catastrophic instructions about the stimuli.
Some limitations have to be taken into account. First, since for all subjects 
stimuli were applied in the same order, we cannot exclude habituation or priming 
effects due to the preceding stimuli. Although it was attempted to minimize inter-
action between stimuli, by intervals in-between the stimuli, in future research the 
sequence of stimuli applied could be alternated. Second, using composite scores 
for the different measures of mechanical, electrical, chemical, and thermal stimuli 
might not be sensitive enough to study different sensory aspects of itch and pain 
sensitivity, while the explorative analyses of the single correlations of all measures 
might lead to possible problems of multiple testing and type I error. Third, to get 
more insight into the causal effects of attentional mechanisms on sensitivity to itch 
and pain, it might be important to experimentally manipulate attentional focus, for 
example by using distraction tasks or attentional focusing tasks [1]. Fourth, this 
study provides support for the role of attentional focus in itch and pain sensitivity 
of healthy female subjects. Since sensitivity to pain differs slightly between men 
and women [39], additional mechanisms and their role in sensitivity to itch and pain 
have to be replicated in men. Fifth, due to possible response bias, it may be pref-
erable to combine the questionnaires with implicit tasks to measure pre-attentive 
processes [26]. Sixth, the items of the questionnaires measuring attentional fo-
cus are about anxiety-related complaints and are generally in contrast to the QST 
stimuli evoking mainly itch or pain. Correlations may be stronger if the attentional 
mechanisms concern sensations related to the specific applied stimuli or if they 
are of direct relevance for the subjects. Since itch and pain are highly relevant to 
patients with chronic itch and pain, respectively, it would be appropriate to include 
these patients in future research. For clinical purposes future research might focus 
on identifying and screening of patients at risk for disturbed attentional processes, 
followed by tailored treatment to reduce dysfunctional hypervigilance for physical 
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symptoms of itch and pain.
In summary, the results of the present study indicate that a greater atten-
tional focus on bodily sensations is not only relevant to the experience of pain, but 
also of itch, suggesting that a generic attentional focus on bodily sensations is a 
mechanism that plays a role in sensitivity to different physical sensations. Future 
research is needed to investigate whether mechanisms of attentional focus may 
also be involved in symptom reporting of patients with skin disease who suffer 
from chronic itch.
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Abstract
Physical complaints, such as pain, can be effectively reduced by placebo 
effects through induction of positive expectations, or increased by nocebo effects 
through induction of negative expectations. In the present study, verbally induced 
nocebo and placebo effects on itch were experimentally investigated for the first 
time. In part 1, the role of verbal suggestions in inducing nocebo effects on itch 
and pain was investigated. All subjects received the same somatosensory quanti-
tative sensory testing stimuli, that is, mechanical and electrical stimuli and appli-
cation of histamine, and verbal suggestions to manipulate expectations regarding 
the stimuli. The suggestions were designed to produce either high expectations 
for itch (itch nocebo) or pain (pain nocebo) or low expectations for itch (itch no-
cebo control) or pain (pain nocebo control). Results showed that high itch and pain 
expectations resulted in higher levels of itch and pain respectively. When compar-
ing nocebo effects induced by verbal suggestions, results were more pronounced 
for itch than for pain. In part 2, verbal suggestions designed to produce a placebo 
effect on itch (itch placebo) or pain (pain placebo), or neutral suggestions (itch 
placebo control and pain placebo control) were given regarding a second applica-
tion of histamine and compared with the first application applied in part 1. Results 
of placebo effects only showed a significantly larger decrease in itch in the itch 
placebo condition than in the pain placebo condition. In conclusion, we showed 
for the first time that nocebo and possibly placebo responses can be induced on 
itch by verbal suggestions.
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Introduction
Placebos can affect a wide variety of subjective, behavioral, and physi-
ological responses, and are effective in, for example, depression, Parkinson’s dis-
ease, irritable bowel syndrome, and pain [4,18,23,30,40,53]. In contrast to the pla-
cebo effect, less attention has been directed to the nocebo effect, which is based 
on the induction of negative expectations and allows investigation of worsening 
of complaints [7,11,37,47]. Research into the mechanisms of placebo and nocebo 
has mainly concentrated on expectation learning processes, involving both verbal 
suggestions and conditioning [9,16]. These studies generally showed that placebo 
effects are larger when verbal suggestions were combined with conditioning; no-
cebo effects were equally effective when verbal suggestions were given alone or 
in combination with conditioning [11,12,33].
Itch is a major symptom of many chronic skin conditions affecting up to 
50% of patients with skin disease in general practice [54]. In both chronic itch and 
pain, comparable processes of central and peripheral sensitization are thought 
to play a main role in symptom-worsening. For example, sensitization phenom-
ena of allodynia and hyperalgesia, well known in pain, similarly play a role in itch 
(alloknesis and hyperknesis) [3,43,45]. Furthermore, in both localized painful and 
pruritic lesions, levels of nerve growth factor are increased, and inflammatory me-
diators, for example, bradykinin, histamine, and prostaglandins, have an acute 
sensitization effect on peripheral nociceptors and also provoke itch [25,29]. From 
a neurophysiological point of view, corresponding brain areas (e.g., the primary 
and secondary somatosensory cortex or anterior cingulate cortex) are activated in 
pain and itch processing, although the brain area activation patterns and neuronal 
processing differs [28,48]. In view of the considerable overlap between itch and 
pain, sensitization processes influenced by expectations regarding increase or de-
crease in physical sensations, as relevant to placebo and nocebo effects, may also 
similarly influence pain and itch. There is some indirect evidence suggesting a role 
of nocebo effects in itch. For example, it has been shown that patients with atopic 
dermatitis react more strongly to histamine when given verbal suggestions for ex-
aggerated skin reactions and itch [44]. Furthermore, the frequency of scratching 
of uninformed subjects was significantly higher during a lecture about itch than 
during a neutral lecture [36]. Taking this into account, nocebo and placebo effects 
induced by verbal suggestions may also be relevant to itch. Investigation of these 
mechanisms in pruritus may also contribute to validation of concepts of nocicep-
tion [43], and studying nocebo and placebo effects on different sensations, such 
as pain and itch, further adds to the knowledge of generic and symptom-specific 
psychophysiological mechanisms of nocebo and placebo responding. The aim of 
the present study was to investigate the role of verbal suggestions in nocebo and 
placebo effects on itch and pain. 
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Methods
Part 1 of this study aimed to explore the role of nocebo effects on itch 
and pain induced by verbal suggestions manipulating expectations (high/low ex-
pectations for itch/pain) regarding various somatosensory stimuli that can evoke 
itch and pain. In part 2 of this study, subjects were given either suggestions of a 
decrease in itch or pain, or neutral suggestions regarding a second application of 
histamine additional to the first application in part 1. The two parts of the study 
were performed on the same day, with a 15-minute interval in-between. 
Part 1: nocebo effects on itch and pain
Participants
One hundred five healthy female subjects aged 18 years and older (mean 
age = 21.8 years, SD = 2.2) were recruited at the university campus of Radboud 
University, Nijmegen, the Netherlands. Exclusion criteria were severe morbidity 
(e.g., multiple sclerosis, diabetes mellitus, heart or lung diseases), psychiatric dis-
orders (e.g., depression), use of pacemaker, use of systemic medication in the pre-
vious 24 h, and chronic itch or pain complaints either currently or in the past. The 
sample consisted of Dutch (96%) or German (4%) nationalities; all could speak 
and write Dutch fluently. Of the subjects, 55% had a partner (11% were married 
or living with their partner), and 69% used oral contraceptives. The protocol was 
approved by the regional medical ethics committee. On arrival at the test facility, 
participants were asked to score their current levels of itch and pain on a visual 
analogue scale (VAS) ranging from 0 (no itch/pain at all) to 10 (worst itch/pain 
imaginable). Mean levels of itch and pain on the day of testing were 0.2 (SD = 
0.6) and 0.3 (SD = 0.6), respectively. Multivariate analyses of variance (MANOVA) 
analysis showed no significant differences between the experimental conditions 
(see section Experimental nocebo conditions) with regard to age, body mass in-
dex, educational level, use of oral contraceptives, and current itch and pain on the 
day of testing. 
General procedure
Self-report questionnaires were sent to the participants 1 week before the 
experiment. On arrival at the test facility, participants were informed about the 
study and all participants gave their informed consent prior to the investigation. 
Participants had earlier been instructed not to drink black tea or coffee 1 h before 
testing. Subjects were informed about the study (including parts 1 and 2 of the 
experiment) by describing the general purpose of the studies in an experimental 
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context of a study investigating sensitivity to somatosensory stimuli. They were 
not aware that they were being randomly assigned to one of the four experimental 
conditions (2 x 2 design with respect to the itch nocebo condition with high expec-
tation, itch nocebo control condition with low expectation, pain nocebo condition 
with high expectation, and pain nocebo control condition with low expectation) or, 
subsequently, to one of the placebo conditions (only subjects in the high expec-
tations itch and pain conditions). Subjects received condition-appropriate verbal 
information about the stimuli to be applied. Somatosensory quantitative sensory 
testing stimuli [26] were applied in the following order: monofilament stimulation, 
electrical stimulation, and histamine iontophoresis (see Figure 1 for a flow diagram 
of the stimuli). The same stimuli were applied to all subjects, either with a prede-
termined intensity (mechanical, electrical and chemical stimulation) or tailored to 
the subject’s threshold (electrical stimulation). For each stimulus and in all experi-
mental conditions, subjects were instructed to rate the perceived levels of itch and 
pain on a VAS ranging from 0 (no itch/pain) to 10 (the worst itch/pain imaginable). 
All subjects were tested by the same male experimenter. 
Figure 1 Flow diagram of the application of stimuli in part 1 (nocebo) and part 2 
(placebo) of the study.
Experimental nocebo conditions
Subjects were randomly assigned to one of four nocebo conditions, two 
for itch and two for pain: itch nocebo condition (high expectation; n = 36), itch 
nocebo control condition (low expectation; n = 20), pain nocebo condition (high 
expectation; n = 33), or pain nocebo control condition (low expectation; n = 16). All 
subjects were told that they were participating in a study investigating sensitivity 
to somatosensory stimuli evoking, for example, itch and pain, and that they were 
randomized to receive either itch or pain stimuli. The following instructions were 
given. 
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Itch nocebo conditions
Subjects in both itch conditions were told that they would receive itch 
stimuli. In the itch nocebo condition (high expectation), subjects were told that 
“95% of healthy people experience itch from these stimuli. Very few, maximally 
5%, experience pain”, in order to induce high itch expectations. Instructions were 
briefly repeated (“nearly all healthy people experience itch from these stimuli, while 
hardly anyone experiences pain”) before the somatosensory stimuli were applied. 
In the itch nocebo control condition (low expectation), subjects were told that “As 
few as 5% of healthy people experience itch from these stimuli, and only 5% of 
healthy people experience pain”, in order to induce low itch expectations. In addi-
tion, before somatosensory stimuli were applied to subjects in the nocebo control 
condition, the instructions were briefly repeated: “hardly any healthy people ex-
perience itch from these stimuli, and hardly anyone experiences pain”. After the 
instructions were given, subjects in both itch conditions were asked to indicate the 
levels of itch and pain they expected to feel from the stimuli on a VAS from 0 to 10. 
As expected, subjects in the itch nocebo condition (high expectation) expected to 
feel significantly higher levels of itch (t = 5.52, P < 0.001) than the subjects in the 
itch nocebo control condition (low expectation), while the levels of pain expected 
by the subjects did not differ between both conditions (t = 1.22, P = 0.21).
Pain nocebo conditions
The instructions for the subjects in the pain nocebo condition (high expec-
tation) and pain nocebo control condition (low expectation) were the same as for 
the itch nocebo conditions, except that the word “itch” was replaced by the word 
“pain”, and vice versa. After the instructions, the subjects in both pain conditions 
were asked to indicate the levels of pain and itch they expected to feel from the 
stimuli on a VAS from 0 to 10. As expected, subjects in the pain nocebo condi-
tion (high expectation) expected to feel significantly higher levels of pain (t = 6.16, 
P < 0.000) than the subjects in the pain nocebo control condition (low expectation), 
while the levels of itch expected did not differ between the conditions (t = 0.73, 
P = 0.47).
Somatosensory stimuli
All subjects received the same somatosensory stimuli of similar intensity 
that have previously been validated for inducing itch and/or pain [50,51]. They 
were asked to report the levels of itch and pain they experienced for each stimulus 
separately on a VAS ranging from 0 to 10. Interval time in-between the stimuli was 
chosen based on earlier studies showing that mean subjective experiences of itch 
and pain were adequately diminished after the stimuli interval times [50,51]. 
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Mechanical stimulation
Mechanical stimulation was applied by using two Semmes-Weinstein von 
Frey calibrated monofilaments of 15.0 and 75.0 g. The choice of filaments was 
based on a previous study of our group investigating when a pricking sensation, 
which can evoke itch, pain, or both, is perceived [51]. The filaments were applied 
vertically consecutively for 2 seconds to the nondominant forearm (2 cm distal to 
the epicondyle of the humerus, C5 dermatome), while avoiding contact with body 
hair. The interval between the filaments was at least 30 seconds and the interval 
between mechanical stimulation and electrical stimulation was at least 5 minutes.
Electrical stimulation
Cutaneous electrodes were applied to the nondominant forearm, 2 cm 
distal to the epicondyle of the humerus (C5 dermatome). Electrical stimulation 
was administered using a constant current nerve stimulator (Pajunk; Geisingen, 
Germany). The electrical tolerance threshold, a tailored measure, taking into ac-
count the subjects’ interindividual variability, was defined by “the moment that the 
sensation becomes unbearable and you want to stop immediately”. The electrical 
tolerance threshold was determined twice by ramping with continuous increasing 
intensity (about 0.2 mA/s) [50]. The electrical stimulation was applied at 100-Hz 
frequency with 0.3-ms pulse duration, a stimulus frequency and intensity previ-
ously shown to evoke pain as well as itch [27,50,51]. The subjects were asked to 
report itch and pain scores immediately after the electrical stimulation. Mean VAS 
scores were calculated. Next, subjects were instructed that they would receive 
three different electrical stimuli of short duration. Subjects actually received three 
similar stimuli for 3 seconds at 6.0 mA intensity (100-Hz frequency, 0.3 mA pulse 
duration). For each electrical stimulus, subjects were asked to score itch and pain 
on the VAS, and the mean of these VAS scores were calculated. The interval be-
tween the threshold measurements and between the three electrical stimuli was at 
least 30 seconds, and the interval between threshold measurements and the first 
short electrical stimulus was at least 5 minutes. The interval between electrical 
stimulation and histamine iontophoresis was at least 15 minutes.
Histamine iontophoresis
Histamine was applied by iontophoresis (Chattanooga Group, Hixson, TN, 
USA). Histamine dihydrochloride (0.5%) was dissolved in a gel of 2% methylcel-
lulose in distilled water and 2.0 mL was placed in an electrode (Chattanooga Ionto 
Ultra Electrode medium), which was applied to the dominant forearm, 2 cm distal 
to the lateral epicondyle of the humerus (C5 dermatome). The reference electrode 
(area: 38.7 cm2) was applied to the skin on the lateral side of the triceps brachial 
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muscle. Current level was set at 1.0 mA and histamine was delivered for 2.5 min-
utes [50]. Histamine iontophoresis is particularly known to induce itch [28], how-
ever, it may also induce low levels of pain [3,50,51]. During histamine application, 
subjects were asked to rate the intensity of itch and pain every 30 seconds. The 
mean VAS scores during application were calculated.
Part 2: placebo effects on itch and pain
Participants
The sixty-nine subjects who were randomized to the high-expectation 
conditions of part 1 (36 subjects of the itch nocebo condition [high expectation] 
and 33 subjects of the pain nocebo condition [high expectation]) also participated 
in part 2. There were no significant differences in demographics and study char-
acteristics of the subjects participating in this part of the study compared with 
those in part 1. Mean levels of current itch and pain were 0.1 (SD = 0.3) and 0.3 
(SD = 0.7), respectively, on the day of testing. MANOVA analysis showed that there 
were no significant differences between the experimental placebo conditions (see 
section Experimental placebo conditions) with regard to age, body mass index, 
educational level, use of oral contraceptives, and current itch and pain on the day 
of testing. 
General procedure
All participants of part 2 had also participated in part 1, when the 2 parts 
of the experiment had been introduced within the same experimental context of 
testing sensitivity to somatosensory stimuli. Subjects from the itch nocebo condi-
tion (high expectation) of part 1 were randomly assigned to either the itch placebo 
or itch placebo control condition, and subjects from the pain nocebo condition 
(high expectation) of part 1 were randomly assigned to either the pain placebo or 
pain placebo control condition (2 x 2 repeated measures design), while for sub-
jects from the itch and pain nocebo control conditions (low expectation) of part 1, 
testing stopped after part 1. Depending on the experimental placebo condition 
(itch/pain placebo or placebo control) subjects were assigned to, they received 
verbal information regarding the sensory stimulus they would receive (see Section 
Experimental placebo conditions). Subsequently, histamine was applied for the 
second time, now to the nondominant forearm, using an identical procedure as in 
part 1 (see Figure 1 for a flow diagram of the stimuli). Subjects were instructed to 
rate the perceived levels of itch and pain on a VAS ranging from 0 (no itch/pain) to 
10 (the worst itch/pain imaginable). 
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Experimental placebo conditions
The subjects from the itch nocebo condition (high expectation) of part 1 
were randomly assigned to 1 of the 2 experimental conditions for itch placebo: 
itch placebo condition (n = 20) and itch placebo control condition (n = 16), while 
the subjects from the pain nocebo condition (high expectation) of part 1 were 
randomly assigned to 1 of the 2 experimental conditions for pain placebo: pain 
placebo condition (n = 15) and pain placebo control condition (n = 18). The follow-
ing instructions were given.
Itch placebo conditions
In the itch placebo condition, subjects received the following suggestions 
before histamine was applied for the second time: “Now I will apply the same gel 
to the other forearm, but I added an itch reducing substance to this gel, which 
reduces itch in such a way that nearly all healthy people do not experience itch 
anymore”. In the itch placebo control condition, subjects received the following 
suggestions before histamine was applied for the second time: “Now I will apply 
the same itching gel to the other forearm. Nearly all healthy people experience itch 
from these stimuli, while hardly anyone experiences pain”. The instructions given 
to the subjects in the placebo control condition, the aim of which was to investi-
gate the effects of repeated application of histamine, corresponded to the instruc-
tions given to the subjects in the nocebo conditions when histamine was applied 
for the first time, as much as possible.
Pain placebo conditions
The instructions for the subjects in the pain placebo and pain placebo 
control conditions were the same as for the itch placebo conditions, except that 
the word “itch” was replaced by the word “pain”, and vice versa. 
Individual psychological characteristics
The individual psychological characteristics of suggestibility, neuroticism 
and social desirability were additionally assessed, because these characteristics 
may affect the magnitude of nocebo and placebo effects [14,21,22]. Therefore, the 
following validated questionnaires investigating individual psychological charac-
teristics had been filled out within 1 week before the testing took place.
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Suggestibility
The Creative Imagination Scale measures the ability to experience sug-
gestions imaginatively [57]. It consists of 10 items, each giving a short description 
of an event to imagine. For each item, subjects rated the degree of imagining when 
compared with experiencing the event for real. Items were rated on a 5-point Likert 
scale, ranging from “totally not the same (0)” to “almost exactly the same (4)”. The 
total score was obtained by calculating the sum of the 10 items. Cronbach alpha 
of the Creative Imagination Scale in the present study was 0.85. 
Imaginative involvement
The Tellegen Absorption Scale was used to measure the subjects’ tenden-
cy to become deeply involved (absorbed) in everyday activities (34 dichotomous 
items; true/false). This measure was designed to test the individuals’ ability to set 
reality aside temporarily while engaging in fantasy [49]. Total scores on the scale 
are the sum of the items identified as “true” on the scale. Cronbach alpha for the 
Tellegen Absorption Scale in the present study was 0.80. 
Social desirability
Social desirability, the tendency to report information colored by social 
desirability concerns, was measured with the social desirability subscale of the 
Eysenck Personality Questionnaire [17]. The total score was obtained by calcula-
ting the sum of the 22 items, which were rated on a dichotomous scale (yes/no). In 
the present study, Cronbach alpha was 0.76.
Neuroticism
Neuroticism, which includes the tendency to have more negative outcome 
expectations, was measured with the neuroticism subscale of the Eysenck Per-
sonality Questionnaire [17]. The total score was obtained by calculating the sum of 
the 22 items, which were rated on a dichotomous scale (yes/no). Cronbach alpha 
was 0.84 in the present study.
Statistical analysis
All analyses were performed using SPSS 16.0 for Windows (SPSS Inc, 
Chicago, IL, USA). Variables were checked for normal distribution. Variables that 
were slightly skewed in one of the experimental conditions were transformed by 
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square root transformation, which resulted in a normal distribution. In order to test 
the main hypotheses of part 1 of this study, general linear model (GLM) MANO-
VAs were conducted separately for itch and pain scores. In order to test nocebo 
effects, we conducted MANOVAs, with all dependent variables, for itch and pain 
scores separately. By using MANOVA tests, the number of tests could be reduced 
to four because the levels of itch/pain evoked by the four different stimuli could be 
tested at once. If MANOVA results showed significant between-group effects, ad-
ditional post hoc ANOVAs were conducted for each stimulus separately to reveal 
possible differential effects for the effect of the manipulated expectations between 
the different somatosensory stimuli. For the itch nocebo analysis, mean itch lev-
els evoked by the different sensory stimuli were taken as dependent variables 
and condition (itch nocebo condition [high expectation] and itch nocebo control 
condition [low expectation]) was taken as an independent variable. The same pro-
cedure was applied for the pain nocebo analysis. Moreover, in order to compare 
the itch nocebo with the pain nocebo condition, GLM multivariate analyses were 
conducted with the itch nocebo condition (high expectation) and the pain nocebo 
condition (high expectation) as independent variables, and both the itch scores 
and pain scores separately as dependent variables. In order to investigate pos-
sible interaction effects between the different stimuli evoking itch and pain and 
the suggestions subjects received to manipulate expectations, profile analyses 
were conducted additionally by applying repeated measures ANOVA with the itch 
or pain scores for the different stimuli as within-subjects factors and the different 
groups as between-subject factors.
Additionally, Pearson correlation coefficients were calculated between the 
levels of expected (after suggestions were given and before stimuli were applied) 
and experienced (evoked by the stimuli) itch or pain in the itch or pain nocebo 
condition (high expectation), respectively.
In order to test the hypotheses of part 2 of this study with repeated ap-
plications of histamine, GLM repeated measures ANOVA was conducted. For the 
itch placebo analysis, itch scores during the first and second application of hista-
mine were taken as within-subject factor, and the itch placebo conditions (itch pla-
cebo and itch placebo control) were taken as between-subject factor. The same 
analysis was applied for the pain placebo analysis. Moreover, in order to compare 
itch placebo with pain placebo, GLM repeated measures ANOVA was conducted 
with the itch placebo and the pain placebo condition as between-subjects factor, 
with the itch and pain scores evoked by the first and second application of hista-
mine separately as within-subjects factor. Placebo analyses were conducted for 
each experimental condition separately and the interaction effects between the 
two applications of histamine and experimental condition were calculated. Finally, 
Pearson correlation coefficients were calculated between the questionnaires mea-
suring individual psychological characteristics of neuroticism, social desirability, 
imaginative involvement, and suggestibility, and the itch and pain scores in the itch 
nocebo condition (high expectation) and the pain nocebo condition (high expecta-
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tion), as well as the change score for itch and pain, that is, the difference between 
the first and second application of histamine, in the itch and pain placebo condi-
tions. 
Results
Part 1: nocebo effects on itch and pain
Regarding part 1 in which we investigated nocebo effects on itch and pain 
regarding different somatosensory stimuli, we expected that levels of itch evoked 
by the stimuli would be higher in the itch nocebo condition (high expectation) than 
in the itch nocebo control condition (low expectation) as well as in the pain nocebo 
condition (high expectation), and vice versa for pain. Mean current intensities of 
the electrical tolerance thresholds, a measure tailored to the subjects, did not sig-
nificantly differ between the nocebo conditions [F(3,101) = 1.09, P = 0.36].
Nocebo effects on itch
Means and SD of itch evoked by the different sensory stimuli are dis-
played in Table 1 (see also Figure 2). MANOVA results of itch nocebo showed that 
itch levels were significantly higher in the itch nocebo condition (high expecta-
tion) than in the itch nocebo control condition (low expectation) [Wilks Lambda 
(Λ) = 0.65, F(4,51) = 6.85, P < 0.001]. For each stimulus separately, univariate tests 
(Figure 2) showed significant effects for higher itch scores in the itch nocebo (high 
expectation) than in the itch nocebo control condition (low expectation), that is, 
for mechanical stimulation [F(1,54) = 15.45, P < 0.001], electrical tolerance thres-
hold [F(1,54) = 9.98, P < 0.01], short electrical stimuli [F(1,54) = 13.12, P = 0.001], 
and histamine iontophoresis [F(1,54) = 12.38, P = 0.001]. In addition to the levels 
of itch, levels of pain were also significantly higher in the itch nocebo condition 
(high expectation) compared to the itch nocebo control condition (low expectation) 
[Λ = 0.83, F(4,51) = 2.67, P < 0.05], with significant univariate effects in the same 
direction for electrical tolerance threshold [F(1,54) = 8.62, P < 0.01] and short elec-
trical stimuli [F(1,54) = 8.70, P < 0.01], borderline significant effects for histamine 
iontophoresis [F(1,54) = 2.91, P = 0.09], and no significant effect for mechanical 
stimulation [F(1,54) = 1.08, P = 0.30].
Comparison of itch scores for the itch nocebo condition (high expectation) 
and pain nocebo condition (high expectation) (Table 1) showed that itch scores 
were significantly higher in the itch nocebo condition than in the pain nocebo con-
dition [MANOVA Λ = 0.43, F(4,64) = 20.88, P < 0.001]. More specifically, univariate 
analysis showed significantly higher itch scores for the itch nocebo condition (high 
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expectation) and pain nocebo condition (high expectation) for all stimuli separately, 
that is, for mechanical stimulation [F(1,67) = 22.43, P < 0.001], electrical tolerance 
threshold [F(1,67) = 42.01, P < 0.001], short electrical stimuli [F(1,67) = 52.60, 
P < 0.001], and histamine iontophoresis [F(1,67) = 32.34, P < 0.001]. 
Profile analyses for the different somatosensory stimuli showed no signifi-
cant interaction effects for evoked pain between the stimuli and the itch nocebo 
condition (high expectation) and itch nocebo control condition (low expectation) 
[F(1,55) = 0.98, P = 0.33]. When itch nocebo and pain nocebo conditions were 
compared, results showed an interaction effect between itch evoked by the differ-
ent stimuli and the experimental conditions [F(1,77) = 7.47, P < 0.01], indicating that 
the effects on itch evoked may differ across stimuli when comparing itch and pain 
nocebo suggestions. Inspection of the profile plot indicated that effects were less 
pronounced for the mechanical stimulation when compared to the other stimuli.
Nocebo effects on pain
Means and SD of pain evoked by the different sensory stimuli are dis-
played in Table 1. MANOVA results of pain nocebo showed that pain levels were 
significantly higher in the pain nocebo condition (high expectation) than in the pain 
nocebo control condition (low expectation) [Λ = 0.81, F(4,44) = 2.66, P < 0.05]. 
For each stimulus separately, univariate tests showed significant effects in the 
same direction, for mechanical stimulation [F(1,47) = 5.59, P < 0.05], short electri-
cal stimuli [F(1,47) = 5.75, P < 0.05], and histamine iontophoresis [F(1,47) = 6.10, 
P < 0.05]. For the electrical tolerance threshold, the univariate test was borderline 
significant [F(1,47) = 3.46, P = 0.07]. In addition to the levels of pain, the levels of 
itch did not significantly differ between the pain nocebo (high expectation) and pain 
nocebo control condition (low expectation) [Λ = 0.86, F(4,44) = 1.73, P = 0.16]. 
Comparison of pain scores for the pain nocebo (high expectation) and itch 
nocebo condition (high expectation) (Table 1), showed that there was no signifi-
cant difference between the pain nocebo and itch nocebo conditions [MANOVA 
Λ = 0.91, F(4,64) = 1.51, P = 0.21]. 
Profile analyses for the different somatosensory stimuli did not show any 
significant interaction effects for evoked pain between the stimuli and the pain no-
cebo condition (high expectation) and pain nocebo control condition (low expecta-
tion) [F(1,55) = 2.50, P = 0.12] or the pain nocebo condition (high expectation) and 
itch nocebo condition (high expectation) [F(1,77) = 0.02, P = 0.89].
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2C 
2D
Figure 2A - D Mean VAS scores for itch with standard error of the mean (SEM) 
of subjects in the itch nocebo condition (high expectation; n =36) and the itch 
nocebo control condition (low expectation; n = 20) for the different somatosen-
sory stimuli applied: mechanical stimulation (A), electrical stimulation at tolerance 
threshold (B), short electrical stimuli (C), and histamine iontophoresis (D). 
*** P ≤ 0.001. ** P < 0.01.
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Relationship between expectation and nocebo response
Means and SD of expected levels of itch and pain are displayed in Table 
2. Significant correlation coefficients were found between the expected and ex-
perienced levels of itch at the electrical tolerance threshold (r = 0.59, P < 0.001) 
and with short electrical stimuli (r = 0.44, P < 0.01) in the itch nocebo condition 
(high expectation), meaning that higher expectations of itch for these stimuli were 
associated with higher levels of experienced itch. Expected levels of pain were 
only marginally significantly correlated with levels of pain experienced (i.e., higher 
expectations of pain tended to correlate with higher experienced pain) with me-
chanical stimulation (r = 0.25, P < 0.10) and at the electrical tolerance threshold 
(r = 0.29, P = 0.10) in the pain nocebo condition (high expectation), but not with 
the other stimuli.
Table 2 
Pretest expectations of itch and pain to be evoked by the different somatosensory 
stimuli in the nocebo conditions.
Itch nocebo
condition 
Itch nocebo 
control condition
Pain nocebo
condition
Pain nocebo 
control condition
Pretest expecta-
tion of itch  M (SD)
5.5 (1.9) 2.7 (1.7) 1.6 (1.6) 1.4 (1.2)
Pretest  expecta-
tion of pain  M (SD)
1.8 (1.5) 1.3 (1.3) 4.9 (1.5) 2.1 (1.3)
Means (M) and standard deviations (SD) of visual analogue scale (VAS) scores for itch and pain levels 
expected to be evoked by the different somatosensory stimuli in the different experimental nocebo 
conditions after the corresponding instructions were given but before application of the stimuli. 
Part 2: placebo effects on itch and pain
Regarding part 2, in which we investigated placebo effects regarding two 
applications of histamine, we expected that subjects in the itch and pain placebo 
conditions would show a greater decrease in itch and pain, respectively, than sub-
jects in the respective control conditions, as well as subjects in the other symptom 
condition, when comparing the first with the second application of histamine.
Placebo effects on itch
Table 3 displays the means and SD of itch evoked by the two applications 
of histamine in the itch placebo and itch placebo control condition (see also Figure 
3). Levels of itch were reduced significantly in the two groups [F(1,34) = 18.42, 
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P < 0.001], but there was no significant interaction effect between the change in 
itch score and the two conditions [F(1,34) = 0.01, P = 0.91]. Comparison of the 
itch placebo and the pain placebo conditions showed a significant effect of time 
in the two groups [F(1,33) = 7.88, P < 0.01], and a significant interaction between 
the change in itch and the condition [F(1,33) = 5.84, P < 0.05], indicating that the 
decrease in itch was larger in the itch placebo condition than in the pain placebo 
condition.
Placebo effects on pain
Table 3 displays the means and SD of pain evoked by the two applica-
tions of histamine in the pain placebo and pain placebo control conditions. Results 
showed a significant time effect in the pain placebo condition and pain placebo 
control condition [F(1,31) = 9.94, P < 0.01], while there was no significant between-
groups difference in the decrease in pain between the conditions [interaction ef-
fect, F(1,31) = 0.04, P = 0.85]. Comparison of the pain placebo and the itch place-
bo conditions revealed an almost significant time effect [F(1,33) = 2.80, P = 0.10], 
but there was no interaction effect between the change in pain score between the 
conditions [F(1,33) = 0.54, P = 0.47].
 
Table 3
Placebo effects on itch and pain induced by verbal suggestions (part 2).
Itch placebo 
condition
Itch placebo 
control con-
dition
Pain placebo 
condition
Pain placebo 
control con-
dition
Itch VAS 
scores 
M (SD)
1st application 
of histamine 
3.84 (2.08) 4.18 (1.92) 0.85 (0.85) 1.45 (1.02)
2nd application 
of histamine
2.68 (1.63) 3.19 (2.15) 0.58 (0.64) 1.19 (1.06)
Pain VAS 
scores
M (SD)
1st application 
of histamine
0.78 (1.03) 0.75 (1.02) 0.85 (0.85) 1.45 (1.02)
2nd application 
of histamine
0.69 (0.94) 0.86 (1.31) 0.58 (0.64) 1.19 (1.06)
Means (M) and standard deviations (SD) of itch and pain evoked by histamine applied the first time with 
the instructions for itch or pain induction (see part 1), and itch and pain evoked by the second applica-
tion of histamine for which instructions of itch or pain reduction (itch placebo condition, n = 20; pain 
placebo condition, n = 15) or neutral itch or neutral pain instructions (itch placebo control condition, n 
= 16; pain placebo control condition, n = 18) were given. 
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Figure 3  Mean VAS scores for itch with standard error of the mean (SEM) of sub-
jects in the itch placebo condition (n = 20) and the itch placebo control condition 
(n = 16) for the first (part 1) and second (part 2) application of histamine. 
Individual psychological characteristics
All Pearson correlation coefficients between the personality characteris-
tics neuroticism, social desirability, imaginative involvement, and suggestibility, 
and itch and pain evoked by the four stimuli in the nocebo conditions for itch and 
pain in part 1 of this study were not significant. There were also no significant cor-
relations between the change score for itch and pain in the itch placebo and pain 
placebo conditions and personality characteristics (neuroticism, social desirability, 
imaginative involvement, and suggestibility) in part 2 of this study.
Discussion
The present study showed, for the first time, that nocebo effects can be 
induced on itch, besides pain, by manipulating expectations through verbal sug-
gestions regarding different somatosensory stimuli. Verbal suggestions designed 
to induce a placebo effect on itch resulted in a significantly greater decrease in itch 
than when pain placebo suggestions were given. 
In part 1, we investigated nocebo effects on itch and pain by manipulat-
ing subjects’ expectations of itch and pain by giving verbal suggestions about 
itch or pain that would be evoked by different somatosensory stimuli. We found 
that subjects who received verbal suggestions to induce high pain expectations 
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reported significantly more pain than subjects who received verbal suggestions 
inducing low pain expectations. These results are consistent with earlier findings 
on verbal suggestions inducing nocebo effects on pain [2,7,11,47]. More impor-
tantly, we showed that nocebo effects could be induced on itch by verbal sug-
gestions regarding different ambiguous somatosensory stimuli [50,51]. Subjects 
who received verbal suggestions inducing high itch expectations experienced sig-
nificantly higher levels of itch evoked by the somatosensory stimuli than subjects 
who received verbal suggestions inducing low itch expectations. Our results are 
consistent with previous studies, which showed that subjects experienced more 
itch when instructions exaggerating itch were given compared to neutral instruc-
tions, or when they listened to a lecture about itch compared to a neutral lecture 
[36,44]. 
The nocebo effects induced by verbal suggestions appeared to be stron-
ger for itch than for pain. This might indicate that itch may be more susceptible 
to suggestion than pain, for example, itch is known to be induced by watching 
other people scratching or by talking about itch [36]. Another explanation might 
be the opposite reflex pattern seen in itch and pain [42]. For example, subjects 
tend to withdraw from a painful stimulus or activity, whereas itch is predominantly 
a trigger for heightened physical activity, such as scratching [55]. In addition, itch 
and pain are influenced by different affective and motivational components, and 
despite the many similarities in sensitization mechanisms, the processing of itch 
and pain occurs via separate neurological pathways [28,43,48]. Itch distinguishes 
from pain by a specific neuronal pathway such as a histamine-dependent itch 
(mechano-insensitive) and an unspecific itch pathway that probably differentiates 
on the pattern of brain activation [28,43]. Furthermore, expectations about pain 
can alter central pain modulation [7,20,24,52], which processes may be different 
for itch expectations. Also, the type or intensity of the somatosensory stimuli used 
may play a role, for example, the stimuli may evoke somewhat higher levels of 
itch than pain (e.g., histamine). Several studies have shown that expectations of 
pain influence pain perception [9,19,32,41,56], and strong correlations between 
expected and experienced pain have been reported [35]. Response expectancies 
may lead to a cognitive readjustment of the appropriate behavior and also play a 
key role in nocebo and placebo effects [31,38]. Endogenous opioid systems and 
the cholecystokininergic pronociceptive system are supposed to play a role in 
the analgesia by expectations, since naloxone can antagonize these effects and 
cholecystokinine antagonists are capable of potentiating analgesia [5,6]. In the 
present study, expectations of itch and pain were significantly or marginally sig-
nificantly correlated with experienced itch and pain evoked by some of the stimuli, 
which partly supports that conscious expectation may be a possible mediator in 
some nocebo- and placebo-related effects [9,38].
In part 2 we investigated the role of verbal suggestions in placebo effects 
on itch and pain regarding two applications of histamine. Itch levels decreased to 
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a greater extent when suggestions of itch reduction were given than when sug-
gestions of pain reduction were given, while the decrease in itch was not signifi-
cantly different when it was suggested that itch would be reduced in comparison 
to neutral suggestions. The repeated application of histamine might have induced 
a habituation effect, resulting in a decreased response to the stimulus [34]. The 
lack of a pain placebo response is probably a consequence of the type of stimulus 
used, as the mean pain scores for the first application of histamine were below 1.5. 
Furthermore, although earlier research has shown that verbal suggestions can be 
effective in inducing placebo effects on pain [1,9,19,38], effects were much stron-
ger in combination with a conditioning procedure [10,33]. Finally, placebo effects 
have been shown to be stronger when contextual factors, for example, by imitat-
ing a clinical setting, are included [15]. 
Besides verbal suggestions, negative (nocebo) or positive (placebo) ex-
pectations for itch or pain can also be induced by conditioning. As an additional 
effect of conditioning to verbal suggestions was found regarding the magnitude of 
the placebo effect [10,33], literature indicates that conditioning does not have such 
an additional effect in nocebo effects on pain [11,37,47]. Future research should 
investigate whether conditioning could lead to nocebo and placebo responses for 
itch. For example for placebo, multiple itch stimuli of decreasing intensity could be 
applied in combination with the suggestion that an itch-reducing substance was 
added. 
Individual psychological characteristics of positive or negative expectation 
tendencies (e.g., neuroticism or catastrophizing), suggestibility (e.g., imagination), 
and social desirability may influence nocebo or placebo responses [14,21,22]. 
However, in the present study we did not find any significant correlation with the 
psychological characteristics. Future research could further clarify the specific role 
of expectation-related personality characteristics in nocebo and placebo effects 
on itch and pain, for example optimism and pessimism [21,22].
The present study had some limitations that should be taken into consid-
eration. First, nocebo and placebo effects require, by definition, the administration 
of inert (placebo) substances. Since an inert substance was administered only in 
the placebo experiment, the effects of the nocebo condition rather reflect noce-
bo-related effects of verbal suggestions after a stimulus induction [4]. In future 
studies, inert substances, for example, nocebo cream, should also be included to 
investigate the effects of the nocebo substance in addition to nocebo suggestions 
only. Moreover, various stimuli were applied to investigate nocebo effects (part 1), 
while we used histamine only to investigate placebo effects (part 2). Consequently, 
it is not yet possible to generalize the findings of part 2 among other stimuli, and 
the results of the nocebo and placebo experiment cannot be compared direct-
ly. Second, since we manipulated expectations for itch and pain simultaneously, 
some interaction effects between itch and pain, such as pain inhibitory effects on 
itch [28,48], cannot be excluded. Since stimuli were applied in the same order for 
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all subjects, we further cannot exclude cross-over (habituation or sensitization) 
effects due to the preceding stimuli. However, we minimized the interaction ef-
fects between stimuli by applying the stimuli with sufficient intervals in-between, 
based on applications of these stimuli in previous studies [50-52]. Third, not all our 
stimuli may be applicable to induce itch and pain to the same extent, in view of, 
for example, the low levels of pain induced by histamine in the placebo conditions. 
In addition, an interaction effect was found with regard to the strength of the itch 
nocebo effects across the different somatosensory stimuli. Inspection of the pro-
file plot suggests that verbal suggestion in the itch versus pain nocebo condition 
is less effective for itch evoked for the lowest-intensity stimulation (mechanical 
stimulation). Future research should look into the efficacy of verbal suggestion in 
inducing placebo and nocebo effects regarding different stimuli modalities. Fourth, 
in addition to the control conditions with low expectations for itch and pain in part 
1, an additional control condition with neutral suggestions without any expecta-
tions might be included in future research. Fifth, brain imagining studies showed 
that placebo responses for pain were accompanied by changes in several brain 
regions [39,40] and future research could, next to itch and pain levels, include ad-
ditional measures of placebo and nocebo responding, such as activation patterns 
of brain areas involved [7,8]. Sixth, since patients with chronic pain and itch have 
been shown to react differently to sensory stimuli, as, for example, chronic pain 
patients have been shown to sensitize differently to repeated pain stimuli than 
healthy subjects [13,46,51], expectations might elicit distinct patterns of nocebo 
or placebo responses in patients compared to healthy subjects. Research of noce-
bo and placebo effects in patients with chronic itch or pain can provide insight into 
the role of expectations in clinical worsening or improvement to develop therapies 
to alter expectations in order to decrease their suffering from chronic itch or pain.
In conclusion, we showed that, besides pain, itch nocebo effects can be 
induced by only giving verbal suggestions. The perception of different ambiguous 
stimuli can be influenced by negative suggestions, in such a way that negative 
expectations can adversely influence the intensity of itch or pain experienced. 
Our results emphasize the importance of expectations in nocebo effects on itch, 
and further suggest that negative suggestions may possibly be more effective in 
inducing itch nocebo responses than pain nocebo responses. In line with earlier 
findings of verbal suggestions on pain, we did find only indirect evidence for a pla-
cebo effect on itch in comparison to pain. Future research should focus on the role 
of expectations induced by conditioning and verbal suggestions in nocebo and 
placebo effects on itch, in particular in patients with chronic itch. In the long term, 
these findings may facilitate the development of therapeutic strategies to reduce 
itch by manipulating patients’ expectations.
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Abstract
Emotions play an important role in somatosensory sensations, such as 
pain. Experimental studies have shown that negative emotions can enhance the 
intensity of pain or reduce tolerance to pain, whereas positive emotions can lead 
to lowered pain sensitivity. To date, however, the role of emotions on somatosen-
sory sensations of itch has not been experimentally studied. The present study 
was performed to investigate the effects of negative and positive emotions on the 
sensitivity to itch and pain. Film fragments were used to induce a negative and 
positive emotional state in healthy female subjects. Itch and pain were induced 
using the following somatosensory stimuli: electrical stimulation, histamine ionto-
phoresis, and the cold pressor test. Electrical and cold pressor tolerance thresh-
olds were determined as well as levels of itch and pain evoked by the stimuli, and 
the perceived unpleasantness. Results showed that the scores for itch and pain 
evoked by histamine and the cold pressor test, respectively, were significantly 
higher in the negative than in the positive emotion condition, whereas tolerance 
thresholds to electrical stimulation and the cold pressor test and stimulus unpleas-
antness scores did not differ between the two conditions. These findings for the 
first time indicate that, in an experimental design, emotions play a role in sensitivity 
to somatosensory sensations of both itch and pain. 
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Introduction
Pain is part of the somatosensory system, which informs one about objects 
in the external environment. Pain is also a nociceptive sensation, which implies 
that it is part of the body’s defense system, warning of potential threat or ongoing 
harm, such as harmful movements or skin burns. Moreover, pain is an emotional 
experience, consisting not only of sensory-discriminative and cognitive-evaluative 
components, but also of affective-motivational components [4]. It is assumed that 
there is a reciprocal relationship between pain and mood [12]. For example, de-
pression is more common in patients with chronic pain than in healthy subjects 
[12,24] and depressed pain-free subjects are, on average, two times more likely 
to develop chronic musculoskeletal pain than non-depressed pain-free subjects 
[5,21]. Moreover, negative and positive emotions induced by mood induction pro-
cedures have been shown to influence the experience of pain differently. Negative 
emotions are associated with increased pain perception, whereas positive emo-
tions are associated with reduced pain perception in healthy subjects and patients 
with chronic pain [27,29,30,41,42,44]. Next to the pain intensity, unpleasantness, 
also called affective pain, seems to be influenced by the valence of the emo-
tional state. Thus, unpleasant emotions are associated with a higher stimulus un-
pleasantness than are pleasant emotions [18,20,27,46]. Furthermore, tolerance to 
stimuli may be influenced by emotions, as some studies have shown that negative 
emotions are associated with a lower tolerance than are positive emotions [11,45], 
although others have not consistently found such an effect [22,41]. 
Itch is also a nociceptive, somatosensory sensation, which has many simi-
larities to pain [16,34]. Therefore, it seems likely that emotions also play a role in 
itch. There is some evidence that depressive psychopathology is correlated with 
higher levels of itch symptoms in patients with chronic skin disease [7,14,37]. In 
addition, there are indications that experimentally induced stress can heighten the 
levels of itch felt by healthy subjects [1,13]. Although it seems likely that emotions 
play a role in the perception of itch, experimental studies investigating the role of 
negative and positive emotions in itch are lacking. The aim of the present study was 
to investigate for the first time whether negative and positive emotions influence 
both itch and pain sensations. The subjects’ emotions were manipulated by using 
film fragments, one of the most effective and standardized methods to induce both 
negative and positive emotions [32]. Different quantitative sensory testing stimuli, 
mechanical, electrical and histamine, were applied to induce itch and pain sensa-
tions. Individual psychological characteristics, such as anxiety sensitivity, alexithy-
mia, and neuroticism, were assessed because these variables may influence the 
emotion induction procedure or the experience of physical sensations such as pain 
[17,33]. We expected that the levels of pain and itch evoked by the stimuli and the 
perceived unpleasantness would be higher when negative emotions were induced 
than when positive emotions were induced. The difference in tolerance thresholds 
between the negative and positive emotion conditions was also explored. 
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Methods
Participants
Seventy-seven participants were recruited via the human subject pool man-
agement system of the university (Sona Systems, Tallinn, Estonia) and via advertise-
ments distributed on the campus of the Radboud University Nijmegen, the Nether-
lands. Fifty-nine healthy female subjects aged 18 years and older (mean age = 21.4 
years, SD = 2.4) participated in the study. The subjects were Dutch (85%) or German 
(15%) and all could speak and write Dutch fluently; 56% of the subjects had a part-
ner (14% were married or living with their partner) and 71% used oral contracep-
tives. On arrival at the test facility, the subjects were asked to indicate their current 
levels of itch and pain on a visual analogue scale (VAS) ranging from 0 (no itch/pain 
at all) to 10 (worst itch/pain imaginable). Mean levels of itch and pain on the day of 
testing were 0.2 (SD = 0.6) and 0.3 (SD = 1.0), respectively. There were no significant 
differences between the two experimental conditions (See section Emotion induc-
tion) with regard to age, body mass index, educational level, use of oral contracep-
tives, and current itch and pain on the day of testing. 
Prior to testing, subjects were screened by means of questionnaires (see 
section Self-report questionaires) and a standardized interview regarding traumatic 
life events, which was based on the items of the Negative Life Events and Trauma 
Questionnaire [25]. Exclusion criteria were severe morbidity (e.g., multiple sclerosis, 
diabetes mellitus, heart or lung diseases, skin disease), psychiatric disorders (e.g., 
depression, anxiety), use of a pacemaker, and chronic itch or pain complaints either 
currently or in the past. Four subjects were excluded from participation because 
they used medication (antidepressants (n = 2), antiviral drugs (n = 1), or medication 
for treatment of attention deficit disorder (n = 1)), 4 subjects were excluded because 
of chronic itch or pain complaints, and 10 subjects were excluded because of direct 
or indirect experience with emotional, sexual, or physical violence. 
General procedure
The protocol was approved by the regional medical ethics committee 
Arnhem/Nijmegen. Self-report questionnaires were sent to the participants in the 
week preceding the experiment. On arrival at the test facility, participants were in-
formed about the study and all gave their informed consent prior to investigation. 
Participants had earlier been asked not to drink black tea or coffee 1 h before test-
ing. Subjects that satisfied the inclusion criteria were randomly assigned to one 
of the two experimental conditions: the positive emotion condition (n = 30) or the 
negative emotion condition (n = 26).
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A flow diagram of the experiment is given in Figure 1. Positive and nega-
tive emotions were induced by showing the subjects either positive or negative 
film fragments. After each film fragment, subjects reported their experience of 
positive and negative emotions. For the somatosensory stimuli (electrical stimula-
tion, histamine iontophoresis, and the cold pressor test), subjects were asked to 
rate the perceived levels of itch, pain, and unpleasantness on a VAS ranging from 
0 (no itch/pain) to 10 (the worst itch/pain imaginable). Stimuli were administered 
alternatingly by two female investigators. Lastly, subjects were debriefed about 
the goal of the experiment and encouraged to contact the experimenter after the 
experiment if they felt any distress after the experiment. None of the subjects con-
tacted the experimenter afterwards. 
After the subjects were shown a neutral film fragment (see section Emotion 
induction – Neutral emotion), they were familiarized with the stimuli in a pretest trial 
with the electrical stimulation. After a 5-minute interval, emotions were induced 
using the first condition-specific (either positive or negative) film fragment (see 
section Emotion induction – Emotion manipalation), after which the electrical toler-
ance threshold was measured twice. After an interval of 10 minutes, the second 
condition-specific film fragment (in the same direction as the first film fragment) 
was shown (see section Emotion induction – Emotion manipulation). Immediately 
thereafter, histamine was applied by iontophoresis; 3 minutes later the cold pres-
sor test was administered. At the end of the experiment, the subjects looked at 
another neutral film fragment (see section Emotion induction – Neutral emotion).
Figure 1 Flow diagram of the experiment: Order of application of the somatosen-
sory stimuli and the film fragments.
Emotion induction
Emotion manipulation
For the positive as well as for the negative emotion condition two frag-
ments were used from commercially available feature films. Film fragments for the 
positive emotion condition were extracted from a humorous film (Happy Feet, G. 
Miller, 2006) and lasted 4.01 and 6.31 minutes. Film fragments for the induction 
of negative emotions, as also used in earlier studies [8,26], contained scenes with 
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strongly aversive content (extreme violence) and lasted 3.39 and 6.15 minutes 
(Irreversible, G. Noé, 2002). Each film fragment was introduced by a slide, shown 
for 30 seconds, that briefly introduced the context of the film fragment and asked 
participants to identify as strongly as possible with the feelings and emotions of 
the main character in the film fragment. In this way, we attempted to involve the 
subjects in the film in order to evoke a maximal effect for emotion manipulation. 
The text was set against a background picture and with music from the respective 
film. All film fragments were extracted from and shown in the original language ver-
sion with Dutch subtitles, using a DVD player and a 70-cm diameter TV screen. 
Neutral emotion
All subjects were shown two neutral film fragments lasting 4.04 minutes 
containing emotionally neutral nature scenes (Romantisches Europa, Discovery 
Channel HD). One fragment (“Buttes Chaumont Park in Paris”) was shown at the 
beginning and one at the end (“Entlang der Maas”) of the experiment.
Self-reported emotions
After each film fragment, the subjects were asked to rate to what extent 
they experienced positive feelings (cheerful, elated, happy) and negative feelings 
(tense, stressed, nervous) at that moment, using a 4-point Likert scale ranging 
from 1 (not at all) to 4 (very strong). The means of the three negative and the three 
positive emotions were calculated separately to obtain total scores for negative 
and positive emotions. In the negative emotion condition, Cronbach alphas for 
the negative emotions were 0.86 and 0.91 for the first and second film fragment 
respectively, and Cronbach alphas for the positive emotions in the positive emo-
tion condition were 0.96 and 0.98, respectively. In addition, subjects were asked 
whether they had seen the film fragments before and they reported how much 
they had felt involved in the film fragments on a VAS ranging from 0 (not at all) to 
10 (very strong). Subjects were also asked to rate both the pleasantness and un-
pleasantness of the film fragments on a VAS ranging from 0 (not at all) to 10 (very 
strong).
Somatosensory stimuli
After negative or positive emotions had been induced, quantitative sen-
sory testing (QST) stimuli were applied in the following order: electrical stimulation, 
histamine iontophoresis and the cold pressor test. Subjects were asked to report 
the levels of itch and/or pain the stimuli evoked on a VAS ranging from 0 (no itch/
pain at all) to 10 (the worst itch/pain imaginable) several times during the applica-
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tion of histamine and the cold pressor test, and once during measurements of the 
electrical tolerance threshold. Mean VAS itch and VAS pain scores were calculated 
for each stimulus separately. Level of unpleasantness was indicated by the sub-
jects once for each stimulus on a VAS ranging from 0 to 10. 
Electrical stimulation
Cutaneous electrodes were applied to the non-dominant forearm, 2 cm 
distal to the epicondyle of the humerus (C5 dermatome). After the neutral film 
fragment, and after the first condition-specific film fragment, electrical stimulation 
was administered using a constant current nerve stimulator (Pajunk, Germany). 
Electrical stimuli consisted of 0.3-ms pulses at a 100-Hz frequency with a con-
tinuously increasing intensity of ca 0.2 mA/s. Subjects were asked to report the 
electrical tolerance threshold, which was defined by “the moment that the sensa-
tion becomes unbearable and you want to stop directly‟. Thresholds were mea-
sured twice with a 30-second interval between measurements, and mean intensi-
ties were calculated. After the threshold measurements, subjects were asked to 
report, on a VAS, the severity of itch and pain elicited by the electrical stimuli and 
the unpleasantness of the stimuli.
Histamine iontophoresis
Histamine was applied by iontophoresis (Chattanooga Group, Hixson, 
USA). Histamine dihydrochloride (0.5%) was dissolved in a gel of 2% methylcellu-
lose in distilled water and 2.5 ml was placed in an electrode (Iomed Iogel Iontopho-
resis Electrode medium). This electrode was applied to the dominant forearm, 2 
cm distal to the lateral epicondyle of the humerus (C5 dermatome). The reference 
electrode (area: 25.8 cm2) was applied to the skin on the lateral side of the triceps 
brachial muscle. Current level was set at 0.4 mA and histamine was delivered for 
2.5 minutes. During histamine application, the subjects reported VAS itch scores 
every 30 seconds and afterwards scored the unpleasantness of the stimulus on a 
VAS.
Cold pressor test
Subjects were instructed to place their dominant hand in a tank of cold wa-
ter (mean temperature 3.9°C, SD = 0.4) “for as long as possible” until the moment 
they could no longer tolerate it. Participants were unaware of the upper time limit 
of 3 minutes. The immersion time was recorded, and subjects were asked about 
the pain they experienced on a VAS every 10 seconds during the first 30 seconds 
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and subsequently every 30 seconds. The participants scored the unpleasantness 
of the stimulus at the moment they withdrew their hand. 
Self-report questionnaires
The self-report questionnaires used have previously been shown to have 
satisfactory reliability and validity. Questionnaires were sent to the participants 1 
week before the experiment. 
The Hospital Anxiety and Depression Scale (HADS) [47] was used to screen 
for anxiety and depression. The HADS consists of two subscales: a 7-item depres-
sion subscale (Cronbach alpha in the present study was 0.70) and a 7-item anxiety 
subscale (Cronbach alpha = 0.76) (total alpha = 0.84). Items were scored on a 
4-point scale ranging from 0 to 3. The Anxiety Sensitivity Index (ASI) was used to 
measure the subjects’ fear of potential negative consequences of anxiety-related 
symptoms and sensations [28]. The ASI consists of 16 items, rated on a 5-point 
Likert scale (1 = very little, 2 = little, 3 = some, 4 = much, 5 = very much). The 
total score was obtained by summing the scores for the 16 items (range 0 – 64): 
Cronbach alpha was 0.79 in this study. Negative affectivity was measured with the 
neuroticism subscale of the Eysenck Personality Questionnaire (EPQ). Cronbach 
alpha in this study was 0.87. The Bermond-Vorst Alexithymia (BVAQ) was used 
to measure the degree to which a person is able or inclined to describe or com-
municate his or her emotional reactions, to define his or her arousal states, and 
the degree to which someone can be emotionally aroused by emotion-inducing 
events [39]. The 40 items were rated on a 5-point Likert scale ranging from 1 (this 
definitely applies to me) to 5 (this in no way applies to me) and the total score was 
obtained by summing all 40 items: Cronbach alpha was 0.90 in this study. 
Statistical analysis
All analyses were performed using SPSS 16.0 for Windows. Variables were 
checked for normal distribution. Subjects were excluded from analyses if they had 
a minimum mean score for the intended emotions, i.e., positive emotions for the 
positive emotion condition and negative emotions for the negative emotion condi-
tion, was 1.0 (minimum level) for one or both of the condition-specific film frag-
ments. As a manipulation check for the emotion induction procedure, repeated 
measures analysis of variance (ANOVA) was conducted for the two experimen-
tal conditions separately with as within-subject variables the mean score for the 
negative or positive emotions during the neutral film fragment and during the first 
or second condition-specific film fragment. 
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Hypotheses were tested by using multivariate analyses of variance (MANO-
VA) with the condition (negative and positive emotion condition) as independent 
variable, and VAS pain (electrical stimulation and cold pressor test), VAS itch (elec-
trical stimulation and histamine) and VAS unpleasantness (electrical stimulation, 
histamine, and cold pressor test) for the different stimuli separately as dependent 
variables. Only if the MANOVA results were significantly different, or tended to be 
significantly different between the conditions, post hoc ANOVAs were performed 
to investigate the effects for each stimulus separately. 
Pearson correlation coefficients were calculated between the valence 
scores attributed to the film fragments and the stimuli outcome measures (VAS 
itch, VAS pain, VAS unpleasantness, and tolerance thresholds) for the negative 
and positive emotion conditions separately (pleasantness for the positive emotion 
condition and unpleasantness for the negative emotion condition). Lastly, Pear-
son correlation coefficients were calculated between scores of the questionnaires 
measuring individual psychological characteristics (anxiety sensitivity, neuroticism 
and alexithymia) and the mean of the intended (negative or positive) emotions as 
well as the VAS scores (itch, pain and unpleasantness) and tolerance thresholds 
of the sensation evoked by the different stimuli for both the negative and positive 
emotion conditions. 
Results
Emotion manipulation check
Three subjects in the negative emotion condition were excluded from the 
analyses, because their mean score for the negative emotions was 1.0, the mini-
mum, for one or both of the condition-specific film fragments. Thirty-seven per-
cent of the subjects in the positive emotion condition had seen the film fragments 
before, while none of the subjects in the negative emotion condition had seen the 
fragments before, which was significantly different between groups [χ2(1, n = 56) = 
22.2, P < 0.001]. Ninety percent and 93% of the subjects in the positive emotion 
condition felt moderately or highly involved (i.e., VAS involvement of 5.0 or higher) 
with the first and second film fragments, respectively. In the negative emotion 
condition, 69% and 92% of the subjects felt moderately or highly involved with the 
first and second film fragments respectively. Involvement with the film fragments 
was rated significantly higher in the positive compared to the negative emotion 
condition [F(1,54) = 6.12, P < 0.05] for the first film fragment, but was not sig-
nificantly different between the conditions for the second film fragment [F(1,54) = 
0.07, P = 0.80]. Mean unpleasantness ratings for the film fragments in the negative 
emotion condition were 8.1 (SD = 1.3) and 8.8 (SD = 1.1), and mean pleasantness 
ratings for the film fragments in the positive emotion condition were 8.0 (SD = 1.0) 
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and 7.9 (SD = 1.4), for the first and second film fragments, respectively.
 Means and standard deviations of the negative (tense, uptight, nervous) 
and positive (elated, cheerful, happy) emotions for the neutral as well as the con-
dition-specific film fragments are shown in Figure 2A (negative emotion condition) 
and 2B (positive emotion condition). In the negative emotion condition, negative 
emotions were significantly higher after the first [F(1,25) = 70.05, P < 0.001] and 
second [F(1,25) = 71.17, P < 0.001] film fragment than after the neutral film frag-
ment, and positive emotions were significantly lower [F(1,25) = 140.50, P < 0.001 
for the first, and F(1,25) = 186.10, P < 0.001 for the second negative film frag-
ments] in comparison with the neutral film fragment. In the positive emotion con-
dition, positive emotions were significantly higher after the first [F(1,29) = 37.08, 
P < 0.001] and second [F(1,29) = 70.66, P < 0.001] film fragments than after the 
neutral film fragment, and negative emotions were around the minimum score 
during all film fragments (see Figure 2A and 2B). Mean scores for the intended 
emotions were significantly higher in the positive (M = 3.0, SD = 0.6) than the nega-
tive (M = 2.1, SD = 0.6) emotion condition [F(1,54) = 30.0, P < 0.001].
Figure 2A Negative emotion condition: means (± SEM) of self-reported negative 
(dashed line) and positive (line) emotions in the negative emotion condition after 
the first neutral film fragment, the two condition-specific negative film fragments 
and the second neutral film fragment.
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Figure 2B Postive emotion condition: means (± SEM) of self-reported negative 
(dashed line) and positive (line) emotions in the positive emotion condition after the 
first neutral film fragment, the two condition-specific positive film fragments and 
the second neutral film fragment.
Sensitivity to somatosensory stimuli: VAS pain, VAS itch, and VAS unpleasant-
ness
Table 1 gives the mean scores for VAS pain, VAS itch, and VAS unpleas-
antness for the negative and positive emotion conditions. MANOVA results for pain 
evoked by the stimuli (electrical stimulation and cold pressor test) showed that 
VAS pain scores tended to be significantly higher in the negative condition than in 
the positive emotion condition [Wilks’ Lambda (Λ) = 0.90, F(2,53) = 3.06, P = 0.06]. 
For each stimulus separately, univariate tests showed that the level of pain evoked 
by the cold pressor test was significantly higher in the negative emotion condition 
than in the positive emotion condition [F(1,54) = 4.19, P < 0.05], while there was 
no significant difference between the conditions in pain elicited by electrical stimu-
lation [F(1,54) = 0.11, P = 0.75]. MANOVA results for the level of itch evoked by 
the stimuli (electrical stimulation, histamine iontophoresis) showed that VAS itch 
scores tended to be significantly higher in the negative emotion condition than in 
the positive emotion condition [Λ = 0.90, F(2,53) = 2.95, P = 0.06]. Univariate tests 
showed that VAS itch scores were significantly higher in the negative than in the 
positive emotion condition for histamine iontophoresis [F(1,54) = 5.95, P < 0.05], 
while itch evoked by electrical stimulation did not differ between the experimental 
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conditions [F(1,54) = 0.09, P = 0.77]. MANOVA results for the VAS unpleasantness 
of the somatosensory stimuli showed no significant differences between the two 
experimental conditions [Λ = 0.92, F(3,52) = 1.53, P = 0.22]. 
The mean electrical tolerance threshold intensity and cold pressor immer-
sion time was 5.4 mA (SD = 1.8) and 83.4 s (SD = 59.3), respectively, in the nega-
tive emotion condition, and 5.7 mA (SD = 3.3) and 98.5 s (SD = 61.9), respectively, 
in the positive emotion condition. Tolerance thresholds did not significantly differ 
between the conditions [Λ = 0.98, F(2,53) = 0.43, P = 0.66].
Table 1
Levels of itch, pain, and unpleasantness evoked by the somatosensory stimuli ap-
plied after induction of negative or positive emotions.
Negative emotion condition Positive emotion condition
M (SD) M (SD)
VAS pain
    Electrical stimulation 3.9 (2.6) 4.2 (2.4)
    Cold pressor test 5.2 (1.9) 4.1 (2.1)
 
VAS itch
    Electrical stimulation 2.8 (3.3) 2.5 (2.3)
    Histamine iontophoresis 4.3 (1.7) 3.0 (2.0)
VAS unpleasantness
    Electrical stimulation 6.2 (2.4) 6.2 (2.3)
    Histamine iontophoresis 5.5 (2.3) 4.9 (2.6)
    Cold pressor test 7.5 (1.9) 6.5 (2.3)
Mean (M) levels and standard deviation (SD) of itch, pain and unpleasantness evoked by the different 
somatosensory stimuli, indicated on a visual analogue scale (VAS) ranging from 0 to 10, in the negative 
(n = 26) and positive (n = 30) emotion condition. 
Correlations of induced emotions
The measures of sensitivity (VAS itch, VAS pain, VAS unpleasantness, and 
tolerance thresholds) were not significantly correlated with the pleasantness ra-
tings of the film fragments in the positive emotion condition. In the negative emo-
tion condition, (borderline) significant correlations were found between a higher 
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unpleasantness rating of the film fragments and lower electrical (r = -0.38, P = 
0.05) and cold pressor (r = -0.47, P < 0.05) tolerance thresholds, and higher VAS 
unpleasantness scores for electrical stimulation (r = 0.38, P = 0.05) and higher VAS 
pain scores during the cold pressor test (r = 0.37, P = 0.06). The individual psycho-
logical characteristics neuroticism, anxiety sensitivity, and alexithymia were not 
significantly correlated with the self-reported negative and positive emotions or 
the tolerance thresholds and VAS itch, VAS pain, and VAS unpleasantness, except 
for significant correlations between a higher anxiety sensitivity and higher scores 
on the negative emotions for film fragment 1 (r = 0.46, P < 0.05) and 2 (r = 0.48, 
P < 0.05), between higher levels of anxiety sensitivity and higher VAS pain scores 
during the cold pressor test (r = 0.43, P < 0.05) in the negative emotion condition, 
and between higher levels of neuroticism and a lower level of electrically evoked 
pain (r = -0.46, P < 0.05) in the positive emotion condition.
Discussion
This study showed for the first time that people have higher levels of itch 
when they are in a negative rather than positive emotional state, and replicated pre-
vious findings that pain levels are increased when a person is in a negative, rather 
than positive, emotional state. The effects of emotions were more pronounced on 
the response to histamine application or the cold pressor test than on the response 
to the, more ambiguous, electrical stimulation. In contrast, emotional state did not 
significantly affect the perceived unpleasantness of the somatosensory stimuli, or 
the tolerance thresholds for electrical and cold pressor stimulation. 
As expected, emotion induction procedures were effective and resulted in 
significantly higher levels of negative emotions in the negative emotion condition 
and higher levels of positive emotions in the positive emotion condition compared 
to the other emotion condition. In line with these emotion inductions, levels of 
pain evoked by the somatosensory stimuli were higher when negative emotions, 
rather than positive emotions, were induced, which is in line with previous findings 
of emotion induction in pain processing [18,22,27,29,31,41,45]. Our findings also 
showed for the first time that the levels of experimentally induced itch were higher 
when negative emotions, rather than positive emotions, were induced, which is 
consistent with the findings of preliminary studies investigating emotional stress 
and itch [1,13]. The effects of emotion manipulation on sensitivity to itch and pain 
were most pronounced for the stimuli inducing distinct sensations of itch (his-
tamine) or pain (cold pressor) than for the more ambiguous sensations induced 
by electrical stimulation. The lack of effect on the response to electrical stimula-
tion may be due to several reasons. Electrical stimulation was applied after the 
first condition-specific film fragment, whereas histamine and the cold pressor test 
were tested after the second film fragment. As the film fragments were relatively 
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short, the effects of emotion manipulation may be stronger after a longer duration 
of exposure (i.e., after viewing of both fragments instead of only the first fragment). 
In addition, although present scores on negative emotions were relatively high 
and the fragment has also been used in earlier studies [8,26], subjects were less 
involved in the first negative film fragment in comparison to the positive film frag-
ment. Also the interval between manipulation and application of the somatosen-
sory stimuli is important, since the physiological reactions attributed to emotion 
manipulation may be delayed [10,23,41]. This is also supported by the observa-
tion that self-reported negative emotions were significantly higher after the second 
compared to the first film fragment in the negative emotion condition, and the 
positive emotions tended to be significantly higher after the second compared to 
the first film fragment in the positive emotion condition (see also Figure 2).
The unpleasantness of the different stimuli did, in contrast to what we 
expected based on earlier findings [20,27], not differ as a result of the emotion 
manipulation. In addition, although a number of studies indicate that tolerance to 
somatosensory stimuli is reduced after negative emotion induction or heightened 
after positive emotion induction [11,45], we did not find significant differences be-
tween the two emotion conditions regarding the tolerance thresholds for the elec-
trical and cold stimuli applied. The strength of the emotion-induction effects on 
tolerance to stimuli seems to also depend on the type of induced emotions [22] 
and the time in-between emotion manipulation and somatosensory stimulation. 
For example, Weisenberg and colleagues found a significant effect of emotion 
induction on pain tolerance 30 minutes, but not earlier, after emotion induction 
[41]. Finally, the definitions of the tolerance thresholds (“the moment that the sen-
sation becomes unbearable and you want to stop directly‟) and unpleasantness 
(“please rate the unpleasantness of the sensation”) rated for the somatosensory 
stimuli were generic rather than pain- (or itch-)specific, and these generic defini-
tions might possibly be influenced more strongly by cognitive-motivational fac-
tors, and therefore less sensitive for the effects of emotion induction. Pain-related 
emotions, such as pain-related fear or, may, for example, have larger effects on 
pain tolerance or pain unpleasantness [27]. 
The individual psychological characteristics of anxiety sensitivity, alexithy-
mia and neuroticism were not related with the self-reported negative and positive 
emotions or the outcome measures of the sensory stimuli and did therefore not 
influence our main results, indicating that these variables do not, or only minimally, 
contribute to the effects of emotions on sensitivity to itch and pain. This may be 
related to the study sample which consisted of healthy subjects with generally low 
scores for these individual characteristics, or to the fact that these characteristics 
are not of direct relevance to pain or itch sensitivity. Future studies might address 
the relevance of other psychological concepts, such as pain- or itch-related fear, 
as possible essential components in the worsening of chronic pain [38] or itch. 
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The question remains which mechanisms underlie the effect of emotions 
on itch and pain sensations. Emotions are processed by (de)activation of various 
brain regions, e.g., the anterior cingulate cortex (ACC) and insula [9,19], which 
are also activated during (the anticipation of) pain and itch sensations [6,16]. That 
these brain areas are common to emotions, pain, and itch underlines the link 
between emotions and these somatosensory sensations. In addition, emotional 
stimuli could either lead to analgesia, e.g., by external, attention-demanding stres-
sors, or to hyperalgesia, e.g., due to anticipatory anxiety about pain [6]. Descend-
ing endogenous modulation processes of itch and pain e.g., through conditioned 
modulation [4,35], may play a role in the modulatory effects of cognitive and affec-
tive factors on these sensations. This is supported by earlier studies indicating that 
cognitive expectations regarding pain and pain catastrophizing can influence pain 
perception by these modulatory mechanisms [15,36]. Moreover, the effects of ex-
pectations on pain in placebo analgesia are also influenced by the affective quality 
of the pain sensation and by the internal affective state of the individual during the 
pain [3]. In addition, cholecystokinin (CCK), one of the key mediators in nocebo 
hyperalgesia, is involved in both anxiety and pain modulation [2], while brain areas 
involved in pain expectations, e.g., rostral ACC, thalamus and insula, are in part 
similar to those involved in emotions [6,40]. Future research should focus on dis-
entangling the processes by which affective and cognitive factors interactively and 
differentially affect the modulatory processing and perception of itch and pain.
There are some limitations of the study that need to be addressed. First, 
while the film fragments were effective in producing the intended emotions, as 
shown by the self-reported negative and positive emotions, the duration of the 
emotion induction procedure or the time in-between this procedure and ap-
plication of the sensory stimuli may not have been long enough to bring about 
physiological effects [10,41], which could explain the lack of emotion-induced dif-
ferences in itch and pain evoked by the electrical stimulation, the first stimulus 
applied. In future research, longer film fragments may be used or the time in-
between emotion manipulation and sensitivity measurements should be longer 
to evoke larger effects. Second, although emotions differed significantly across 
conditions, levels of induced emotions were not completely comparable between 
the two emotion conditions, which is inherent to emotion induction procedures. 
Specifically, positive emotions were slightly higher than negative emotions for the 
respective emotion induction. This may also be a result of the neutral film fragment 
which may have had an elative effect on the emotional state in both conditions. 
Future research should also include an experimental condition without neutral film 
fragments in order to enhance emotion induction. Third, since the application of 
different stimuli could cause interaction effects between itch and pain sensations 
induced, stimuli were applied with intervals in-between. However, these intervals 
might have diminished the effects of the emotion induction to some degree. In 
future research a film fragment should be shown before the application of each 
somatosensory stimulus. Fourth, we only included women in the present study. 
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Since prior research indicated that women and men differ in their perception and 
reaction to emotional stimuli [32] and sensitivity to sensory stimuli [43], future re-
search should also include men. 
To conclude, the present study indicates for the first time with an experi-
mental design that emotions not only influence the experience of somatosensory 
sensations of pain, but also of itch. The induction of negative emotions in compari-
son to positive emotions is associated with higher levels of itch and pain elicited 
by specific itch and pain stimuli, respectively. Future research should investigate 
whether emotions might, like the perception of itch and pain in healthy subjects, 
influence symptom reporting by patients with chronic symptoms of itch and pain 
in a way that negative emotions could enhance physical symptoms, which, in turn, 
are known to have an inherent aversive threat value and induce negative emo-
tions. In this line, treatments could be increasingly directed to interrupt this circle, 
in which somatosensory symptoms of itch and pain are amplified by psychological 
factors such as emotional state.
7
role of neGatIve and posItIve emotIons In sensItIvIty to Itch and paIn
148
Reference List
[1]  Arnetz BB, Fjellner B, Eneroth P, Kallner A. Endocrine and dermatological concomitants of mental 
stress. Acta Derm Venereol Suppl 1991;156:9-12.
[2]  Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mecha-
nisms of the nocebo effect. Neuroscience 2007;147:260-271.
[3]  Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the 
placebo effect. J Neurosci 2005;25:10390-10402.
[4]  Calvino B, Grilo RM. Central pain control. Joint Bone Spine 2006;73:10-16.
[5]  Carroll LJ, Cassidy JD, Cote P. Depression as a risk factor for onset of an episode of troublesome 
neck and low back pain. Pain 2004;107:134-139.
[6]  Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaes-
thesiol 2007;20:435-439.
[7]  Conrad R, Geiser F, Haidl G, Hutmacher M, Liedtke R, Wermter F. Relationship between anger 
and pruritus perception in patients with chronic idiopathic urticaria and psoriasis. J Eur Acad 
Dermatol Venereol 2008;22:1062-1069.
[8]  Cousijn H, Rijpkema M, Qin S, van Marle HJ, Franke B, Hermans EJ, van Wingen G, Fernandez 
G. Acute stress modulates genotype effects on amygdala processing in humans. Proc Natl Acad 
Sci U S A 2010;107:9867-9872.
[9]  Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LL, Parvizi J, Hichwa RD. Sub-
cortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 
2000;3:1049-1056.
[10]  De Brouwer SJ, Kraaimaat FW, Sweep FC, Creemers MC, Radstake TR, van Laarhoven AI, van 
Riel PL, Evers AW. Experimental stress in inflammatory rheumatic diseases: a review of psy-
chophysiological stress responses. Arthritis Res Ther 2010;12:R89.
[11]  De Wied M, Verbaten MN. Affective pictures processing, attention, and pain tolerance. Pain 
2001;90:163-172.
[12]  Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: ante-
cedent or consequence of chronic pain? A review. Clin J Pain 1997;13:116-137.
[13]  Fjellner B, Arnetz BB, Eneroth P, Kallner A. Pruritus during standardized mental stress. Rela-
tionship to psychoneuroendocrine and metabolic parameters. Acta Derm Venereol 1985;65:199-
205.
[14]  Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mecha-
nisms, and interventions. Dermatol Clin 2005;23:681-694.
[15]  Goodin BR, McGuire L, Allshouse M, Stapleton L, Haythornthwaite JA, Burns N, Mayes LA, 
Edwards RR. Associations between catastrophizing and endogenous pain-inhibitory processes: 
sex differences. J Pain 2009;10:180-190.
[16]  Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev 
Neurosci 2006;7:535-547.
[17]  Katz J, Martin AL, Page MG, Calleri V. Alexithymia and fear of pain independently predict heat 
pain intensity ratings among undergraduate university students. Pain Res Manag 2009;14:299-
305.
[18]  Kenntner-Mabiala R, Andreatta M, Wieser MJ, Muhlberger A, Pauli P. Distinct effects of attention and 
affect on pain perception and somatosensory evoked potentials. Biol Psychol 2008;78:114-122.
7
chapter 7 
149
[19]  Lane RD, Reiman EM, Ahern GL, Schwartz GE, Davidson RJ. Neuroanatomical correlates of hap-
piness, sadness, and disgust. Am J Psychiatry 1997;154:926-933.
[20]  Loggia ML, Mogil JS, Bushnell MC. Experimentally induced mood changes preferentially affect 
pain unpleasantness. J Pain 2008;9:784-791.
[21]  Magni G, Moreschi C, Rigatti-Luchini S, Merskey H. Prospective study on the relationship be-
tween depressive symptoms and chronic musculoskeletal pain. Pain 1994;56:289-297.
[22]  Meagher MW, Arnau RC, Rhudy JL. Pain and emotion: effects of affective picture modulation. 
Psychosom Med 2001;63:79-90.
[23]  Mittwoch-Jaffe T, Shalit F, Srendi B, Yehuda S. Modification of cytokine secretion following mild 
emotional stimuli. Neuroreport 1995;6:789-792.
[24]  Mongini F, Ciccone G, Ceccarelli M, Baldi I, Ferrero L. Muscle tenderness in different types of 
facial pain and its relation to anxiety and depression: A cross-sectional study on 649 patients. 
Pain 2007;131:106-111.
[25]  Morgan HJ, Janoff-Bulman R. Positive and negative self-complexity: Patterns of adjustment fol-
lowing traumatic versus non-traumatic life experiences. J Soc Clin Psychol 1994;13:63-85.
[26]  Qin S, Hermans EJ, van Marle HJ, Luo J, Fernandez G. Acute psychological stress reduces work-
ing memory-related activity in the dorsolateral prefrontal cortex. Biol Psychiatry 2009;66:25-32.
[27]  Rainville P, Bao QV, Chretien P. Pain-related emotions modulate experimental pain perception 
and autonomic responses. Pain 2005;118:306-318.
[28]  Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the 
prediction of fearfulness. Behav Res Ther 1986;24:1-8.
[29]  Rhudy JL, Bartley EJ, Williams AE. Habituation, sensitization, and emotional valence modulation 
of pain responses. Pain 2010;148:320-327.
[30]  Rhudy JL, Williams AE, McCabe KM, Rambo PL, Russell JL. Emotional modulation of spinal 
nociception and pain: the impact of predictable noxious stimulation. Pain 2006;126:221-233.
[31]  Rhudy JL, Williams AE, McCabe KM, Russell JL, Maynard LJ. Emotional control of nociceptive 
reactions (ECON): do affective valence and arousal play a role? Pain 2008;136:250-261.
[32]  Schaefer A, Nils F, Sanchez X, Philippot P. Assessing the effectiveness of a large database of 
emotion-eliciting films: A new tool for emotion researchers. Cogn Emotion 2010;24:1153-1172.
[33]  Scherrer MC, Dobson KS. Predicting responsiveness to a depressive mood induction procedure. 
J Clin Psychol 2009;65:20-35.
[34]  Stander S, Schmelz M. Chronic itch and pain--similarities and differences. Eur J Pain 2006;10:473-
478.
[35]  Van Laarhoven AIM, Kraaimaat FW, Wilder-Smith OH, van de Kerkhof PCM, Evers AWM. Hetero-
topic pruritic conditioning and itch - analogous to DNIC in pain? Pain 2010;149:332-337.
[36]  Van Wijk G, Veldhuijzen DS. Perspective on diffuse noxious inhibitory controls as a model of 
endogenous pain modulation in clinical pain syndromes. J Pain 2010;11:408-419.
[37]  Verhoeven EW, Kraaimaat FW, Jong EM, Schalkwijk J, van de Kerkhof PC, Evers AW. Effect of 
daily stressors on psoriasis: a prospective study. J Invest Dermatol 2009;129:2075-2077.
[38]  Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a 
state of the art. Pain 2000;85:317-332.
[39]  Vorst HCM, Bermond B. Validity and reliability of the Bermond-Vorst Alexithymia Questionnaire. 
Pers Individ Differ 2001;30:413-434.
7
role of neGatIve and posItIve emotIons In sensItIvIty to Itch and paIn
150
[40]  Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Co-
hen JD. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 
2004;303:1162-1167.
[41]  Weisenberg M, Raz T, Hener T. The influence of film-induced mood on pain perception. Pain 
1998;76:365-375.
[42]  Wiech K, Tracey I. The influence of negative emotions on pain: behavioral effects and neural 
mechanisms. Neuroimage 2009;47:987-994.
[43]  Wiesenfeld-Hallin Z. Sex differences in pain perception. Gend Med 2005;2:137-145.
[44]  Willoughby SG, Hailey BJ, Mulkana S, Rowe J. The effect of laboratory-induced depressed mood 
state on responses to pain. Behav Med 2002;28:23-31.
[45]  Zelman DC, Howland EW, Nichols SN, Cleeland CS. The effects of induced mood on laboratory pain. 
Pain 1991;46:105-111.
[46]  Zhao H, Chen AC. Both happy and sad melodies modulate tonic human heat pain. J Pain 2009;10:953-
960.
[47]  Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-
370.
7
chapter 7 
General IntroductIon 
151
1
Chapter 8
summary
152
8
chapter 8 
153
Pain is a nociceptive somatosensory sensation that is part of the body’s 
defense system, serving as a warning system against danger or threat. In people 
suffering from chronic pain, this defense mechanism does not function as it should. 
Knowledge of the mechanisms underlying pain and its processing is increasing. 
Research focuses not only on the physiological mechanisms of pain processing, 
but also on psychological mechanisms of pain aggravation. Understanding the 
mechanisms underlying acute and chronic pain may reveal targets for therapy to 
reduce the burden of pain. Next to pain, itch is also a nociceptive somatosensory 
sensation and is part of the body’s defense system against potential invasive stim-
uli. However, much less is known about the psychophysiological factors involved 
in the aggravation of itch. Given that both itch and pain are nociceptive sensa-
tions, with a broad overlap with regard to neurophysiological and psychological 
processing and their consequences on functioning, corresponding psychophysi-
ological factors may play a role in both sensations. To our knowledge, this thesis 
is the first to focus on various sensory, cognitive, and affective factors influencing 
both itch and pain, with a psychophysiological model as basis. Part I of this thesis 
investigated sensory factors (Chapters 2 – 4), Part II was directed at investigating 
cognitive factors (Chapters 5 and 6), while Part III investigated affective factors 
(Chapter 7) influencing itch and pain. Findings are summarized for the three parts 
separately. 
Sensory factors
Chronic pain is based on a characteristic alteration in the processing of 
both nociceptive and non-nociceptive signals as a result of long-term nociceptive 
input, which is thought to be due to sensitization processes, including disturbed 
endogenous modulation of pain. Comparable mechanisms of sensitization have 
been proposed for itch, but have been less systematically investigated, particular-
ly not in comparison with pain. The first part of this thesis describes three studies 
investigating heightened sensitivity to itch and pain, as a measure of sensitization, 
and endogenous modulation of itch and pain in patients with chronic itch or pain. 
In Chapters 2 and 4, patients’ sensitivity to different quantitative sensory testing 
(QST) stimuli inducing itch and pain was investigated. Results of these studies 
indicated that patients with chronic itch or pain may be more sensitive to itch and 
pain, respectively. The patients with chronic itch (psoriasis and atopic dermatitis) 
generally reacted with higher levels of itch, while the patients with chronic pain 
(fibromyalgia and rheumatoid arthritis) generally were more pain-reactive in re-
sponse to various somatosensory stimuli (Chapters 2 and 4). It was, consequently, 
concluded that patients with chronic itch or pain may specifically display an in-
creased sensitivity to itch or pain, respectively. In Chapters 3 and 4, endogenous 
modulation of itch by diffuse pruritic inhibitory control (DPIC) was investigated, for 
the first time, using a conditioned itch modulation (CIM) paradigm, which is com-
parable to the frequently applied conditioned pain modulation (CPM) paradigm for 
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quantifying endogenous modulation of pain by diffuse noxious inhibitory control 
(DNIC). In healthy subjects, intact functioning of DPIC and DNIC was demonstrat-
ed, while in patients with chronic itch or pain, both DPIC and DNIC were found to 
be disturbed (Chapters 3 and 4). In line with the frequently demonstrated disturbed 
DNIC of patients with chronic pain as indicator for a disturbed endogenous modu-
lation of pain, a disturbed DPIC in patients with chronic itch may also be indicative 
of a disturbed endogenous modulation of itch, possibly related to their symptoms. 
The finding of a disturbance of both DPIC and DNIC in patients with chronic itch or 
pain suggests that endogenous modulation may be a generic mechanism, which 
is disturbed across different conditions and sensations associated with chronic 
itch or pain (Chapter 4). The studies in Part I support the idea that sensitization 
processes and a disturbed modulation of itch may play a role in the symptoms of 
patients with chronic itch. Consequently, as for chronic pain, long-term nocicep-
tive itch input may result in a characteristic alteration of the processing of itch sig-
nals due to central sensitization, contributing to the maintenance and aggravation 
of chronic itch.
Cognitive-evaluative factors
The second part of this thesis describes studies investigating the role of 
attentional focusing and expectations on sensitivity to itch and pain in healthy 
subjects. In the first study of Part II (Chapter 5), more attention to bodily sensations 
was associated with a higher sensitivity to itch and pain evoked by various soma-
tosensory stimuli. In patients with chronic itch, attentional focusing on somatosen-
sory sensations and signs may, as in chronic pain, play a role in increasing their 
symptoms. In the second study (Chapter 6), the role of expectations on itch and 
pain was studied by inducing nocebo and placebo suggestions. In this study, indi-
cations for a nocebo effect on itch were found, as demonstrated by the finding that 
expectations regarding a high probability of receiving itch stimuli evoked higher 
levels of itch than when expectations of a low probability of itch were induced by 
verbal suggestion. There were also some indications that placebo effects on itch 
might be induced by verbal suggestion. The effects found in this study appeared 
to be stronger for itch than for pain, which may be related to the fact that people 
are more susceptibility to suggestion for itch than for pain. Reducing nocebo ef-
fects and promoting placebo effects on itch-related treatments could be used in 
the future to optimize the clinical treatment of itch in patients with skin diseases.
 Affective-motivational factors
The third part of this thesis describes a study investigating affective fac-
tors, specifically the effects of negative and positive emotions on the sensitivity to 
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itch and pain (Chapter 7). The results of this study show that the induction of nega-
tive emotions resulted not only in an increased sensitivity to pain, but also in an 
increased sensitivity to itch for specific somatosensory stimuli, when compared to 
the induction of positive emotions. Consequently, this study showed that negative 
emotions when compared to positive emotions can directly affect the perception 
of itch. Since negative emotions reciprocally interact with pain, similar recipro-
cal interactions may also account for itch, i.e., negative emotions result in higher 
levels of itch, while itch can lead to negative emotions, possibly contributing to a 
vicious circle of itch-emotions-itch. This knowledge might stimulate the develop-
ment of treatment possibilities for patients with chronic itch that frequently suffer 
from high levels of negative emotions. 
Personality and disease characteristics
Individual characteristics known to play a role in health-related problems, 
particularly the personality characteristics of neuroticism and anxiety sensitivity, 
and disease-related characteristics were investigated, because they may influ-
ence psychophysiological factors relevant to itch or pain. Overall, these factors did 
not appear to be relevant to the quantitative sensory testing stimuli applied or to 
the itch and pain sensations evoked by the stimuli. Future studies should focus on 
individual characteristics that may be of particular relevance to psychophysiologi-
cal factors influencing itch and pain, such as optimism in relation to the placebo 
effect on itch. 
Conclusion
In this thesis, the role of psychophysiological factors on itch has been 
investigated for the first time in laboratory studies in direct comparison to pain by 
using various QST stimuli and self-report measures. The findings support the hy-
pothesis that sensory (central modulation and sensitization processes), cognitive 
(attentional focusing and negative expectations), and affective (negative emotions) 
factors play a role in the sensitivity to itch in a similar manner as they do in pain 
perception and processing. In view of possible common mechanisms underlying 
the influence of psychophysiological factors on itch and pain, knowledge of the 
mechanisms that give rise to pain aggravation and chronification of pain could be 
of great value to the diagnosis and treatment of acute and chronic itch. 
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When trying to understand the psychophysiological mechanisms underly-
ing itch (pruritus), comparison with another nociceptive somatosensory sensation, 
such as pain, can help to identify common and distinct factors underlying these 
sensations, and provides the opportunity to identify generic and symptom-specific 
mechanisms that play a role in increased sensitivity and processing of different so-
matosensory sensations. The pain literature shows that sensory (e.g., pain modu-
lation and sensitization processes), cognitive (e.g., attentional focusing or nega-
tive expectations), and affective (e.g., negative emotions) factors can influence the 
perception of pain and its behavioral consequences. In addition, there are indica-
tions that sensory, cognitive, and affective factors relevant to itch may show, at 
least partly, correspondence to pain, while the acute behavioral responses seem 
to differentiate itch from pain, i.e., scratching versus escape behavior respectively. 
Therefore, the studies of this thesis focused on the role of sensory, cognitive, and 
affective factors in itch and pain, according to models describing psychophysi-
ological factors of these sensations [53,89,100,140]. 
In this chapter, the findings of our studies with regard to the sensory, cogni-
tive and affective factors studied are discussed in relation to the existing literature 
of itch and pain. Itch and pain are compared in terms of the behavioral responses, 
the specificity and chronicity of symptoms, and the role of personality and disease 
characteristics. The chapter closes with a discussion of potential limitations of the 
studies performed, suggestions for future research, an overview of the implica-
tions of the findings for clinical practice, and a short conclusion. 
Psychophysiological factors
The cascade of physiological events triggered by afferent signals in the 
nociceptive pathways reaching the brain, where the perception and evaluation of 
a stimulus takes place, depends on the integration of the sensory-discriminative, 
cognitive-evaluative, and affective-motivational information encoded in these sig-
nals [53,100]. Knowledge of the different psychophysiological factors influencing 
the sensation of pain was used to investigate the role of different sensory, cogni-
tive, and affective factors in itch in comparison to pain, as discussed below. 
Sensory factors
The sensory-discriminative aspects of physical sensations, such as itch 
and pain, refer to the way these sensations are processed and are finally perceived 
after they are modulated by different sensory processes (e.g., sensitization, endo-
genous modulation). Central sensitization leads to an altered perception of a sen-
sation that may no longer be associated with peripheral input [2,3,28,127,170]; the 
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role of sensitization processes in the development and aggravation of chronic pain 
has been investigated since many years. Nociceptive input from the spinothalamic 
tract is perceived as pain after the signal is modulated via pathways that descend 
in the dorsal horn of the spinal cord [22,67]. Thus, (disturbed) endogenous modu-
lation can also be supposed to play a key role in sensitization processes. In the 
present thesis, we focused on the altered sensitivity to itch and pain as indicator 
of sensitization in patients with chronic itch and pain (Chapters 2 and 4) and on 
endogenous modulation of itch and pain (Chapters 3 and 4).
Sensitivity to itch and pain
The studies described in Chapters 2 and 4 showed that patients with 
chronic pain due to fibromyalgia (FM) and rheumatoid arthritis (RA) were more 
sensitive than controls to specific quantitative sensory testing (QST) stimuli. The 
patients had a lowered tolerance to different sensory stimuli (FM and RA) and 
reported experiencing more pain (FM), suggesting that they were more sensitive 
to pain. These results are consistent with the literature showing that patients with 
chronic pain of various origins, e.g., osteoarthritis, tension-type headache, tem-
poromandibular joint pain, or FM, generally not only report clinical pain symptoms, 
but also display an increased sensitivity to experimental pain stimuli [28,170]. In 
addition, other studies have shown that patients with, for example, low back pain, 
RA and FM also have a lowered tolerance to different mechanical, electrical or 
thermal QST stimuli [34,38,55,137]. Processes of particularly central sensitization 
are thought to underlie this heightened sensitivity in patients with chronic pain. 
Central sensitization is a form of synaptic plasticity, such that previously sub-
threshold inputs now activate nociceptive neurons, inducing significant changes 
in functional properties, e.g., increased synaptic strength, reduced inhibition, or 
increased membrane excitability, which may lead to suprathreshold action poten-
tials [3,170]. Sensitization processes can enhance the severity, duration, and spa-
tial properties of the peripheral stimulus, which can result in increased sensitivity 
to pain [3,170].
Similar sensitization mechanisms are suggested to play a role in the chro-
nification of itch and pain [128]. On a peripheral level, it has been shown that many 
classical inflammatory mediators, e.g., bradykinin, serotonin, prostaglandins, or 
histamine, can acutely sensitize nociceptive nerve endings, but can also activate 
pruriceptors. Moreover, the neurotrophin nerve growth factor (NGF), which can 
induce acute sensitization of nociceptors by up-regulating neuropeptides, e.g., 
substance P and calcitonin gene-related peptide, can provoke structural changes 
by nociceptor sprouting in both chronic pain and chronic itch [128]. In addition, 
patterns of central sensitization to itch, and associated functional and anatomical 
neuroplasticity, are reflected by the phenomena of alloknesis, i.e. touch-evoked 
pruritus, and hyperknesis, i.e., enhanced itch reactions to more intense prick-in-
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duced itch, which are comparable to the phenomena of allodynia and hyperalgesia 
in pain [75,128]. Congruently with the findings for pain, the results of the studies 
described in Chapters 2 and 4 showed that patients with chronic itch due to atopic 
dermatitis (AD) and psoriasis (PS), have a lowered tolerance to different soma-
tosensory stimuli (AD) or react with heightened levels of itch (AD and PS). This 
finding is consistent with preliminary evidence showing that patients with chronic 
itch react with heightened levels of itch to different QST stimuli [74,128]. Although 
the sensitization phenomenon of hyperknesis was not investigated directly in this 
thesis, the results of our studies indicate that sensitization processes may, simi-
larly to pain, also play a role in the patients with chronic itch. 
Modulation
Impaired central modulation processes may underlie the heightened sen-
sitivity of patients with chronic itch or pain. A conditioned pain modulation (CPM) 
paradigm, in which test stimuli are given before and after tonic conditioning stimu-
lation, was applied as measure for the functioning of central pain modulation by 
diffuse noxious inhibitory control (DNIC) [117,172]. We found that DNIC function-
ing was intact in subjects without chronic itch or pain, by showing that the level 
of pain evoked by an electrical stimulus decreased after subjects were subjected 
to a tonic painful cold stimulus (Chapter 3). However, DNIC was impaired in pa-
tients with RA suffering from chronic pain, with electrical test stimuli applied before 
and after painful conditioning being perceived as equally painful (Chapter 4). With 
some exceptions, the literature consistently shows that DNIC is impaired in vari-
ous patient groups with chronic pain [171]. 
The modulation of electrically evoked itch by itch-conditioning stimulation 
using histamine was investigated in a conditioned itch modulation (CIM) paradigm, 
comparable to the CPM paradigm (Chapters 3 and 4). In itch- and pain-free sub-
jects, we showed that heterotopically applied histamine inhibited the itch induced 
by electrical stimulation, thereby providing evidence for a mechanism of diffuse 
pruritic inhibitory control (DPIC). Moreover, we demonstrated that DPIC might be 
impaired in patients suffering from chronic itch (Chapter 3). Just as an impaired 
DNIC in patients with chronic pain is thought to be involved in the increased symp-
tom reporting [153,171], a disturbed DPIC may contribute to increased symptom 
reporting in patients with chronic itch. Earlier studies investigating the modula-
tion of itch mainly focused on the inhibition of itch by painful stimuli, with distally 
applied noxious counter-stimuli (e.g., scratching, electrical stimulation, heat, and 
cold) causing activation of mechanically sensitive polymodal C- and Aδ-fibers [30]. 
The mechanism underlying the descending inhibition of itch by painful stimulation 
is thought to be comparable to the descending inhibition of pain at the level of 
the spinal cord [30]. Whether this proposed itch-inhibitory mechanism by painful 
conditioning is similar to the mechanism of itch modulation by itch conditioning 
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through DPIC (see Chapter 3), remains to be investigated. Given that the modula-
tion of itch and pain by DPIC and DNIC, respectively, was found to be disturbed in 
patients with chronic itch or pain, these modulatory mechanisms might represent 
a generic process that contributes to a heightened sensitivity to various nocicep-
tive somatosensory sensations (see section Specificity of itch and pain). 
In summary, the studies in this thesis support the role of sensitization pro-
cesses in chronic pain and itch. Thus, patients with chronic itch and pain were 
more sensitive to specific somatosensory stimuli. Furthermore, the heightened 
sensitivity to itch and pain of patients with chronic itch or pain, respectively, may 
also result from impaired endogenous modulation by, for example, DPIC and 
DNIC. Similarly to chronic pain [2,90,170], a reorganization of central processing 
may underlie chronic itch. 
Cognitive-evaluative factors
Several psychological models have described the role of cognitive fac-
tors for the perception of sensations such as anxiety-related symptoms and 
their possible relevance for somatosensory sensations of both pain and itch 
[53,83,89,91,93,100,140,160]. These models suggest that cognitive factors such 
as heightened attention or expectations can play a key role in the chronification of 
itch and pain. As both attentional focusing and expectations have been shown to 
play a role in the sensitivity to pain, these factors were investigated in this thesis 
for their role with regard to sensitivity to itch and pain. 
In Chapter 5, it was demonstrated that the tendency to focus on bodily sen-
sations was associated with higher pain reporting for various experimental stimuli. 
This is in line with earlier studies showing that increased attention for bodily sensa-
tions is associated with increased reporting of pain elicited by experimental stimuli 
[20,80]. Moreover, patients with chronic pain showed an increased attention to pain 
and pain-related stimuli [126]. In Chapter 5, we showed for the first time that the 
tendency of increased attention to bodily sensations was associated with increased 
reporting of itch in healthy subjects in response to QST stimuli. This is consistent 
with the finding that patients with psoriasis show an increased attentional focus 
towards disease-related stimuli, including itch stimuli [51]. 
Heightened attentional focusing on potential threat, a mechanism de-
scribed as hypervigilance, may aggravate anxiety symptoms [143] and pain [126], 
and might also be applicable to itch. In line with this theory, focusing attention 
on itch and the interpretation of stimuli in the context of the patient’s main symp-
tom (e.g., patients with chronic itch interpreting stimuli as itchy) might lead to 
increased bodily awareness and increased symptoms. It has, for example, been 
shown that participants who repeatedly attempt to control the pain they expe-
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rience give greater priority to stimuli related to pain than do participants who do 
not attempt to control the pain they experience [106]. This focus of attention on 
symptom-related information in an attempt to control symptoms might be espe-
cially noticeable when symptoms have an uncontrollable and long-term character, 
such as in chronic pain. Since attention is directed to salient stimuli automatically 
selected from the environment [91,106], this attentional focus is possibly at the 
expense of attention that could be directed to other relevant stimuli [36]. Similarly, 
focusing attention on itch-related stimuli in order to control itch could lead to an 
attention-prioritizing towards itch-related stimuli, possibly at the expense of atten-
tion for other stimuli.
At a neurophysiological level, attentional focus leads to activation of the 
posterior parietal cortex (PPC), anterior cingulate cortex (ACC), dorsolateral pre-
frontal cortex (DLPFC), and thalamus. In contrast, when subjects were distracted, 
resulting in a decrease in pain, there was increased activation of the affective com-
ponent of the ACC and the orbitofrontal cortext (OFC) as well as a decreased 
activation of the thalamus, insula, and the cognitive component of the ACC [7]. 
Although neurobiological substrates of attentional processes in itch have not yet 
been studied, it is likely that the influence of attentional mechanisms on the in-
creased perception of itch and pain (Chapter 5) are based on comparable mecha-
nisms. 
The interpretation of physical sensations in the context of a patient’s symp-
tom or negative expectations about the intensity of symptoms might lead to the 
aggravation of symptoms [150,160]. For example, pain catastrophizing or nega-
tive expectations regarding anticipated or actual pain experiences have repeatedly 
been demonstrated to be linked with increased pain as well as with physical and 
psychological dysfunctioning in several clinical and non-clinical pain populations 
[79,141]. The role of expectations in the perception of pain has further extensively 
been investigated in the context of the placebo effect [11,115]. Characteristics of 
the placebo effect have been used as a model for understanding the reciprocal 
and antagonistic action of systems that are involved linking psychological factors, 
such as cognitions, to physical sensations such as pain [13]. Mainly from the pain 
literature, it is known that positive expectations can reduce physical sensations, 
e.g., by the placebo effect, as a result of activation of the reward system with in-
volvement of the dopaminergic system [107,132]. Within placebo analgesia, the 
endogenous opioid system is critically important, which has been demonstrated 
by the antagonizing effect of the opioid-receptor blocker naloxone as well as the 
enhanced placebo response when the cholecystokinin (CCK) antagonist proglu-
mide, which modulates opioid activity, is given [10,107]. In contrast, negative ex-
pectations can aggravate sensations, e.g., by the nocebo effect, for example, as 
a result of anticipatory anxiety. In nocebo hyperalgesia, anticipatory anxiety is as-
sociated with increased activity in the hypothalamic-pituitary-adrenal (HPA) axis 
and with activation of cholecystokininergic mechanisms; the latter facilitate pain 
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transmission by acting as neuromodulator of both pain and anxiety [13,14]. During 
nocebo hyperalgesia, brain areas related to the anticipation of pain, such as the 
ACC, prefrontal cortex (PFC), and the insula, are activated [14,24,132]. Placebo 
and nocebo effects have, in contrast, not yet been systematically examined for 
sensations of itch in comparison to pain.
In Chapter 6, suggestions that induced high expectations for pain increase 
resulted in increased levels of pain evoked by different experimental somatosen-
sory stimuli through a mechanism akin to the nocebo effect. In this study we further 
demonstrated that, by manipulating expectations regarding itch, nocebo effects, 
and possibly also placebo effects, on itch could be induced (Chapter 6). These 
findings are supported by preliminary evidence showing that subjects experienced 
enhanced levels of itch when instructions exaggerating itch were given compared 
to neutral instructions, or when they listened to a lecture about itch compared to 
a neutral lecture [104,130]. The findings of nocebo effects on pain and even stron-
ger nocebo effects for itch and the possible evidence for placebo effects on itch 
induced by verbal suggestion are in line with earlier studies investigating nocebo 
and placebo effects on pain by manipulating expectations by verbal suggestion 
[14,15,23,26]. However, in order to produce stronger or longer-lasting nocebo and 
placebo effects, conditioning has been shown to be important for pain [25,26]. 
Whether conditioning might be accordingly effective in inducing nocebo and pla-
cebo effects on itch remains to be investigated.
In summary, our and previous studies indicate that attentional focusing 
and expectations regarding itch or pain are associated with an increased sensiti-
vity to itch and pain. Consequently, it seems likely that cognitive factors may play 
a role in itch through similar mechanisms as they play a role in pain.
Affective-motivational factors
It is known that pain and emotions interact on multiple fronts, for example, 
negative emotions of psychological distress may precipitate symptoms, modulate 
the severity of pain, prolong pain, and can be a consequence of persistent pain 
[9]. Negative emotions, such as psychological distress, anxiety, and depressive 
symptoms, might not only be a reaction to chronic pain, possibly mediated by 
patients’ negative appraisals about the impact of the pain on their life or the per-
ceived inability to control pain, but might also play a causal role in chronic pain 
[53,94]. In the study described in Chapter 7, we showed that negative in compari-
son with positive emotions were associated with increased experimental pain. Our 
findings are in line with the majority of experimental studies showing that negative 
emotions are associated with increased pain perception, in contrast to positive 
emotions which are related to reduced pain perception [97,119,121,151,167]. Un-
derlying mechanisms may be explained in analogy with the motivational priming 
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theory of Lang, which proposes that emotions are driven by two opposing motiva-
tional systems, i.e., the appetitive system that engenders approach behavior, and 
the aversive system that promotes avoidance behavior [89,97]. According to this 
theory, negative emotions may enhance pain perception, while positive emotions 
attenuate it. This is also supported by prospective studies showing that negative 
emotions of psychological distress are a significant predictor of physical symp-
toms (e.g., pain) and of impaired physical functioning [53,149]. It should, however, 
be noted that, dependent on the context, negative emotions that are associated 
with a high arousal can temporarily result in short-term hypoalgesia, for example, 
stress-induced analgesia when someone is in acute danger [21,124].
We extended the findings for pain by showing that negative rather than 
positive emotions were also associated with heightened levels of itch (Chapter 7). 
This is consistent with preliminary evidence from clinical studies in which the levels 
of itch in patients with skin diseases are associated with symptoms of psychologi-
cal distress, such as anxiety [44] or depressive symptoms [52,66]. Further support 
for the effect of emotions on itch comes from an experimental study showing that 
experimentally induced mental stress is associated with increased itch reporting 
[49] and a prospective study showing that daily stressors were significantly associ-
ated with an increase in itch 4 weeks later [158]. It is well known that the relation-
ship between negative emotions and somatosensory sensations can be mediated 
by physiological reactions. For example, psychological distress responses are as-
sociated with activation of the HPA axis and the autonomic nervous system (ANS), 
leading to the secretion of stress hormones, such as corticotrophin-releasing hor-
mone, adrenocorticotropic hormone, and cortisol [1,32,102]. Stressor-induced 
activation of the HPA axis and autonomic responses, for example, can result in 
degranulation of mast cells to release histamine and worsen itch [4,110,155]. 
Moreover, the ANS has been associated with increased itch reactivity in response 
to an acute stressor in patients with atopic dermatitis [147]. At a neurobiologi-
cal level, emotions mainly activate (para)limbic areas of the brain, such as the 
ACC, insula, and amygdala [111], which areas are also activated by itch and pain 
[68,75,92,148]. Furthermore, activity in cortical areas involved in affect regulation, 
e.g., ACC, DLPFC and insula, has been shown to be correlated with more disease 
severity and levels of itch in patients with atopic dermatitis [76]. 
Taken together, the studies in this thesis provided some support that, as 
with pain, a reciprocal relationship exists between itch and emotions, whereby 
emotions aggravate itch, which, in turn, induces negative emotions.
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Behavioral responses to itch and pain
The behavioral responses to itch and pain are closely associated with the 
different sensory, cognitive, and affective factors described in this thesis. The goal 
of the behavioral responses to acute itch and pain are both based on avoiding and 
escaping from these sensations, which usually provide acute relief of symptoms. 
However, the actual behavioral responses to acute itch and pain diverge. Whereas 
pain may lead to rubbing of the painful area or retreating from the painful source, 
itch evokes a scratching response [159,177]. Imaging studies have shown that the 
behavioral responses to itch and pain elicit divergent patterns of brain activation, 
i.e., no activation of the secondary somatosensory cortex (S2) and a predomi-
nant activation of the motor areas in itch [75]. This itch-specific pattern of brain 
activation could be related to the acute scratch response and the urge to scratch 
[71,75]. While these responses to itch and pain can be effective in the short term, 
this behavior has negative consequences in the long term, especially when the 
symptoms persist. For example, avoidance and retreating behavior are stimulated 
by a patient’s worries about symptom development and anticipation of stimuli or 
activities that are expected to increase symptoms, such as itch or pain, which may 
ultimately increase symptoms [160]. Persistent avoidance behavior can become a 
maladaptive response, leading to increased fear, limited activity, and other physi-
cal and psychological consequences that contribute to disability and persistence 
of pain and psychological distress [53]. Patients suffering from chronic itch show 
patterns of avoidance behavior partly similar to those shown by patients with 
chronic pain [155,159]. More specifically, chronic scratching can damage the skin, 
which can result in systemic and devastating infections. Healing of damaged skin 
can induce itch, which in turn increases the urge to scratch, which frequently leads 
to a vicious itch-scratch cycle that increases itch symptoms and finally avoid-
ance behavior, e.g., quitting activities or retreating to a restful environment when 
experiencing itch [155]. Moreover, scratching may aggravate the sensation of itch 
because patients with chronic itch have been shown to perceive painful stimuli, 
such as scratching, as itchy [174]. Furthermore, scratching can also be a source 
of social embarrassment as a result of the appearance of the affected skin and 
the preoccupation with scratching in social situations. This may further increase 
avoidance behavior, while persisting avoidance behavior is associated with higher 
levels of itch, more scratching, and higher levels of disease-related disability, and 
reduced quality of life [155]. The interaction between psychophysiological factors 
and the behavioral responses to itch merits further investigation.
In summary, whereas the specific behavioral responses to acute itch and 
pain seem to differ, the goal of avoiding or removing itch and pain eliciting stimuli 
is comparable for both sensations. In the longer term, similar avoidance behavior 
is seen in patients with chronic itch or pain, which may be of influence on the ex-
acerbation and maintenance of symptoms. 
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Specificity of itch and pain
In the studies described in this thesis, psychophysiological factors of itch 
and pain were investigated concurrently (Chapters 2 – 7), which offers the unique 
opportunity to compare these sensations and to identify possible common and 
distinct psychophysiological factors. 
In the past, the “intensity theory” was used to describe the relationship 
between itch and pain. According to this theory itch and pain are closely related 
and mediated by a common pathway, where weak activation of nociceptors re-
sults in itch and stronger activation results in pain [75]. However, the discovery of 
a separate neuronal pathway for itch [129], in combination with the knowledge that 
polymodal nociceptors are insensitive to histamine or only weakly activated by it, 
strongly supported the “specificity theory of itch” [75,128]. More specifically, itch 
might be processed through a histamine-selective neuronal pathway or by poly-
modal C-fibers that excite only a subpopulation of the polymodal neurons in the 
spinal cord, which leads to a selective projection to supraspinal neurons [30,177]. 
The specificity theory supposes that itch and pain are distinct qualities with sepa-
rate, but interacting, sensory pathways. For example, it is well known that pain can 
inhibit itch, e.g., by scratching responses [75,139]. Rubbing or scratching can lead 
to a temporary suppression of itch by stimulating low threshold mechanoreceptors 
[31], which antagonistic interaction is supported by experimental studies in which 
painful stimuli were applied to reduce itch [105,162]. Although itch and pain can 
be processed through distinct, but interacting, neurons, there is a considerable 
overlap in neurophysiological processing between itch and pain. For example, the 
brain areas activated by itch, namely, mainly the ACC, PFC, primary somatosen-
sory cortex (S1), premotor area (PMA), supplementary motor area (SMA), PPC, 
and cerebellum, are, in general, comparable to the brain areas involved in pain 
[75]. Furthermore, it has been suggested that the mechanisms of sensitization in 
patients with chronic itch show similarities to those in chronic pain (see section 
Sensory factors) [75]. However, the exact mechanisms by which pruritic and pain-
ful stimuli are peripherally and centrally processed are still not fully understood 
[128]. Even less is known about the specific pathways involved in the interaction 
between itch and pain at a sensory, cognitive, affective, and behavioral level. 
Sensitization processes are thought to play a prominent role in the chroni-
fication of itch and pain. An important question for sensitization processes include 
the issue whether sensitization processes result in patients being more sensitive 
to somatosensory stimuli in general or specifically in the context of their main 
symptom. When comparing patients with chronic itch with patients with chronic 
pain (Chapters 2 and 4), we found preliminary evidence that patients with chronic 
itch or pain experience different sensations in the context of their main symptom. 
More specifically, patients with chronic itch displayed higher levels of itch, while 
patients with chronic pain displayed higher levels of pain (Chapter 2), or lower tol-
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erance thresholds (Chapter 4) in response to specific experimentally applied stim-
uli. Heightened sensitivity in the context of patients’ main symptom is consistent 
with studies showing that normally painful electrical and chemical stimuli can be 
perceived as itchy by patients with chronic itch [70,74,161], while stimulation with 
histamine can be perceived as painful by patients with chronic (neuropathic) pain 
[8]. More importantly, whereas repetitive noxious heat and scratching inhibit itch 
in healthy subjects [175], painful stimuli, such as electrical, noxious heat pain and 
scratching stimuli, applied distally from an itchy stimulus, increase itch in patient 
with chronic itch [74,174]. However, modulation of both itch and pain by DPIC and 
DNIC was found to be disturbed in both patients with chronic itch and pain (Chap-
ter 4), indicating that endogenous modulation processes seem to represent a ge-
neric mechanism in sensitization processes that contribute to the chronification of 
physical symptoms, such as itch and pain. Modulation processes could be dis-
turbed across conditions, comparable to the unifying concept of central sensitivity 
syndromes. According to this concept, conditions characterized by various physi-
cal symptoms, such as irritable bowel syndrome, headache, and chronic fatigue 
syndrome, might be affected by central sensitization processes, disturbed modu-
lation of the symptoms, e.g., by DNIC, and accompanying psychological factors 
[82,98,178,179]. More insight into the mechanisms of sensitization and modulation 
may ultimately increase our knowledge of generic and specific psychophysiologi-
cal processes underlying the amplification of sensations such as itch and pain. 
Although the effects of the psychophysiological factors were not com-
pared directly between itch and pain in this thesis in terms of effect sizes, results 
generally showed stronger effects of sensory, cognitive and affective factors for 
itch than for pain. For example, in the studies described in Chapters 2 and 4, the 
effects of higher itch sensitivity in the patients with chronic itch, in comparison to 
the control subjects, were stronger than the effects of higher pain sensitivity in 
the patients with chronic pain. Furthermore, the correlation between itch or pain 
and self-reported attentional focus on bodily sensations was overall stronger for 
itch sensitivity than for pain sensitivity (Chapter 5), whereas the nocebo effects 
for itch induced by verbal suggestion were stronger than the nocebo effects for 
pain (Chapter 6). The stronger effects for itch might be due to the fact that sub-
jects are more susceptible to suggestions about itch than to suggestions about 
pain: watching other people scratching can induce a scratching response, previ-
ously described as “contagious itch” [75,109]. Moreover, scratching an itchy area 
can also lead to “referred itch”, the perception of itch elsewhere [42,75,109]. The 
phenomenon of contagious itch may be related to “mirror neurons”, which are 
involved in the planning, preparation, and execution of motor actions as well as in 
imitation and learning [75], which might possibly play a dominant role in itch. 
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To conclude, psychophysiological factors influencing itch and pain show 
many similarities with even stronger effects on itch than on pain, which may be 
explained by the differences in neurobiological processing and specific behavioral 
responses to these sensations.
Chronic itch and pain 
Acute pain, which is normally associated with injury, arises from activation 
of the peripheral nervous system and complex higher level processing, and lasts 
as long as the injury lasts [22,120]. Acute itch is an experience that is associated 
with an actual or perceived disruption to the skin that produces a desire to scratch, 
and can usually be abolished by scratching briefly at or near the itching area [30]. 
In contrast, chronic itch and pain imply the presence of symptoms for a longer 
duration with the involvement of altered signal processing and central sensitization 
[2,3,75,139]. Moreover, chronic symptoms of itch and pain are accompanied by 
avoidance behavior, which has broad long-term consequences, such as symptoms 
of psychological distress, limitations in daily functioning, and social problems. 
Within the studies of this thesis, acute itch and pain were induced by ap-
plication of different somatosensory stimuli to patients with chronic itch or pain 
(Chapters 2 – 4) and healthy subjects (Chapters 2 – 7) in order to investigate the 
role of psychophysiological factors in itch and pain. Investigation of sensory fac-
tors demonstrated that the processing of itch signals may be altered in patients 
with chronic itch similarly to the processing of pain in patients with chronic pain 
(see section Sensory factors). Investigation of the cognitive and affective factors 
showed that these factors were of influence on the perception of acute itch and 
pain in healthy subjects. However, investigation of these factors in sensitivity to 
itch and pain in healthy subjects does not take into account the altered stimu-
lus processing of patients with chronic itch or pain. Consequently, the interaction 
between sensory, cognitive, and affective factors should be further investigated 
in patients with chronic itch, and the specific similarities and differences when 
compared to chronic pain have to be studied in more detail. Systematic evalua-
tion of studies comparing healthy subjects with patients with acute and chronic 
itch and pain, prospective studies of patients with acute and chronic itch, and re-
search involving individuals who recover spontaneously or who adapt adequately 
to their condition could provide valuable information about how acute physical 
symptoms become chronic and about the psychophysiological mechanisms un-
derlying chronic itch. 
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Personality and disease characteristics
The perception of sensations such as itch and pain may be influ-
enced by personality characteristics, such as neuroticism or anxiety sensitivity 
[6,41,45,46,60,81,155]. Particularly in chronic pain, it is well known that personal-
ity characteristics of neuroticism and anxiety sensitivity can play a role, e.g. by 
enhancing cognitive, affective, or sensory factors of pain responses [6,45,46,81]. 
Much less is known about these and other personality characteristics regarding 
acute or chronic itch sensations. In the studies of this thesis, different personal-
ity characteristics were taken into account for their putative influence on sensory, 
cognitive, or affective factors modulating the sensitivity to itch or pain. Examples 
include factors related to suggestion, such as social desirability, imaginative in-
volvement, and suggestibility, and affective factors, such as neuroticism, anxiety 
sensitivity, or alexithymia. However, these personality characteristics were found 
to have no, or a rather small, effect, as indicated by the mainly non-significant cor-
relations with the sensitivity outcome measures, and the unaltered main effects 
after controlling for these variables (Chapters 2 – 7). Consequently, these charac-
teristics do not appear to be particularly relevant to the short-term stimuli applied, 
or to the sensations evoked by the stimuli, such as itch and pain. Symptom-relat-
ed characteristics, such as pain- or itch-related fear, which may be acquired as a 
result of a person’s experience of pain and itch, might have a larger influence on 
pain and itch sensitivity, respectively, than the more general personality charac-
teristic of anxiety sensitivity, as investigated in the studies described in this thesis. 
In addition, the role of several other individual characteristics that are possibly of 
direct relevance to the psychophysiological factors of itch and pain has not yet 
been studied, such as optimism, which has been shown to be related to a stronger 
placebo response [54]. Understanding the individual variability in sensitivity to itch 
and pain, including the role of personality characteristics, may be crucial to the 
prevention and treatment of these symptoms. 
Condition- and disease-related characteristics such as disease duration, 
intensity, and symptoms of itch and pain, may be associated with the altered sen-
sitivity to and sensitization of itch and pain in patients with chronic itch and pain 
(see also section Chronic itch and pain). However, in our studies, disease dura-
tion, disease intensity and levels of itch and pain at the day of testing overall did 
not affect the outcome measures of itch and pain in the patients (Chapters 2 – 4). 
Future studies may further investigate the role of condition- and disease-related 
characteristics on sensitivity to itch and pain. 
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Study limitations
Ecological and external validity
There are several limitations with respect to the ecological and external 
validity of the studies described in this thesis, e.g., the generalizability with regard 
to patients with various diseases, differences between male and female patients, 
and the distinction between patients and healthy subjects. 
First, the studies investigating symptom-specific sensitivity and endog-
enous modulation of itch and pain were carried out with specific patients groups 
with chronic itch or pain in a limited number of different diseases (Chapters 2 – 4). 
For further evidence for the specificity of the disturbance of endogenous modula-
tory processing, e.g., DPIC and DNIC, and heightened sensitivity to itch and pain 
(see also section Specificity of itch and pain), these mechanisms have to be inves-
tigated in patient groups with chronic itch or pain other than those investigated in 
this thesis. 
Second, half of the studies were performed with healthy subjects (Chapter 
5 – 7). Although it is important to investigate psychophysiological factors in healthy 
individuals first, this approach has its limitations. Investigation of the sensitivity to 
itch and pain in healthy subjects cannot be extrapolated to the sensitivity to itch 
and pain in patients with chronic itch or pain, because of the underlying pattern 
of altered itch and pain processing, respectively (see also sections Sensory fac-
tors and Chronic itch and pain). Consequently, the psychophysiological effects of 
the cognitive and affective factors investigated cannot be directly extrapolated 
to patient groups with chronic itch or pain [3]. For example, the mechanisms by 
which attention and expectations influence itch and pain may differ in patients with 
chronic itch or pain and in healthy subjects, as suggested by the finding that at-
tentional processes and (catastrophic) expectations can influence pain perception 
through pain modulatory processes [18,40,47,57,58,146], and that itch and pain 
modulation, by DPIC and DNIC, respectively, may be disturbed in patients with 
chronic itch and pain. Moreover, experimental stimuli evoke short-lasting sensa-
tions in an artificial laboratory setting, so that experimentally investigated mecha-
nisms of itch and pain cannot be extrapolated to longer-lasting sensations.
A third limitation concerns the enrolment of exclusively female par-
ticipants. The use of a relatively homogeneous cohort reduces the variability of 
measurements. However, the results of sensitivity to and modulation of soma-
tosensory stimuli as well as the influence of negative affectivity cannot directly 
be translated to men, due to possible gender-specific effects [48,113,123]. In ad-
dition, we controlled for the pre- or post-menopausal status of the participants, 
because the menopause is associated with skin changes and increased itch and 
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pain [19,35]. Moreover, there is preliminary evidence that the sensitivity to soma-
tosensory stimuli and endogenous modulation changes throughout the menstrual 
cycle [87,125,144], although this evidence is inconsistent [84]. Possible effects 
of gender-specific or hormonal influences, such as the menstrual cycle and the 
menopause, on the sensitivity to itch and pain remain to be investigated. 
A fourth limitation concerns the possible interaction between itch and pain 
sensations (see also section Specificity of itch and pain). The question remains 
whether the present findings would have been comparable if itch had been inves-
tigated independently of pain, for example, by applying stimuli that evoke solely 
itch sensations, or by asking subjects to report only the sensation of itch evoked. 
Given that the suggestion of pain [118] can lead to the perception of pain and ac-
tivation of pain-related brain areas, and that pain can inhibit itch [75,139], thinking 
about pain might also have possible itch-reducing effects. Consequently, the role 
of psychophysiological factors when investigating the sensitivity to itch and pain 
concurrently or separately remains a point of attention. 
Psychophysiological measures 
The psychophysiological measures used in the studies of this thesis were 
found to be useful to study psychophysiological factors for nociceptive soma-
tosensory sensations of itch and pain within the same experimental design. How-
ever, there are a number of potential disadvantages to the psychophysiological 
measures used in the studies. 
First, measuring the levels of itch and pain (Chapters 2 - 7) by use of a 
VAS could be criticized due to possible limited test-retest reliability and external 
validity [77,116]. The perception of sensory stimuli may further differ as a function 
of stimulus modality, intensity, and type, and a large variability between subjects 
is common in clinical and experimental studies [3,29]. Moreover, the correlation 
between different pain measures (different stimulus types, and non-painful, barely 
painful, and intolerable intensities) has been shown to be relatively low [103]. In or-
der to take individual and interstimulus differences into account, we used stimuli of 
different modality and intensity and assessed both the (tolerance) thresholds and 
levels of itch and pain. Additionally, behavioral measures (e.g., scratch monitoring 
systems or observed itch and pain behavior), neural correlates of brain activation 
for itch and pain, and endocrine or autonomic responses (e.g., heart rate, skin 
conductance, or cortisol levels) should be evaluated as additional support for the 
validation of itch and pain measures [3,32,100,104,147]. 
Second, in view of the large variability in subjects’ sensitivity to soma-
tosensory stimuli and for ethical reasons, restricted stimulus intensities were used, 
which means that the levels of itch and pain induced by the different stimuli were 
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generally relatively mild. Even at the tolerance thresholds for mechanical (Aδ-
fiber threshold), electrical, or cold pressor stimulation, the reported levels of itch 
and pain were relatively low. This may be explained by the fact that the tolerance 
thresholds were defined in general terms (i.e., the moment that the sensation be-
comes unbearable and you want to stop immediately”) and not with regard to itch 
or pain. All stimuli have been previously reported to be able to induce itch and/or 
pain sensations. However, although histamine is reported to induce both itch and 
pain [135,136], it induced moderate to high levels of itch, but low levels of pain in 
our studies (Chapters 5 and 6), which suggests that histamine is primarily an itch 
stimulus (see Chapters 3, 4, and 7). In addition, the cold pressor test had previ-
ously been validated for pain induction and induced in our studies moderate to 
high levels of pain, but a number of subjects reported low itch sensations in one of 
our studies (see Appendix). Finally, (intradermally applied) capsaicin was originally 
used to investigate the desensitization of nerve fibers and pain and to a lesser ex-
tent itch [64,114,136]. However, topical application of capsaicin did not produce 
pain in our experiment, and the levels of itch were relatively low with a large inter-
subject variability (Chapter 5), suggesting that topical capsaicin is less capable of 
inducing reliable itch and pain sensations than histamine and the cold pressor test, 
respectively. In future research, stimulus intensity, duration, and modality as well 
as the sensation quality reports should be varied in order to increase the variability 
in the levels of itch and pain induced [e.g., 16]. For example, to increase the inten-
sity of the perceived sensation, the stimulation could be tailored to the subject’s 
level of itch or pain, for example, by applying stimuli at an intensity associated with 
a VAS score for itch or pain of 6 out of 10 [5]. 
Third, the present studies could have been affected by interaction effects, 
both between the sequential stimuli (e.g., stronger itch and pain stimuli could pos-
sibly modulate subsequent sensations by DNIC and DPIC; see also section Sen-
sory factors) and between itch and pain sensations (e.g., pain can inhibit itch; see 
also sections Specificity of itch and pain and Study limitations – Ecological and 
external validity). Stimulus-interaction effects were reduced as much as possible 
when multiple somatosensory stimuli were used (Chapters 2 – 7). For example, 
intervals between the stimuli were chosen in such a way that most participants 
no longer felt itch and pain before the next stimulus was applied, and the order 
of the stimuli was chosen in such a way that the stimuli evoking the lowest levels 
of itch and pain were applied first (e.g., the mechanical stimulation with von Frey 
monofilaments). Since this strategy might induce priming effects, e.g., inducing 
expectations concerning the next stimulus, the application of stimuli should be 
counterbalanced and randomized whenever possible.
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Future research 
Given that different sensory, cognitive, and affective factors might play a 
role in the perception and processing of itch and pain, future research should fur-
ther clarify the influence of these factors and the mechanisms underlying itch and 
pain, and identify targets to improve diagnostics and therapy.
The studies of Part I of this thesis indicated that patients with chronic itch 
and pain might be more sensitive to physical sensations in the context of their 
main symptom, whereas the endogenous modulation of itch and pain seems to be 
disturbed in a generalized way (see also section Specificity of itch and pain). Future 
studies should provide additional support for the hypothesis of symptom-specific 
heightened sensitivity as well as generalized disturbance of conditioned modula-
tion by investigating different types of conditions associated with chronic itch or 
pain, for example, different types of conditions (e.g., inflammatory and non-inflam-
matory conditions, itch in other patient groups than skin diseases) associated with 
acute as well as chronic itch [17,95,157]. Future prospective research should also 
focus on the predictive value of heightened itch sensitivity and altered itch modu-
lation as risk factors for disease progression and chronic itch in the long term. Pain 
responses have been shown to prospectively predict higher levels of postsurgical 
pain and poorer responses to treatment for chronic pain [37,62,63,108], and DNIC, 
measured in a CPM paradigm, has shown to be a risk factor for the development of 
chronic pain [61,165,169,173]. Considering that DNIC has been shown to improve 
after effective treatment of patients with chronic pain [85], future studies should 
focus on the improvement of DPIC after effective treatment of itch in patients with 
chronic itch. To this end, it is important to investigate the mechanisms underlying 
DPIC, which may, comparably to the mechanisms underlying DNIC, be based on 
supraspinal descending endogenous modulation of nociceptive signals [28,67]. 
Part II of this thesis focused on cognitive-evaluative factors of itch and 
pain. In line with the findings reported in Chapter 5, in which attentional focus on 
bodily sensations was shown to be related to the sensitivity to different soma-
tosensory stimuli evoking itch and pain in healthy subjects, future studies should 
investigate the role of attentional focusing on itch in patients with chronic itch. 
Automatic attentional focusing could be investigated using implicit measures of 
attention, e.g., the dot-probe task [112], complementary to explicit measures such 
as questionnaires. In addition to attention, the tendency of interpreting ambigu-
ous stimuli as pain-related and threatening is considered to be a vulnerability fac-
tor for the development of chronic pain [112,154]. Future research could investi-
gate whether patients with chronic itch have the tendency to interpret ambiguous 
stimuli as related to itch or threatening, so that patients with skin disease could 
be screened in an early stage for a possible vulnerability to develop chronic itch. 
In Chapter 6, we showed that negative expectations induced by verbal sugges-
tion were able to evoke nocebo effects on both itch and pain for various soma-
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tosensory stimuli. In view of the relatively strong and consistent effects of particu-
larly nocebo and, to a lesser extent, placebo suggestions for itch, future studies 
should investigate the induction of nocebo and placebo effects on itch in depth. 
For acquiring longer-term expectations, expectations can be learned through con-
ditioning by associating specific cues with responses through repetitive pairing, 
such as happens when patients couple antecedent factors preceding the onset of 
their symptoms with the actual perception of symptoms [163,166]. Conditioning 
is, consequently, expected to produce stronger nocebo or placebo effects of lon-
ger duration than does verbal suggestion [25,26]. Future studies could investigate 
whether conditioning may also be effective in inducing nocebo and, particularly, 
placebo effects on itch, for example, by the association of different visual or verbal 
stimuli. Because negative and positive expectations about itch play an essential 
role in the perception of itch, itch therapies may benefit from the placebo effect. 
Indeed, some clinical trials investigating itch-reducing medication, have reported 
a reduction of itch in the placebo study arm [56,86,96]. Since optimism is associ-
ated with better placebo responding [54], and optimism and hope are associated 
with lower levels of experimentally induced pain [27,138], future research should 
investigate whether creating a more optimistic attitude towards itch symptoms, by 
training positive outcome expectancies, reducing rumination, or improving prob-
lem-solving skills is effective in reducing itch. 
Part III of this thesis focused on affective-motivational factors of itch and 
pain, and showed that emotions can affect the perception of itch, just as emotions 
can affect pain. While the effects of a person’s emotional state on pain seem to 
depend on the type and the context of the emotion [21,89,97,122,151], it is not 
known whether this is the case for itch. Given that acute itch triggers scratching 
behavior, which is indicative of an activating behavioral response [155], emotions 
associated with various degrees of physiological arousal can be expected to have 
differential effects on itch. Consequently, future research should focus on the ef-
fects of different emotional states, such as depression, fear, anxiety, or anger, on 
the perception of itch in comparison to pain. Moreover, future research should 
also focus on the effects of positive emotions independently of negative emo-
tions, which may, similarly to pain [121,142], be associated with a reduction in itch. 
Furthermore, the reciprocal relationship between itch and emotions should be in-
vestigated in prospective studies with several assessment points in the short- and 
long-term, for example, by investigating the extent to which negative emotional 
states can influence pruritus and scratching and vice versa in patients with acute 
or chronic itch. Moreover, the degree of psychological distress and related physi-
cal sensations a patient experiences may also be dependent on emotion regula-
tion processes, e.g., automatic and strategic styles of experiencing, processing 
and modulating emotions [65]. Since emotion regulation strategies are suggested 
to be helpful in regulating distress and reducing pain in patients with chronic pain 
[94], it may also be effective in relation to itch.
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On the level of behavioral responses, future research may clarify the neu-
rophysiological basis of the perception of itch when viewing others scratching, 
which may be related to the mirror neuron system [72,73]. In addition, future re-
search could also focus on the differences in automatic behavioral responses be-
tween itch and pain. For example, the approach avoidance task (AAT) could be 
used to measure automatic behavioral responses [69], by using pictures associ-
ated with itch or skin disease in patients with chronic itch. Since the AAT could 
also be used to automatically retrain patients’ approach or avoidance behavior in 
order to regain control over automatic behavior [133,168], future research could 
focus on retraining automatic scratching behavior of patients with chronic itch in 
order to break the itch-scratch cycle. 
Although sensory, cognitive, affective, and behavioral factors can be dis-
entangled and assessed separately, these factors are considered to act interde-
pendently in the experience of pain [22,174], and thus it seems likely that these 
factors also have an interactive role in the sensitivity to itch. It has been put for-
ward that the more the psychophysiological factors interact, the more physical 
symptoms are enhanced [88]. Future research should investigate the interactions 
between the psychophysiological factors, for example, concerning the role of at-
tentional focusing, expectations of itch exacerbation, emotional state, and auto-
nomic, endocrine, and immune itch reactivity in itch and scratching behavior.
Implications for clinical practice
The findings of the present thesis have several implications for clinical 
practice with regard to the diagnosis and treatment of patients with itch. In rou-
tine clinical practice, physicians should take psychophysiological influences into 
account to optimize the therapeutic outcome. When considering the multidimen-
sional burden of patients suffering from itch [164,176], it may be desirable for 
clinicians to focus on the presence of itch and altered itch processing in addition 
to determining patients’ disease severity and asking patients about their general 
quality of life.
Understanding the psychophysiological mechanisms underlying itch ag-
gravation may, in the long term, lead to the development of better diagnostics 
and pharmacological and non-pharmacological treatments for itch management 
in various skin diseases. A wide variety of diagnostic instruments and treatments 
have been developed, both on a pharmacological and psychological level, to re-
duce the burden of itch or pain. Some of these diagnostic instruments and inter-
ventions as well as suggestions for improvement are discussed below. 
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At a sensory level, it may be useful to measure the sensitivity to and modu-
lation of itch in patients with chronic itch in clinical practice. Just as QST mea-
surements of sensitization processes and endogenous modulatory functioning are 
used as a prognostic tool in patients with chronic pain [37,61-63,108,165,169,173], 
the increased sensitivity to and impaired modulation of itch might possibly also be 
used as a prognostic indicator of worse disease prognosis and long-term treat-
ment outcomes in patients with chronic itch. Although further empirical support 
is mandatory, measures of itch sensitivity and endogenous itch modulation could 
be incorporated in clinical diagnostic procedures for patients with skin disease, to 
evaluate whether they are at risk of developing chronic itch. In addition, pharma-
cological treatments, such as gabapentinoids, associated with a reduction in cen-
tral sensitization phenomena of pain [59,131], have been found to be also effective 
to reduce itch [101], possibly through reducing sensitization phenomena of itch. 
At a cognitive-behavioral level, several cognitive-behavioral therapies are 
directed to learn patients how to cope with itch and to reduce scratching beha-
vior. Therapies such as habit reversal therapy [99] and multipackage itch-coping 
programs [39,43,152], have been proven effective in reducing itch and scratching 
behavior. Main focuses of these therapies are controlling the patient’s desire to 
scratch, modifying the awareness of itch and scratching behavior, and retraining 
catastrophic cognitions into helpful cognitions [39,43,92]. Itch-reducing therapies 
could also focus on reducing selective attention for possible itch-inducing stimuli, 
as has been applied in patients with chronic pain [33]. In addition, therapies spe-
cifically aimed at extinguishing negative expectations by helping patients learn 
new, positive expectations, and reappraisal of symptoms, or by training patients 
to recognize exceptions in the previously acquired associative relationships [e.g., 
134,145], can be expected to possibly also reduce symptoms of itch. For exam-
ple, in clinical practice, physicians can be trained in communication strategies to 
avoid inducing fear and unintended negative expectations of symptom worsening 
in their patients when aggravation of symptoms is not to be expected [12]. Positive 
expectations can be induced regarding the evidence-based efficacy of treatment, 
e.g., the antipruritic effect of medication, which might increase the therapeutic 
yield of treatment during regular care. 
At an affective level, it is essential to take the emotional state of the pa-
tient into account when attempting to reduce symptoms of itch. More specifically, 
negative emotions not only seem to aggravate itch, but itch may also influence 
the emotional state, which may ultimately lead to a vicious cycle of symptom exa-
cerbation. As psychological distress, e.g., in the form of daily stressors, has been 
shown to influence symptoms of itch [156], patients extensively suffering from itch 
should be monitored for heightened levels of psychological distress on a regular 
basis. Therapies directed at ameliorating psychological distress, e.g., stress man-
agement training, relaxation or mindfulness therapy [39,50,78], can bring about a 
reduction in symptoms of itch in these patients. 
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Most pharmacological and psychological treatments are directed to differ-
ent psychophysiological factors. Disentangling and defining the mechanisms by 
which the separate psychophysiological factors exert their function, for example, 
in experimental intervention studies manipulating just one component, could reveal 
which psychophysiological factors are most powerful. This could lead to a shift of 
the accent of the therapy, and finally to improvement of the working mechanisms 
and increase in the therapeutic yield. 
Conclusions
The main conclusions that can be drawn from the results of the studies 
presented in this thesis can be summarized as follows:
-  It is possible to study specific psychophysiological factors for nociceptive 
somatosensory sensations of itch and pain within the same experimental design 
using quantitative sensory testing.
-  Specific psychophysiological factors play a role in the perception and processing 
of itch, such as sensory factors (e.g., central modulation and altered sensitivity to 
itch), cognitive factors (e.g., negative expectations aggravating itch), and affec-
tive factors (e.g., negative emotions enhancing itch perception). 
-  These sensory, cognitive, and affective factors seem to influence the perception 
and processing of itch in a similar manner to the perception and processing of 
pain. 
-  In view of the possible common mechanisms underlying the influence of 
psychophysiological factors for itch and pain, knowledge of the mechanisms 
that give rise to pain aggravation and chronification of pain could be of great 
value to the diagnosis and treatment of acute and chronic itch. 
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resPonse to the commentary “you may  
(not always) exPerIence what you exPect:  
In search For the lImIts oF the PlaceBo and  
noceBo eFFect”
Published as letter to the editor:
Van Laarhoven AIM, Evers AWM. Response to the commentary “You may (not 
always) experience what you expect: in search for the limits of the placebo and 
nocebo effect. Pain 2011;152:1931-1932.
The authors thank Prof Crombez and Dr Wiech for their comments [7] 
regarding our article, “Induction of nocebo and placebo effects on itch and pain 
by verbal suggestions” recently published in Pain [12], and we appreciate the op-
portunity to reply to their points. 
There is no doubt that placebo and nocebo effects can alter the percep-
tion of a wide variety of symptoms. However, the magnitude of the evoked effects 
seems to be dependent on the procedure used, including the nature of the stimu-
lus, the contextual setting, and individual factors, such as the patient’s desire for 
symptom relief. Expectations seem to play a crucial role in placebo and nocebo ef-
fects, as revealed, for example, by the reduced effectiveness of medication when 
it is given covertly, without any verbal suggestion [5]. Although verbal suggestions 
can induce nocebo and placebo effects, expectations learned automatically by 
conditioning evoke an even more robust and persistent placebo effect than con-
scious expectations [6]. Because placebo or nocebo effects can be learned by as-
sociation with a wide variety of cues, the main issue might be to what extent, with 
what strength, and for how long the alteration in symptom perception is brought 
about, rather than whether expectations can alter the perception of a sensation. 
We therefore do not per se agree with Crombez and Wiech that a person’s ex-
pectations are updated when there is a mismatch between the expected and ob-
served information. For example, Arntz et al. [1] showed that underpredicting the 
level of pain to be expected led to lower levels of perceived pain in healthy female 
volunteers who were given painful stimuli during a discrimination task. Crombez 
and Wiech further point out that ambiguous experiences are more malleable to 
expectations than experiences with clear perceptual characteristics. However, in 
line with the central role of expectancy learning in placebo effects, it may be more 
important that the expected increase or decrease is associated with the stimulus, 
regardless of whether that stimulus is ambiguous or not. For example, nocebo ef-
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fects on pain can also be induced for non-painful stimuli [6] or for light mechanical 
stimulation with monofilaments as shown in our study. Discussion of the effects 
of expectations regarding ambiguous or unambiguous stimuli seems to be linked 
to the second point raised by Crombez and Wiech, namely, that expectations that 
are highly compatible with the actual experience will be more susceptible to pla-
cebo and nocebo effects. Using the cold pressor test, we tested whether verbal 
suggestions could induce nocebo effects for itch and found that 24% of the sub-
jects who expected to feel itch indeed reported some degree of itch (data not 
published), suggesting that placebo or nocebo effects can also be induced for 
sensations not initially associated with the stimulus. Instead of mismatching or 
ambiguity of the stimuli, the strength of the induced expectation for a stimulus 
might be the crucial factor determining the magnitude of placebo and nocebo ef-
fects. The mechanisms of the induced expectation might differ between placebo 
and nocebo effects, as raised in their third point concerning the possible influence 
of behavioral costs. Whereas anxiety underlies nocebo hyperalgesia, moderated 
by the HPA axis and CCK-ergic systems, placebo analgesia is related to the re-
ward system of the brain, i.e., to dopamine activation in the nucleus accumbens 
and endogenous opioid release. In addition, nocebo effects are inversely related 
to the reward system, as evidenced by a deactivation of dopamine and endog-
enous opioid release [2,3]. The asymmetry between nocebo and placebo effects 
could be related to the threat value underlying negative expectations. Negative ex-
pectations generally have an intrinsic threat value, which may lead to heightened 
awareness and attention, which from an evolutionary perspective may promote 
survival [13]. Studies investigating more enduring patterns of negative expecta-
tions, such as catastrophizing, generally show that catastrophizing is associated 
with increased pain intensity and other unfavorable health outcomes, including 
mortality [8,10]. The extent to which behavioral costs are determinants of the dif-
ference between placebo and nocebo effectiveness remains to be investigated. 
Finally, with regard to the effects of expectancies that may vary as a function of 
repeated experiences, the last point raised by Crombez and Wiech, it has been 
shown that placebo effects can be induced by expectation learning, by condi-
tioning after multiple conditioning trials, whereas nocebo effects can be induced 
by verbal suggestion alone or after a single conditioning trial [6]. This difference 
again highlights the different mechanisms underlying placebo and nocebo effects. 
Future research might, consequently, focus on the role of different individual char-
acteristics, such as catastrophizing and optimism [9], and the divergent neurobio-
logical mechanisms underlying nocebo and placebo effects as well as possible 
clinical targets for enhancing placebo effects (e.g., by optimism training [11]) and 
reducing nocebo effects (e.g., by symptom-related stress reduction [4]).
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AAT Approach avoidance task
ACC Anterior cingulate cortex
AD Atopic dermatitis
ANCOVA Analysis of covariance
ANOVA Analysis of variance
ANS Autonomic nervous system
ASI Anxiety sensitivity index
BMI Body mass index
BSQ Body sensations questionnaire
BVAQ Bermond-Vorst alexithymia questionnaire
BVS Body vigilance scale
CCK Cholecystokinin
CI Chronic itch
CIM Conditioned itch modulation
CP Chronic pain
CPM Conditioned pain modulation
DAS Disease activity score
DLPFC Dorsolateral prefrontal cortex
DNIC Diffuse noxious inhibitory control
DPIC Diffuse pruritic inhibitory control
EPQ Eysenck personality questionnaire
FM Fibromyalgia
GLM General linear model
HADS Hospital anxiety and depression scale
HC Healthy controls
HPA axis Hypothalamic pituitary adrenal axis
HNCS Heterotopic noxious conditioning stimulation
HPCS Heterotopic pruritic conditioning stimulation
ISDL Impact of chronic skin disease on daily life
LSD Least significant difference
M Mean
MANCOVA Multivariate analyses of covariance
MANOVA Multivariate analyses of variance
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lIst of abbrevIatIons
NSAID Non-steroidal anti-inflammatory drugs
OFC Orbitofrontal cortex
PAG Periaqueductal gray
PFC Prefrontal cortex
PMA Premotor area
PPC Posterior parietal cortex
PS Psoriasis
PSWQ Penn state worrying questionnaire
QST Quantitative sensory testing
RA Rheumatoid arthritis
RADAI Rheumatoid arthritis disease activity index
RVM Rostral ventromedial medulla
S1 Primary somatosensory cortex
S2 Secondary somatosensory cortex
SD Standard deviation
SEM Standard error of the mean
SMA Supplementary motor area
VAS Visual analogue scale
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Chronische jeuk en pijn zijn veelvoorkomende klachten die een grote 
invloed kunnen hebben op het dagelijks functioneren van de patiënt. Meer dan 
50% van de patiënten die een huisarts bezoeken voor een chronische huidaan-
doening, zoals eczeem of psoriasis, heeft last van jeukklachten, waarvan de helft 
zelfs in relatief ernstige mate. Chronische pijn komt voor bij ongeveer 5-20% van 
de volwassenen als symptoom van vele aandoeningen, zoals rugpijn, migraine, 
ontstekingen, fibromyalgie of reumatoïde artritis. Chronische jeuk en pijn hebben 
vaak negatieve consequenties voor het dagelijks functioneren van de patiënt, zo-
als functionele beperkingen, vermoeidheid, slaapproblemen, angst en depressieve 
klachten. 
De mechanismen die verondersteld worden bij te dragen aan chronische 
jeuk en pijn vertonen veel overeenkomsten. Jeuk en pijn zijn onderdeel van het 
afweersysteem van het lichaam. De waarneming van deze lichamelijke sensaties 
dient als waarschuwingssignaal tegen mogelijke bedreiging of beschadiging. Bij 
chronische klachten werkt de functie van waarschuwingssignaal niet meer naar 
behoren. Ook op neurobiologisch gebied bestaan veel overeenkomsten tussen 
jeuk en pijn, bijvoorbeeld in de hersengebieden die worden geactiveerd door beide 
sensaties. Het is bekend dat tevens psychofysiologische factoren, zoals aandacht 
of verwachtingen, een rol kunnen spelen bij pijn. Zo kunnen pijnklachten bijvoor-
beeld toenemen wanneer de patiënt veel aandacht richt op de pijn of wanneer deze 
negatieve verwachtingen heeft ten aanzien van het verloop van de klachten. Over 
de rol van psychofysiologische factoren bij jeuk is echter nog weinig bekend.
Gezien de vele overeenkomsten tussen jeuk en pijn is het aannemelijk dat 
mogelijk overeenkomstige psychofysiologische factoren een rol spelen bij jeuk. De 
kennis omtrent de rol van psychofysiologische factoren bij pijn kan waardevol zijn 
om meer inzicht te krijgen in de mechanismen waardoor jeukklachten toenemen. 
Dit kan aanknopingspunten bieden voor de preventie en behandeling van jeuk-
klachten. Bovendien kan het ophelderen van algemene mechanismen bijdragen 
aan de behandeling van diverse lichamelijke klachten. Immers, wanneer verschil-
lende lichamelijke klachten volgens vergelijkbare mechanismen kunnen verergeren, 
kunnen zij mogelijk ook op vergelijkbare wijze gunstig beïnvloed worden. 
In het huidige proefschrift werd voor het eerst de rol van verschillende psy-
chofysiologische factoren ten aanzien van jeuk bestudeerd en vergeleken met hun 
rol bij pijn. In verschillende onderzoeken werd de rol van sensorische (sensitisatie 
en modulatie), cognitieve (aandacht en verwachtingen) en affectieve (emoties) fac-
toren bestudeerd bij gezonde personen en/of patiënten met chronische jeuk of 
pijn. Jeuk en pijn werden geïnduceerd door lichamelijke prikkels van quantitative 
sensory testing (QST), namelijk mechanische, electrische, chemische (histamine en 
capsaïcine) en koude prikkels.
199
samenvattInG (dutch summary)
Sensorische factoren
  Pijn ontstaat wanneer nociceptoren, oftewel pijnreceptoren, worden ge-
activeerd. Dit gebeurt bijvoorbeeld bij een ontsteking of weefselschade. Deze no-
ciceptoren kunnen dan via de zenuwbanen signalen doorgeven aan de hersenen, 
waardoor men zich bewust wordt van de pijn. Langdurige activatie van nocicep-
toren, zoals bij chronische pijn, kan leiden tot veranderingen in de verwerking van 
pijnsignalen waardoor het pijnsysteem prikkelbaarder wordt. Door deze verhoogde 
prikkelbaarheid kan het pijnsysteem worden geactiveerd door niet-nociceptieve 
(niet-pijnlijke) signalen, die daardoor als pijnlijk worden ervaren, en kan het pijnsys-
teem extra gevoelig reageren op nociceptieve signalen, die daardoor als intenser 
kunnen worden ervaren. 
Vanuit het pijnonderzoek is bekend dat deze veranderingen in de verwer-
king van pijn kunnen optreden door verstoringen op onder andere twee niveaus: 
de centrale modulatie van pijnsignalen en sensitisatieprocessen. Verondersteld 
wordt dat in een staat van chronische pijn de centrale modulatie van pijnsignalen 
verstoord kan zijn, waardoor intensere pijn wordt waargenomen. In een gezonde 
situatie wordt de transmissie van pijnprikkels gereguleerd (pijnmodulatie) vanuit 
hoger gelegen delen van het centrale zenuwstelsel. Sterkere pijnprikkels kunnen 
bijvoorbeeld zwakkere pijnprikkels elders in het lichaam inhiberend moduleren 
(verminderen of doen wegnemen) door centrale modulatieprocessen vanuit de 
hersenstam. Het is gebleken dat deze modulatie bij verschillende chronische 
pijnaandoeningen verstoord is. Naast modulatie wordt tevens verondersteld dat 
sensitisatieprocessen een belangrijke rol spelen bij chronische pijn. Bij sensiti-
satieprocessen treden er veranderingen op in de structuur van het pijnsysteem, 
waardoor een verhoogde prikkelbaarheid voor pijn ontstaat. Hierdoor kan de in-
tensiteit en de duur van de pijn worden versterkt, en het gebied waar pijn wordt 
waargenomen worden vergroot. Men wordt dan gevoeliger voor pijn, en de drem-
pelwaarde waarop men pijn voelt, wordt lager. 
Recentelijk zijn deze processen ook in verband gebracht met chronische 
jeuk. Echter, sensitisatieprocessen en centrale modulatie van jeuk door een sterk-
ere jeukprikkel zijn nog niet eerder systematisch onderzocht, zeker niet in directe 
vergelijking met pijn. 
Deel I van dit proefschrift beschrijft studies waarin sensorische factoren 
van jeuk zijn onderzocht in vergelijking tot pijn. In deze studies werden sensiti-
satieprocessen en de effectiviteit van centrale modulatie van jeuk en pijn onder-
zocht bij patiënten met chronische jeuk of chronische pijn. 
De gevoeligheid voor jeuk en pijn, als maat voor sensitisatieprocessen, 
werd bepaald bij patiënten met chronische jeuk of pijn door gebruik te maken 
van verschillende QST prikkels, waaronder mechanische, electrische, chemische 
(histamine) en koude stimulatie (Hoofdstukken 2 en 4). De resultaten wijzen erop 
dat de patiënten met chronische jeuk, als gevolg van atopisch eczeem, en patiën-
ten met chronische pijn, als gevolg van fibromyalgie, gevoeliger zijn voor licha-
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melijke prikkels dan mensen zonder chronische lichamelijke aandoening. Dit is 
in overeenstemming met eerder onderzoek. In deze studies wordt tevens voor 
het eerst de gevoeligheid van patiënten met chronische jeuk (ten gevolge van de 
huidaandoeningen atopisch eczeem of psoriasis) vergeleken die van met patiënten 
met chronische pijn (ten gevolge van fibromyalgie of reumatoïde artritis). Uit deze 
vergelijking komt naar voren dat patiënten met chronische jeuk specifiek gevoe-
liger lijken te zijn voor jeukprikkels, terwijl patiënten met chronische pijn specifiek 
gevoeliger lijken te zijn voor pijnprikkels. 
In de studies naar de effectiviteit van centrale modulatie (Hoofdstukken 3 
en 4) werd een methode toegepast die veelvuldig wordt gebruikt om pijnmodulatie 
te onderzoeken, namelijk een conditioned pain modulation (CPM) model. In dit 
model wordt gebruik gemaakt van een sterkere pijnprikkel die de gevoeligheid 
voor een zwakkere pijnprikkel kan verminderen. Vergelijkbaar met de methode van 
CPM voor pijn, werd voor het eerst ook jeukmodulatie onderzocht in een condi-
tioned itch modulation (CIM) model (Hoofdstukken 3 en 4). De resultaten van deze 
studies laten zien dat gezonde proefpersonen een effectieve pijnmodulatie heb-
ben, zoals gevonden in eerder onderzoek. Daarnaast blijken gezonde personen 
ook een effectieve jeukmodulatie te hebben zoals onderzocht met het CIM model 
(Hoofdstuk 3). In lijn met wat bekend is uit eerder onderzoek bij patiënten met 
chronische pijn, werd ook in deze studie gevonden dat de centrale pijnmodulatie 
bij de patiënten met chronische pijn, ten gevolge van reumatoïde artritis, verstoord 
lijkt te zijn. Voor het eerst werden tevens aanwijzingen gevonden dat de jeukmodu-
latie bij de patiënten met chronische jeuk, ten gevolge van psoriasis, verstoord zou 
zijn (Hoofdstukken 3 en 4). 
De studies in deel I van dit proefschrift naar de invloed van sensorische 
factoren op jeuk en pijn duiden erop dat een verstoorde centrale modulatie en 
sensitisatieprocessen niet alleen een rol spelen bij chronische pijnklachten, maar 
ook bij de klachten van patiënten met chronische jeuk. Vanuit hetgeen bekend is 
op het gebied van chronische pijn, is het aannemelijk dat een langdurige activatie 
van jeukreceptoren mogelijk kan resulteren in een verandering van de verwerking 
van jeuksignalen. Sensitisatieprocessen en een verstoorde centrale modulatie van 
jeuk kunnen daarmee bijdragen aan het in stand houden en verergeren van jeuk. 
In de kliniek kan het vaststellen van sensitisatieprocessen en een eventuele ver-
stoorde jeukmodulatie mogelijk worden gebruikt ter ondersteuning van de diag-
nostiek. Patiënten waarbij acute jeukklachten chronisch dreigen te worden kunnen 
zo mogelijk in een vroeger stadium worden getraceerd.
Cognitieve factoren  
De rol van cognitieve factoren bij het ervaren van pijn is reeds veelvuldig 
onderzocht. Zo is bekend dat een hoge mate van aandacht voor lichamelijke prik-
kels, of hypervigilantie, een rol speelt bij de pijnervaring van patiënten met acute 
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of chronische pijnklachten. Naast aandacht is ook de invloed van verwachtingen 
ten aanzien van pijn frequent onderzocht, met name in relatie tot het placebo ef-
fect. Bij het placebo effect kunnen positieve verwachtingen van bijvoorbeeld een 
behandeling resulteren in een afname van de klachten. Anderzijds kunnen bij het 
nocebo effect negatieve verwachtingen ook leiden tot een toename in de klachten. 
In tegenstelling tot pijn, is op het gebied van aandacht en verwachtingen ten aan-
zien van jeuk nog weinig onderzoek gedaan.
Deel II van dit proefschrift beschrijft studies waarin voor het eerst de rol 
van aandacht en verwachtingen werd onderzocht met betrekking tot de gevoe-
ligheid voor jeuk in vergelijking tot pijn. Uit de studie in Hoofdstuk 5 blijkt dat 
meer aandacht voor lichamelijke verschijnselen verband houdt met meer jeuk en 
pijn opgeroepen door de QST prikkels bij de gezonde proefpersonen. Aandacht 
kan, zoals bij chronische pijn, mogelijk dus ook een rol spelen bij het verergeren 
en in stand houden van jeuk. Als de aandacht wordt gericht op de symptomen, 
bijvoorbeeld jeuk, kan dat ten koste gaan van de aandacht die kan worden besteed 
aan andere belangrijke prikkels. Aangezien afleiding en het trainen van gerichte 
aandacht effectief kan zijn bij het reduceren van pijn, zou dit mogelijk ook effec-
tief kunnen zijn om jeukklachten te verminderen. Aannemelijk is dat cognitieve 
gedragstherapeutische behandelingen die er specifiek op zijn gericht om de aan-
dacht voor de jeuk en voor het krabben te verminderen effectief zijn bij de behan-
deling van jeukklachten. 
In de studie in Hoofdstuk 6 werd de invloed van verwachtingen op het 
ervaren van jeuk in vergelijking tot pijn, experimenteel onderzocht. Verwachtingen 
werden geïnduceerd door negatieve (nocebo) of positieve (placebo) verbale sug-
gesties te geven ten aanzien van de QST prikkels die jeuk en/of pijn oproepen. 
De resultaten toonden aan dat een hoge verwachting van jeuk inderdaad kan re-
sulteren in meer jeuk dan wanneer men een lage verwachting voor jeuk heeft. 
Hiermee zijn voor het eerst aanwijzingen gevonden voor het nocebo effect ten 
aanzien van jeuk. De bevindingen van het effect van negatieve verwachtingen 
op pijn waren vergelijkbaar met die voor jeuk en in overeenstemming met eerder 
onderzoek. Ook werden er aanwijzingen gevonden dat een positieve verwachting, 
geïnduceerd door verbale suggestie, kan leiden tot een afname van jeuk (placebo 
effect). De invloed van verwachtingen bleek over het algemeen groter voor jeuk 
dan voor pijn. Dit sluit aan bij het gegeven dat de sensatie van jeuk erg beïnvloed-
baar is door suggestie. Kennis aangaande nocebo en placebo effecten voor jeuk 
kan worden gebruikt om behandelingen voor patiënten met chronische jeuk te 
optimaliseren. Daarbij kan worden gefocust op het reduceren van nocebo effecten 
en het bevorderen van placebo effecten ten aanzien van jeuk door te voorkomen 
dat negatieve verwachtingen van verergering van de symptomen onnodig bij de 
patiënt worden opgeroepen.  
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Affectieve factoren
  Het is bekend dat pijn enerzijds kan leiden tot meer negatieve emoties, en 
anderzijds kunnen negatieve emoties bijdragen aan een toename in de pijn. Emo-
tionele distress, zoals klachten van angst en depressie, kan een gevolg zijn van 
chronische pijn, bijvoorbeeld door het gevoel van onvermogen de pijn te kunnen 
verminderen. Tevens kan emotionele distress ook bijdragen aan het verergeren en 
in stand houden van de pijnklachten. Er zijn tevens aanwijzingen dat een dergelijke 
relatie tevens van toepassing is op jeuk. Klinische studies laten bijvoorbeeld zien 
dat emotionele distress samenhangt met jeukklachten bij patiënten met chroni-
sche jeuk. Echter een mogelijk causale rol van emoties bij het ervaren van jeuk is 
niet eerder systematisch onderzocht. 
In Deel III (Hoofdstuk 7) van dit proefschrift werd de invloed van negatieve 
en positieve emoties op jeuk in vergelijking tot pijn onderzocht. Uit de resultaten 
bleek enerzijds dat, in vergelijking tot positieve emoties, negatieve emoties in-
derdaad kunnen leiden tot een verhoogde gevoeligheid voor pijn. Tevens werd 
gevonden dat de inductie van negatieve emoties kan leiden tot een verhoogde ge-
voeligheid voor jeuk, zoals geïnduceerd door histamine. De resultaten suggereren 
dat de interactie tussen emoties en jeuk mogelijk vergelijkbaar is met de interactie 
tussen emoties en pijn. Negatieve emoties kunnen mogelijk leiden tot een verer-
gering van jeuk, terwijl jeuk kan resulteren in meer negatieve emoties. Behandeling 
van de emotionele klachten kan mogelijk dan ook een positief effect hebben op de 
jeuk die de patiënt ervaart. 
 
Persoonlijkheid en ziektegerelateerde factoren
De relatie tussen psychofysiologische factoren en jeuk en pijn kan óók 
worden beïnvloed door persoonlijkheids- en ziektegerelateerde factoren, zoals 
neuroticisme of de ziekte-ernst. In de studies beschreven in dit proefschrift werd 
rekening gehouden met verschillende persoonlijkheids- en ziektegerelateerde 
kenmerken van de gezonde proefpersonen en de patiënten. Deze individuele ken-
merken bleken over het algemeen geen of nauwelijks invloed te hebben op de 
relatie tussen psychofysiologische factoren en de jeuk en pijn zoals opgeroepen 
door de QST prikkels. In toekomstig onderzoek zouden andere individuele ken-
merken die mogelijk ook van invloed zijn op de psychofysiologische factoren bij 
jeuk en pijn kunnen worden onderzocht, zoals bijvoorbeeld optimisme bij onder-
zoek naar placebo effecten op jeuk. 
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Conclusie
In het huidige proefschrift werd voor het eerst de rol van verschillende 
psychofysiologische factoren onderzocht ten aanzien van de gevoeligheid voor 
jeuk in vergelijking met pijn door gebruik te maken van quantitative sensory tes-
ting (QST). Daarbij werd gefocust op het bestuderen van sensorische (een ver-
hoogde gevoeligheid voor jeuk en pijn ten gevolge van sensitisatieprocessen en 
centrale modulatie van jeuk en pijn), cognitieve (de rol van aandacht voor licha-
melijke klachten en de rol van negatieve verwachtingen) en affectieve  (de invloed 
van negatieve emoties) factoren bij de jeuk- en pijnervaring. Uit de verschillende 
onderzoeken in dit proefschrift kunnen drie hoofdconclusies worden getrokken. In 
de eerste plaats bleek het mogelijk om deze specifieke psychofysiologische facto-
ren te onderzoeken ten aanzien van jeuk en pijn binnen eenzelfde experiment door 
gebruik te maken van quantitative sensory testing. Ten tweede bleek uit de resul-
taten dat de verschillende psychofysiologische factoren, namelijk de sensorische 
(centrale modulatie en sensitisatieprocessen), cognitieve (aandacht en negatieve 
verwachtingen) en affectieve (negatieve emoties) factoren, van invloed zijn op de 
gevoeligheid voor jeuk. Ter derde lijken deze factoren op vergelijkbare manier van 
invloed te zijn op jeuk als op pijn. 
Gezien de overeenkomsten tussen jeuk en pijn kan de bestaande kennis 
op het gebied van de psychofysiologie van pijn waardevol zijn voor jeuk. Kennis 
over de psychofysiologische factoren die jeukklachten beïnvloeden, kan bijdragen 
aan verbetering van de diagnostiek en behandeling van (chronische) jeukklachten. 
Vervolgonderzoek zal erop gericht moeten zijn om de relatieve bijdrage van de ver-
schillende psychofysiologische factoren, hun onderlinge interactie en de onder-
liggende psychofysiologische mechanismen te verhelderen. De focus van de 
behandeling kan hierop dan zoveel mogelijk worden aangesloten. Daarnaast kan 
algemene kennis over instandhoudende factoren voor verschillende lichamelijke 
klachten, zoals jeuk en pijn, van nut zijn voor een breder scala aan lichamelijke 
klachten. Het valt hierbij te verwachten dat ook de behandeling van andere licha-
melijke klachten gebaat kan zijn bij de reeds verworven kennis en behandelervar-
ing op het gebied van de psychofysiologie van jeuk en pijn. 
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 Een proefschrift schrijf je niet zonder de inbreng van anderen. Het is een 
traject waarbij veel discussie wordt gevoerd en kennis wordt uitgewisseld over 
de opzet en uitvoering van de experimenten, de interpretatie van de data en de 
rapportage van de resultaten. Iedere speler in het veld heeft zijn eigen expertise 
en manier van benaderen. Dit is een van de belangrijkste redenen waarom de 
wetenschap zo inspirerend is. Wetenschap is teamwork, en daarom wil ik allen 
bedanken die op enigerlei wijze hebben bijgedragen aan de totstandkoming van 
dit proefschrift. Uiteraard kan ik niet iedereen persoonlijk noemen, daarom wil ik 
hier een aantal mensen in het bijzonder bedanken voor hun bijdrage.
Mijn dank gaat in de eerste plaats uit naar de vele patiënten en proefper-
sonen die hebben deelgenomen aan de experimenten. Ondanks dat er bij proef-
personen soms enige terughoudendheid viel te bespeuren ten aanzien van “de 
prikkels die enige mate van jeuk of pijn kunnen oproepen”, bleek het achteraf over 
het algemeen “toch wel mee te vallen”. 
Dan wil ik mijn promotoren en copromotor hartelijk bedanken:
Professor dr. A.W.M. Evers, Andrea, ik weet nog dat ik jaren geleden ken-
nis met je maakte omdat ik erg geinteresseerd was in de medische psychologie 
en hier graag een onderzoeksstage in wilde doen. Daar ik me buiten de gebaande 
paden van de opleiding Biomedische Wetenschappen begaf, had ik meteen je 
interesse gewekt. Er was wel een “onderzoeksprojectje” dat kon worden uitge- 
voerd. Dit “projectje” bleek iets ambitieuser dan mijn geplande vier maanden 
stage, maar legde daarmee wel de basis voor het promotietraject waar ik mij de 
jaren die volg-den mee heb verenigd. Ik ben je zeer dankbaar voor alles wat je mij 
hebt geleerd, niet alleen vakinhoudelijk, maar ook op andere gebieden. Je passie 
voor de wetenschap, je gedrevenheid om het hoogsthaalbare te willen bereiken, je 
inventiviteit als het gaat om onderzoeksdesigns, je veelzijdigheid en je vele bena-
deringen om probleemsituaties op te lossen. Ik vind het prettig dat ik nog steeds 
altijd bij je kan aankloppen. Op dit project begon je als mijn co-promotor, maar ik 
ben vereerd dat ik als eerste mag promoveren onder jouw hoogleraarschap. 
Professor dr. F.W. Kraaimaat, Floor, vanaf het eerste moment wist je mij 
te inspireren en te boeien. Je vertelde veel over de onderzoeken die aan de basis 
staan van de psychologie. We hebben menige discussie gevoerd over de opzet 
van telkens weer een nieuw onderzoeksdesign en bijbehorende analysemethoden. 
En je daarbij steeds terugkerende vraag “hoe past dit experiment in je model?” 
heeft me regelmatig wat uurtjes diep nadenken bezorgd. Uiteindelijk zijn we geluk-
kig allen tevreden over het model!
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Professor dr. P.C.M. van de Kerkhof, Peter, in onze overleggen bracht je 
mij tot steeds weer nieuwe inzichten over het onderzoek, veelal verpakt in een 
verrassende, metaforische manier van verwoorden. De link naar de klinische prak-
tijk was voor mij erg stimulerend, immers we doen uiteindelijk onderzoek om de 
patiënten te helpen!
Dr. O.H. Wilder-Smith, Oliver, jarenlang mijn vraagbaak als het ging om 
de quantitative sensory testing, pijn en zenuwbanen. Ik ben je erg dankbaar voor 
al je feedback bij het schrijven van manuscripten en de algemene introductie en 
discussie van dit proefschrift, welke niet altijd even eenvoudig te schrijven bleken. 
Het verheugt mij zeer dat jij mijn co-promotor bent. 
Wetenschappelijke stagiaires Michiel Vogelaar en Annika Walker, ontzettend 
bedankt voor jullie inzet bij het verkrijgen en verwerken van de onderzoeksdata 
van twee top-experimenten. Michiel, na tig keer (ongeveer) hetzelfde (afhankelijk 
van de onderzoeksconditie) verhaaltje te hebben verteld, ging zelfs proefpersoon 
130 nog enthousiast naar huis, petje af! Annika, het was niet altijd even mak-
kelijk om proefpersonen te interviewen over hun emotionele ervaringen, maar wel 
noodzakelijk voor het emotieonderzoek. Je hebt dit fantastisch gedaan! Ook wil ik 
nog een aantal personen bedanken die bij het onderzoek betrokken zijn geweest. 
Professor dr. P.L.C.M. van Riel en drs. H. Cats hartelijk bedankt voor de prettige 
samenwerking en de feedback op de manuscripten. Dr. S. Kroeze, bedankt voor 
de fijne samenwerking bij het begeleiden van de studenten. 
Alle collegae van de afdeling Medische Psychologie wil ik bedanken voor 
de leuke en gezellige tijd. Met name wil ik Ria te Winkel-Slotboom noemen. Ria, 
bedankt voor je hulp bij de datainvoer, SPSS checks en al mijn vragen over de 
dataverwerking en -invoer. Ook Annelien Hachmang, bedankt voor het invoeren 
van de vele vragenlijstboekjes. Dan de dames van het secretariaat, Nancy van 
de Steeg, Helma Wouters en Jacintha Stoots. Dank voor het ontvangen van alle 
proefpersonen die zich bij jullie meldden en van jullie een glaasje water kregen 
in de wachtkamer (geen koffie of thee, want dat kan invloed hebben op de me-
tingen). Ook mijn dank voor jullie praktische hulp, goede raad en de momentjes 
om een babbeltje te maken. Mijn collegae junior-onderzoekers, ook zij die reeds 
gepromoveerd zijn, wil ik bedanken voor het delen van deze gezellige, soms hef-
tige, maar vooral ook leerzame tijd. Vooral binnen de onderzoekerskamer heb-
ben wij menige emotie gedeeld. Elk promotietraject gaat gepaard met toppen 
en dalen. Frustraties over slechtlopende inclusie, spanning voor een presentatie, 
opwinding als de data klaarstaat voor analyse, blijdschap wanneer een artikel is 
geaccepteerd, en zo kan ik nog vele andere voorbeelden noemen. Degenen die 
nog midden in het promotietraject zitten wil ik veel succes wensen bij de voltooiing 
van hun promotietraject. 
206
dankwoord (acknowledGements)
Dan Marinda Verhoeven, zonder jou was mijn manuscript niet omgetoverd 
tot een echt proefschrift. Bedankt voor je geduld en het in de praktijk vertalen van 
mijn detailgerichte manier van benaderen van het vak van de vormgeving.
Ik wil ook mijn vrienden en familie bedanken voor de interesse, belang-
stelling en betrokkenheid die zij hebben getoond voor mijn promotiebezigheden. 
Enkelen van hen wil ik met name noemen. Hub, bedankt voor de mooie tijd, waarin 
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